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1. SEMLIKI FOREST VIRUS (SFV)
a) History
Semliki Forest virus (SFV) was originally isolated from a pool of 130 
female Aedes abnormal is mosquitoes captured in Bundinyama, Uganda in 
1942 (Smithburn and Haddow, 1944).
b) Classification
SFV is classified as a member of the genus alphavirus, of the family 
Togaviridae (Matthews, 1982). It was originally described as an 
arbovirus ("arthropod-borne" virus) (Casals and Brown, 1954) since it 
infects vertebrates and is transmitted by mosquito vector. However, 
later studies showed that the biochemical properties of the arboviruses 
were variable. For example, some members of the famiy Bunyaviridae 
were originally classified as arboviruses and these have a genome of 
three (negative sense) RNA segments whereas SFV has positive sense 
genomic RNA.
A large number of the arboviruses were found to be morphologically 
similar, sharing certain structural and biochemical characteristics. 
These were grouped together and termed togaviruses (toga - shroud, 
cloak, envelope) (Andrewes, 1970). Two major serologically unrelated 
genera of the Togaviridae were recognised and were termed group A and 
group B. These were later designated the genera alphavirus (e.g. SFV) 
and flavivirus (e.g. yellow fever virus) (Wildy, 1971. Later, two
other genera of the 
are the rubiviruses 
cholera virus) and,
family Togaviridae were also recognised and these 
(e.g. rubella virus) and pestiviruses (e.g. hog 
to date, there are also five unclassified viruses.
Using the Baltimore classification scheme (Baltimore, 1971) for viruses, 
togaviruses are members of group IV since they contain a single RNA 
genome of positive polarity (i.e. it is the same sense as mRNA).
SFV is relatively non-pathogenic for man and has been used as a model 
system for studying alphaviruses. Other alphaviruses are pathogenic for 
man and cause serious, sometimes fatal, diseases (e.g. Eastern (EEE), 
Western (WEE) and Venezuelian (VEE) equine encephalitis viruses) and it 
is only recently that studies on these viruses have been reported.
c) Hosts and Geographical Distribution
SFV is found throughout much of Africa and has been isolated from mice, 
birds and several species of mosquitoes (Berge, 1975). However,
serological studies suggest that the virus is far more widespread than
1
just Africa. Neutralising antibodies have been found in man in Africa, 
India, Malaya, Borneo, Vietnam, Thailand and the Philippines (Berge,
1975). To date only one human, a laboratory technician in Germany, is 
known to have developed clinical illness due to SFV and this resulted in 
a fatal encephalitis (Willems it al., 1979). There is no information 
about the natural vector-hoat cycle of the virus.
d) Pathogenesis
SFV was originally discovered by the ability of mosquito extracts to 
cause disease in mice (Smithburn and Haddow, 1944), and it is on this 
animal host that the majority of studies on the pathogenesis of the 
virus have been performed. The original study showed that intracerebral 
inoculation of SFV caused paralysis in one mouse (out of 6 inoculated) 
after 27 days incubation. However, a brain suspension taken from this 
mouse caused sickness after only 4 days incubation in other mice after 
intracerebral inoculation. These original studies also showed that the 
virus was lethal for guinea-pigs, rabbits and rhesus and red-tailed 
monkeys after intracerebral inoculation. This was confirmed by 
Henderson e£ al^ . (1967), Boulter et^  a K  (1971) and Bradish e£ a_l. (1971) 
who also showed that the virus caused infection after inoculation by 
various routes. Examination of tissues from infected animals showed 
that the virus and pathology were mainly in the brain, hence the virus 
is described as being neurotropic.
Smithburn and Haddow (1944) also showed that the virus became adapted to 
mice after passage by intracerebral inoculation and the incubation 
period and average survival time of infected mice decreased during 
passage. The latter was only 2.6 days at passage 21. Thus, most 
laboratory strains of SFV are mouse pathogenic derivatives of the 
original isolate. Bradish and co-workers have made use of this fact to 
derive variants of SFV with a gradient of low, intermediate and high 
neurovirulence (Bradish e£ a K , 1971). These variants were found to 
have equal particle to infectivity ratios in tissue culture and were 
lethal to suckling mice. Differences in the variants were seen in their
virulence for mice of 15 days of age or older. "Virulent" variants 
killed mice, while "avirulent" variants did not. Many complex 
experiments have shown that the virus populations are heterogeneous in 
their neurovirulent properties for adult mice (Bradish e£ a^., 1971, 
1972; Bradish and Allner, 1972). However, these studies have failed to 
show which properties of the virus determine virulence.
Studies on the distribution of virus, in mice infected by different 
virus variants, showed that virus titres were similar for the first 
hours after infection and it was only after approximately 48 h that 
differences became apparent. Virulent variants were found to show 
higher infectivities than avirulent variants. Also the rate of growth 
of virulent virus was greater than avirulent virus (Pusztai et al.,
1971; Bradish and Allner, 1972; Fleming, 1977). Woodward and Smith
(1979) have reported that avirulent virus is temperature sensitive, but 
the significance of this finding is unknown. Recently, Atkins (1983) 
has shown that the avirulent and virulent virus did not differ in 
adsorption to cells, nucleocapsid synthesis, protein synthesis, the 
ratio of 42S to 26S RNA, particle to infectivity ratio, interferon 
induction and defective interfering particle production; however, 
avirulent virus did synthesise less total viral RNA but was incorporated 
into virions more efficiently than virulent virus. Thus, it is possible 
that high virulence is associated with a high rate of virus replication, 
such that virus growth exceeds the build up of immune responses. It is 
also possible that the slower replication of avirulent virus allows the 
intervention of the host immune response to limit the avirulent virus 
infection or that avirulent and virulent virus infect different cells of
5the central nervous system (see below).
In general, virulent virus causes a fatal encephalitis in young mammals, 
while avirulent virus produces a focal self-limiting encephalitis which 
is usually sub-clinical. However, Atkins et^  al^ . (1982) have reported 
that the avirulent virus will kill embryos in pregnant mice. Also using 
the intraperitoneal route of inoculation, it has proved possible to 
convert avirulent virus infection into virulent virus infection by 
blockading the phagocytic function of macrophages with colloidal gold 
(Allner ££ a K , 1974; Oaten et^  al^ . , 1982). The reason for this change 
in pathogenesis is unknown at present.
Both virulent and avirulent virus cause distinct histopathological 
lesions in the brains of infected mice. Virulent strains affect 
neurones and oligodendrocytes causing acute degenerative changes, 
including neuronal necrosis, while avirulent strains cause demyelination 
by destruction of oligodendrocytes (Mackenzie a K , 1978; Suckling et^  
al., 1978; Barrett et_ a_l., 1980; Sheahan £t a_l., 1981; Atkins and 
Sheahan, 1982).
The pathogenesis of demyelination in SFV infection is controversial.
The work of Atkins and colleagues suggests that it is the direct 
cytopathic effect of virus on oligodendrocytes that causes demyelination 
and the host immune response is of secondary importance, while the group 
of Webb e£ si. propose that the host immune response is responsible for 
the lesions in the brain. The situation has yet to be clarified.
Atkins' experiments centre on using mutagenesis to isolate neurovirulent 
mutants of the virulent L10 strain (Barrett ejt £1^ . , 1980) and to study 
the effect of the mutation on the development of the disease in the 
host. Atkins and Sheahan (1982) have presented evidence that 
demyelination is associated with the destruction of oligodendrocytes. 
Later studies (Sheahan e£ al^ ., 1983) also suggest that virus induced 
injury to oligodendrocytes plays a major role in the cause of 
demyelination and that the immune response is also important, but plays 
a subsiduary role.
On the other hand, Webbs' group has concentrated on studying the 
pathogenesis of the avirulent A774 strain. They propose that 
demyelination is immune mediated (Jagelman e£ al^ ., 1978; Suckling £t 
al., 1978; Berger, 1980; Kelly £t al_., 1982). Jagelman £t £l. (1978) 
reported that the brains of athymic "nude" (nu/nu) mice (impaired T cell 
responses and production of thymus dependent antibody) have no lesions 
yet heterozygous litter mates (nu/+) do have lesions. However, Chew-Lim 
(1979) finds that inflammatory reactions in nude mice were not absent, 
but merely less severe than immunocompetent mice. Bradish £t a 1 . (1979) 
reported that nude mice had an encephalitis similar to nu/+ mice, while 
Berger ( 1 9 8 0 )  showed that nude mice had a reduced brain pathology 
compared with mouse controls. Recently, Fazakerly e£ al. ( 1 9 8 3 ) have 
transferred normal immune spleen T cells to nude mice and reconstituted 
the brain pathology. Clearly the results are conflicting. Supportive 
evidence for immune mediated lesions is the failure to detect virus 
particles in oligodendrocytes (Chew-Lim, 1 9 75 ; Chew-Lim £t al., 19 77 ; 
Pathak e£ al., 1 9 76 ; Pathak and Webb, 1 9 7 8 ; Kelly et tl., 1 9 8 2 ) .
Finally, Zlotnik et^  al^ ., (1972) have reported on delayed pathological 
changes in mice which had survived infection with the avirulent strain 
A8 . Mice initially had brain lesions but these were undetectable at 6 
weeks pi, however at 2 years pi they developed extensive pathology in 
brain. Unfortunately, this study has not been confirmed and the 
significance has yet to be assessed.
Although the two groups have conflicting results, these may in part be
explained by the use of neurovirulent mutants by Atkins and avirulent
A774 strain by Webb which may give different responses in mice.
e) Structure
SFV is an enveloped virus with an overall diameter of approximately 
55nm. The virus consists of an icosahedral nucleocapsid surrounded by a 
lipid bilayer (Murphy, 1980) and has four structural proteins. The 
nucleocapsid consists of the genome surrounded by capsid (C) protein. 
Electron microscopy, sucrose gradient centrifugation and PAGE have shown 
that the genome consists of one single-stranded RNA molecule of 
sedimentation coefficient 42S (Friedman e£ al_., 1966) and a Mf of 4.3 x 
10^ (Simmons and Strauss, 1972b; Simmons and Strauss, 1972a and.Hsu et^  
al., 1973). The genome is infectious (Sonnabend e£ a K , 1967) and can 
thus act as a mRNA. At the 3' end of the genome there is a poly A tract 
of approximately 60 nucleotides (Armstrong ^t al., 1972; Eaton and 
Faulkner, 1972) and a cap structure (an inverted 7-methyl guanosine) has 
been found at the 5' terminus (Hefti e£ al., 1976; Dubin e£ al., 1977; 
Pettersson e£ al., 1980). The C protein has s Mr of 30,000 and has s
clustering of basic amino acids and prolines near the amino terminus. 
These are thought to be involved in binding of RNA in the nucleocapsids 
(Garoff e£ a K , 1980a).
The lipid bilayer has external glycoprotein spikes each consisting of 
three different glycosylated polypeptides known as El, E2 and E3, of 
Mr's 49,000, 52,000 and 10,000 respectively (Simons e£ a K , 1973;
Garoff £t^  a K , 1974; Ziemiecki and Garoff, 1978). El contains the 
determinants for haemagglutination and haemolysin activity, while E2 has 
the determinant for neutralisation (Dalrymple et^  al^ ., 1976; Chanas e£ 
al., 1982). E3 has only been found in SFV and it is thought that E3 is 
released into the extracellular fluid by other alphaviruses (Welch and 
Sefton, 1979). The aminoterminal region of E3 functions as a signal 
sequence for the E3-E2 precursor protein p62 (see below, Section I.f.vi, 
"Translation of structural proteins") (Garoff et^  £l_., 1980a).
It is thought that El, E2 and E3 exist as a trimer and form the spike­
like structures observed on the surface of the virus (Ziemiecki and 
Garoff, 1978). E2 spans the lipid bilayer with approximately 30 amino 
acids present on the internal side of the membrane (Garoff and 
Soderlund, 1978; Garoff £t a 1., 1980a) such that the hydrophobic 
carboxyterminus interacts with the nucleocapsid. El is attached to the 
lipid bilayer by ita hydrophobic carboxyterminus and E3 is thought to be 
inserted on the extenal side of the membrane (Uterman and Simons, 1974; 
Garoff and Simons, 1974; Pfefferkorn and Shapiro, 1974; Strauss and 
Strauss, 1977; Ziemiecki and Gsroff, 1978; Garoff and Soderlund,
1978). In BHK cells, El and E3 contain one oligosaccharide unit each,
9while E2 has two (Mattila £t a_l., 1976; Pesonen and Reskonen, 1976, 
1977). The lipid bilayer is of host cell origin (Pfefferkorn and 
Hunter, 1963). All the structural proteins are present in equimolar 
quantities of 240 molecules per virion (Laine et^  a_l., 1973; Garoff e£ 
al., 1974) and the overall chemical composition of the virus is 6.32 
RNA, 12.22 C protein, 44.42 envelope proteins, 30.82 lipid and 6.32 
carbohydrate (Laine e£ al^ ., 1973). To date, the Togoviridae is the only 
of enveloped virus to have only one protein in the nucleocapsid. 
The majority of enveloped viruses have an additional internal protein 
usually known as the matrix or M protein.
f) Multiplication
A scheme for the replication cycle of SFV is shown in Figure 1. 
i) Multiplication
SFV multiplies entirely in the cytoplasm of the cells it infects 
(Grimley £t a K , 1968). It grows in a wide variety of cell types and 
over a wide temperature range of between 20 to 41°C (Pfefferkorn and 
Shapiro, 1974). At 37°C the growth cycle normally takes 6 to 10 h 
(Dulbecco and Vogt, 1954); whereas at lower temperatures of 27 to 29°C 
this time can be doubled (Burge and Pfefferkorn, 1966). In the majority 
of cases, the replication of the virus causes a severe cpe usually 
resulting in death of the host cell within 10 to 20 h at 37°C (Hardy and 
Brown, 1961; Acheson and Tamm, 1967; Erlandson e£ al., 1967). The 
host cell DNA, RNA and protein synthesis are rapidly and extensively 
inhibited within 3 to 5 h pi by mechanisms at present not understood
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(Taylor, 1965; Lust, 1966; Strauss a K , 1969; Mussgay ££ al., 
1970; Mantaai and Kato, 1975; Atkins, 1976; Simizu e£ a_l., 1976; 
Wengler, 1980). During a lytic infection as many as 20,000 progeny 
virus particles are released per cell (Pfefferkorn and Shapiro, 1974). 
Multiplication of the virus in invertebrate cells at 28°C has a slower 
cycle of 12 to 24 h (Igarashi ££ al_., 1977; Stollar a K , 1975) and 
there is often little or no cpe or inhibition of host macromolecular 
synthesis (Peleg, 1969, 1972; Stevens, 1970; Logan, 1980; Stollar, 
1980). These infections often become persistent, with only a few cells 
producing virus (Stollar et^  al^ ., 1973; Shenk e£ a_l., 1974; Stollar, 
1980). However, Stollar ^t £1^ . (1973) have reported a cytolytic 
infection of cloned mosquito cells. Recent studies have suggested that 
host transcription is required for the replication of alphaviruses in 
both vertebrate and arthropod cells, but this finding has yet to be 
elucidated (Sheefers-Borshe 1 ££ a K  , 1981; Baric et^  £l^., 1983; Erwin 
and Brown, 1983).
ii) Uptake of the virus
The nature of the receptor for adsorption of the virus into the cell is 
still unknown. However, removal of the virus spikes leads to 
inactivation of the virus, suggesting that the envelope proteins play an 
essential role in attachment of the virus to cells (Osterrieth, 1965; 
Coopans, 1971; Sefton and Gaffney, 1974; Uterman and Simons, 1974). 
Current theories propose that SFV entered the cell by receptor mediated 
endocytosis (Fan and Sefton, 1978; Helenius et al., 1980) and uncoating 
is thought to occur in endosomes by the fusion of the virus and endosome
#
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membranes when the pH falls below 6 (Helenius et^  £l^., 1980; Marsh and 
Helenius, 1980; White and Helenius, 1980; White £t a_l., 1980; Marsh 
et al., 1983). It has been suggested that SFV has multiple receptors 
for binding and in BHK-21 cells the virus preferentially binds to 
microvilli (Fries and Helenius, 1979; Helenius et^  a K , 1980). Since 
SFV has a wide host range it must either have a wide range of cell 
surface receptors or one which is evolutionarily conserved. Helenius e£ 
al. (1978) support the latter view suggesting that the virus binds to 
proteins encoded by the major histocompatibility complex, but Oldstone 
et al. (1980) have reported that these are not the only proteins which 
function as receptors for SFV.
iii) Translation of non-structural proteins
Once inside the cell, the 42S RNA+ genome is translated to produce the 
non-structural proteins which form the virus polymerase. Translation of 
42S RNA begins at an initiation site two-thirds of the length down the 
molecule. The precursor polypeptide produced is then
cleaved to yield the various non-structural polypeptides, i.e. the non- 
structural polypeptides are produced by post-translational cleavage 
(Lachmi and KaariJinen, 1976; Brzeski and Kennedy, 1977; Glansville et 
al., 1978; Fuller and Marcus, 1980a; Lehtovaara et_ al., 1980; Collins 
et al., 1982).
The components of the virus RNA polymerase have not yet been well 
characterised. Studies with temperature sensitive mutants of SV suggest 
that the polymerase consists of four viral polypeptides (Strauss et al.,
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1976) (but see Clewley and Kennedy, 1976, below), and in fact four non- 
structural polypeptides have been detected for SFV of Mr's 70,000 
(ns70), 86,000 (ns86), 72,000 (ns72) and 60,000 (ns60) (Lachmi and
tl u vKaariainen, 1976, 1977; Glanville and Lachmi, 1977; Glanville et al., 
1978; Lehtovaara ££ > 1980; Keranen and Ruohenen, 1983). From
these studies the order of translation was proposed as being NH2-ns70- 
ns86-ns72-ns60-COOH, however recent studies suggest it is NH2-ns70-ns86- 
ns60-ns72-COOH (Keranen and Ruohonen, 1983) Clewley and Kennedy (1976) 
have reported the isolation and purification of the SFV polymerase and 
showed that it contains only two virus-specific non-structural 
polypeptides of Mr 63,000 and 90,000 and possibly also host proteins. 
Clearly the results differ, but may in part reflect technical 
differences in PAGE. Kennedy et_ a K  used the system of Laeramli (1970), 
while Kaariainen e£ a_l. used that of Neville (1971) which resolves more 
non-structural polypeptides. Indeed, KerSnen and Ruohonen (1983) failed 
to detect all the non-structural proteins of SFV using the Laemmli 
system.
iv) RNA synthesis
The first RNA species to be synthesised in infected cells is the 
complementary strand of the genome (i.e. 42S RNA-). This is used as the 
template for the synthesis of two species of RNA*, either new genomes 
(42S RNA*) or a subgenomic 26S RNA*, which codes for the four structural 
polypeptides of the virus. Synthesis of 42S RNA- begins at about 1 h 
pi, and reaches a maximum rate at about 2.5 h, and ceases by 4 h pi 
(Bruton and Kennedy, 1975; Sawicki and Sawicki, 1980). In contrast,
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Che rates of syntheses of both 42S RNA* and 26S RNA* are constant 
throughout the replication cycle (Bruton and Kennedy, 1975; Sawicki and 
Sawicki, 1980). It is thought that the regulation of RNA synthesis is 
controlled by the virus polymerase since the virus polymerase 
synthesising RNA- has a shorter half life than that controlling RNA* 
(Sawicki and Sawicki, 1980; Sawicki e£ al_., 1981).
The major mRNA species in infected cells is 26S RNA. Hybridization 
studies have shown that this RNA (Mr 1.6 x 10*) represents one-third of 
the 42S RNA (Simmons and Strauss, 1972a), oligonucleotide mapping has 
shown that the 26S RNA represents the 3' end of the 42S RNA (Kennedy, 
1976; Wengler and Wengler, 1976) and sequence studies have shown the 
26S RNA and 42S RNA are co-terminal (Ou £t a_K, 1981). The 26S RNA has 
a poly A tract at the 3' terminus and is capped at the 5' terminus 
(Dubin et al., 1979; Pettersson et aK, 1980). Recent studies have 
shown that the transcription of 26S RNA takes place by internal 
initiation rather than by a "jumping" polymerase (Pettersson et^  al., 
1980).
The 42S RNA is synthesised in a double-stranded replicative intermediateri!>0Auc&4i£
structure (RIa ), which after mild / treatment is converted tp a 
pseudo double-stranded form of 42S RNA consisting of a core of 
complementary strands (RNA* and RNA-), known as replicative form, RFI 
(Mr 8.8 x 10*). The 26S RNA is synthesised in a different replicative 
intermediate (RIj,) which is converted to RFII (Mr 5.6 x 10*), a duplex 
of the 5' two-thirds of the genome, and RFIII (Mr 3.2 x 10*), a duplex 
of the 26S RNA (Simmons and Strauss, 1972a,b; Kennedy, 1976; Wengler
ir^ T Y
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and Wengier, 1976) (see Fig. 2). Recently sequence studies have 
confirmed the RFI structure and also shown that the 5' cap is absent 
from 42S RNA + (Wengier £t^  a K  , 1982b).
Other single-stranded RNA species have been detected with sedimentation 
values of 38S and 33S (Simmons and Strauss, 1974; Kaariainen and 
Gomatos, 1969) but these have been shown to be conformational variants 
of the 42S and 26S RNA species respectively (Simmons and Strauss, 1972a, 
1974; Kennedy, 1976; Wengier and Wengier, 1976).
v ) Genome sequence and structure
Recently, the majority of the SFV genome has been sequenced (the genome 
consists of approximately 12,700 nucleotides, Simons e£ a_K, 1982) and 
comparison with other alphaviruses has identified regulatory elements 
important in the replication of alphaviruses. Four distinct control 
elements have been recognised (see Fig. 3). On the 42S RNA+ strand, at 
the 3' terminus, adjacent to the poly A tract, a 19 nucleotide sequence 
is thought to be the polymerase recognition site for initiation of RNA- 
synthesis (Ou e£ al., 1982b). Part of a 51 nucleotide conserved 
sequence near the 5' end is also thought to be the complement of1the 
sequence involved in the initiation of RNA- synthesis (see below) (Ou e£ 
al., 1983). A 21 nucleotide sequence has been found at the junction 
between the 26S RNA (2 nucleotides) and the non-structural polypeptide 
coding sequence (19 nucleotides) and is thought to be the initiation 
sequence on the 42S RNA- strand for transcription of 26S RNA (Ou e£ a 1., 
1982a; Reidel et al., 1982) (also see Fig. 3). The sequences of the 3'

Figure 3. Sequence and structure of alphavirus genomes
(adapted from Ou et al., 1982b, 1983). Numbers refer to nucleotides
a.nl a r e  n  u _ *v \Wti 4- ro/*\ r fjL f 1 or V ~fvr/*i'nnt a s  a  .
end (19 nucleotides) and the junction (21 nucleotides) control elements 
are different, which presumably allows differential regulation of RNA 
synthesis.
At the 5' terminus, a 44 nucleotide sequence is present which can be 
formed into a stem and loop structure while about 150 nucleotides from 
the 5' end a 51 nucleotide sequence (see below) is found which contains 
complementary sequences such that two stable hairpin structures can be 
formed. It is thought that these structures on the RNA- strand may be 
involved in the initiation of RNA* synthesis (Ou et a 1., 1983). Within 
the 266 nucleotide non-coding region, present at the 3’ end of the 
genome (Garoff e£ al.. 1980b; Ou et_ a_l., 1982b), the first 50 
nucleotides adjacent to the 3' terminal poly A tract are highly A + U 
rich (80Z) and it is thought that this sequence may be a signal for 
polyadenylation (Ou e£ al_., 1982b). Two 33 nucleotide repeat sequences 
have also been found in the 3' non-coding region but the significance of 
these is not understood at present (Ou e£ a 1., 1982b).
Earlier studies by Hsu ££ al^ . ( 1973) and Frey e£ a_l. (1979) suggested 
that alphavirus RNAs are able to cyclise and form panhandle structures. 
From sequence studies, Ou e£ al. (1983) have suggested that a panhandle 
structure is possible using part of the 51 nucleotide sequence at the 5' 
end of the RNA and complementary sequences near the 3* end of the 
genome. In this model both 3' and 5' termini are not present in the 
stem of the panhandle. It should be noted that Ou e£ a 1. (1983) were 
unable to match sequences perfectly, and so this model should be 
interpreted with caution. The features of the sequence studies are
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summarised in Figure 3. The sequence data discussed above will become 
importanC when compared to the sequence content of DI RNA species (see 
later).
vi) Translation of structural proteins
The subgenomic 26S RNA codes for all the structural proteins and these 
are translated from a single initiation site (Clegg and Kennedy, 1975). 
The proteins are synthesised sequentially as a large precursor 
polypeptide of Mr 130,000 (Clegg, 1975; Clegg and Kennedy, 1975) and 
the individual polypeptides are formed by post translation cleavages of 
the nascent precursor (see Fig. 4).
Recently, a small non-structural polypeptide (Mr 6,000) has been found 
to be encoded by the 26S RNA and it is thought that it serves as a 
recognition sequence for cleavage of El (Welch and Sefton, 1979, 1980; 
Garoff et^  al^ ., 1980b; Hashimoto e£ a K  , 1981). The C polypeptide is 
cleaved from the nascent precursor immediately after it is completed and 
associates with the progeny genomes to form nucleocapsids in the cell 
cytoplasm (Garoff et_ a K , 1978). After the cleavage of C polypeptide on 
free ribosomes, the ribosomes move to the rough endoplasmic reticulum 
where the synthesis of the envelope polypeptides takes place. This is 
accompanied by membrane translocation and glycosylation (Garoff e£ al., 
1978). The 26S mRNA is unusual in directing the synthesis of proteins 
which are distributed to different parts of the cell, i.e. the C 
polypeptide into the cytoplasm and envelope polypeptides into the 
endoplasmic reticulum.
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Figure 4 . Post-translational cleavages in the formation of the
structural proteins of SFV
The cleavage of 6K has not yet been characterised and its position in 
the cleavage pattern is speculative, and is assumed from its position in 
the sequence of the 26S RNA.
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vii) Assembly
The way in which C protein binds to the 42S RNA + is unknown at present, 
but Wengler £l^ , (1982a), using an rn vitro system, have suggested 
that assembly of nucleocapsid depends upon the relative concentrations 
of protein and RNA available. Only 42S RNA+, and not 26S RNA+, is 
encapsidated (Ulmanen al^, 1976), therefore the 5’ two-thirds of the 
genome probably has a specific binding site for C protein.
The newly synthesised p62 and El glycopolypeptides form a complex which 
is transported through the Golgi complex to the plasma membrane of the 
host cell. Here p62 is cleaved to form E2 and E3. The
glycopolypeptides are inserted into the plasma membrane by fusion of the 
transport vesicles with the cell surface (Kaariainen and Renkonen, 1977; 
Ziemiecki et^  a_l., 1980; Garoff e£ a K  , 1982).
Electron microscopy has shown that the nucleocapsid attaches to the 
cytoplasmic side of the modified plasma membrane, which then begins to 
form a bud partly surrounding the nucleocapsid (Acheson and Tamm, 1967; 
Erlandson e£ a K , 1969; Bykovkay e£ al_., 1969; Grimley and Friedman, 
1970; Grimley £t £l., 1972; Brown et al., 1972). This process 
probably is helped by the nucleocapsid attaching to the cytoplasmic side 
of the transmembrane portion of the virus spike (Garoff and Simmons, 
1974). Since E2 is thought to span the membrane to attach to C protein; 
membrane is able to engulf the nucleocapsid by the E2 portion of the 
spike binding to sites present on the C protein of the nucleocapsid.
Once all the binding sites are occupied and the nucleocapsid is 
completely surrounded by the membrane, the bud finally breaks off thus
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producing a progeny virus particle. In mosquito cells it is thought 
that virus assembles at intracellular membranes, budding into vacuoles 
which release the virus particles into the extracellular environment by 
fusing with the plasma membrane (Whitefield et_ a 1. , 1971, Raghow e£ al., 
1973; Gliedman et al., 1975).
2. DEFECTIVE INTERFERING VIRUSES
a ) Glossary
The following terms are commonly used when discussing defective 
interfering viruses:
Standard virus (S virus) is an infectious virus preparation.
Defective interfering virus (DI virus) has part of the S virus genome 
deleted and is thus non-infectious. Consequently, propagation requires 
the presence of S virus and this results in interference with the 
multiplication of S virus.
Co-infection is when a cell is infected by DI virus and S virus.
DI virus preparations are the stocks of DI virus grown in tissue culture 
for use in the experiments described below. They contain S virus 
(usually <10^ pfu/ml) in addition to DI virus.
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Serial undiluted passage is the method used for the propagation of DI 
virus preparations. The progeny from one passage is used as the 
inoculum for the next passage while maintaining a moi of SO by the 
addition of S virus as necessary.
Passage (p) number refers to the number (X) of serial undiluted 
passages, (pX).
Interference occurs when co-infection of cells results in the DI virus 
competing with the S virus for a limited component of the virus 
multiplication cycle. This results in the replication of DI virus at 
the expense of S virus, thus the term interference. Interference is 
usually specific for the parental S virus and is referred to as 
homologous interference.
Generat ion are the initial events which result in the loss of S genome 
sequence and the production of DI virus.
Enrichment is the phenomenon by which DI particles increase in a 
population, usually after serial undiluted passage.
b) Historical overview
In 1947 von Magnus reported that non-infectious virus appeared when 
undiluted influenxa virus was passaged by allantoic inoculation of 
embryonated chicken eggs. Successive passages resulted in a decrease in 
the ratio of virus infectivity to haemagglutinin (von Magnus, 1951a, b,
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1954). He termed the non-infectious virus "incomplete". Co-infection 
of eggs with "late" passage (incomplete virus) and "early" passage virus 
resulted in interference with the multiplication of "early" passage 
virus. However, if the "late" passage virus was diluted before being 
used as inoculum for the next passage, the ratio of infectivity to 
haemagglutinin remained high and no interference was detected.
In the 10 years following von Magnus' observations little work was 
published on the interference phenomenon but in 1959, Bellett and Cooper 
first demonstrated the interference phenomenon in tissue culture with 
vesicular stomatitis virus (VSV). From 1959 onwards, as the techniques 
of molecular biology rapidly increased, so did the studies on the 
phenomenon of interference. In 1970 Huang and Baltimore defined 
defective interfering (DI) particles as the cause of interference and 
described key properties of these particles in order to distinguish this 
type of interference from other types. The properties of DI particles 
are shown in Table 1 and all originate from the fact that DI particles 
possess a genome derived by a process of deletion from standard virus. 
Huang and Baltimore went on to speculate that DI viruses may play a role 
in the modulation of acute and persistent virus infections in nature.
c ) Nomenclature
To date a vast literature has been accumulated on DI particles which has 
used a variety of terms to describe DI and standard virus:
DI virus particles have been termed non-infectious, von Magnus, auto-
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Table 1 Properties of PI particles
1. Have a genome derived by deletion from the genome of the S virus.
2. Use the S virus structural proteins and hence are antigenica1ly 
identical.
3. Require the presence of S virus for replication. Consequently, DI 
particles cannot propagate unaided. Thus the virus is termed 
DEFECTIVE.
4. Reduce the yield of S virus from the progeny of the co-infected 
cells. Thus the virus INTERFERES.
5. Interfere specifically with the homologous S virus.
6. During co-infection DI virus interferes with an intracellular step 
of the growth cycle of the S virus.
7. Must possess a "functional" nucleic acid, i.e. interference is not 
due to a protein or "soluble factors".
8. Interferon plays no role in the interference phenomenon, although DI 
particles themselves may induce interferon.
9. Prior UV irradiation of the DI particles destroys the interference
phenomenon
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interfering, incomplete, defective, interfering, deleted or immature 
virus. Many of these terms are used interchangeably and are ambiguous 
and do not fully describe the properties of these viruses. Therefore, 
this thesis will use the term defective interfering (DI) virus particles 
exclusively. For standard virus the terms, wild-type, ts+, complete, 
parental, normal, non-defective, competent or helper virus have been 
used. In this thesis the term standard (S) virus will be used.
d) Interference and DI particles
At least three types of virus interference have been described: 
interference by unconditional defective (DI) particles, conditional 
defective particles (temperature sensitive mutants) (Youngner and 
Quaglina, 1976) or non-defective heterotypic virus (Legault et^  al. ,
1977) and very little is known about the mechanisms involved in any of 
these three types of interference. It should be emphasised here that 
serial high multiplicity passage results in the formation of many types 
of genetic variant besides DI particles, including temperature sensitive 
mutants, which have also been found to be capable of producing 
interference (Stollar e£ a K , 1973; Youngner and Quaglina, 1976; 
Keranen, 1977; Chakraborty e£ al_., 1979; King e£ a K , 1979). In 
particular, work with reovirus has shown that serial high multiplicity 
passage results in the formation of DI particles, temperature sensitive 
mutants and growth attenuated mutants (Ahmed e£ a 1., 1980; Ahmed and 
Fields, 1981). The latter were found to be small plaque/low yield 
mutants which could be rescued by mixed infection with S virus. Non­
interfering and interfering defective particles (Frenkel e£a_l., 1973;
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Kawai and Matsumoto, 1977) and infectious virus resistant to DI 
particle-mediated interference (Jacobson and Pfau, 1980; Horodyski and 
Holland, 1980; Weiss and Schlesinger; 1981; Brinton and Fernandez, 
1983) have also been reported. However, the latter have only been 
isolated from persistent infections and are thought to represent the 
continuous and extensive mutational changes or "evolution of viruses" 
involved in these types of infections (for a review see Holland £t a 1., 
1982).
DI particles and/or interference phenomena have been observed in almost 
every group of animal viruses grown in tissue culture (Huang and 
Baltimore, 1977; Perrault, 1981) and although DI particles have not 
been characterised in each system, it seems probable that DI particles 
are ubiquitous. DI particles of plant viruses (Huang, 1973) and 
bacteriophage (Enea and Zinder, 1975) have also been described.
e) Properties of DI particles
Since the discovery of DI particles, a vast literature on the subject 
has developed. Many virus systems have been shown to have DI particles 
with properties unique to that virus group, and a variety of 
interference mechanisms are evident. Consequently reviews on DI 
particles are now appearing on a single virus group rather than on the 
whole subject (see Table 2), although the review by Perrault (1981) 
provides an excellent, but unfortunately already dated, survey of DI 
particles. With this in mind, a review of all DI particles would be 
beyond the scope of this thesis, so the discussion of DI particles will
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Table 2 Recent reviews of DI particles from various virus groups
Subject Reference
General Huang and Baltimore, 1970, 1977; 
Huang, 1973.
RNA viruses Holland et al., 1980; Lazzarini, et a_l., 1981; 
Perrault, 1981.
Alphaviruses Stollar, 1979, 1980.
Arenaviruses Pfau, 1977.
Herpesviruses Frenkel, 1980.
Influenza viruses von Magnus, 1954; Nayak, 1980.
Poliovirus Cole, 1975.
Rhabdoviruses Reichmann and Schnitzlein, 1979; Huang, 1982.
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centre on alphaviruses and, where appropriate, comparisons will be made 
with other virus systems.
f) PI alphaviruses Sm JLj
DI alphaviruses were first reported for^ (Sv) by Schlesinger £t^  al^ . (1972) 
and Inglot £t ajk (1973) and later by Bruton and Kennedy (1976) for SFV 
and Martin e£ (1979) for Ross River virus. To date these are the 
only alphavirus DI particles described. Like other DI viruses, DI 
alphaviruses arise on serial undiluted passage and reduce the yield of S 
virus (Schlesinger £t a_l., 1972; Bruton and Kennedy, 1976). Virus 
purified from low multiplicity passage was found to contain only 42S 
standard virus RNA, while virus obtained after serial undiluted passage 
contained 2 or more species of RNA. Although some 42S RNA was observed, 
the majority was found to be smaller than the genomic RNA. It was 
suggested that these were DI RNA species (Shenk and Stollar, 1973a;
Weiss and Schlesinger, 1973; Johnston e£ al^ ., 1975; Bruton and 
Kennedy, 1976).
i) Separation of DI particles
Attempts at separating alphavirus DI and S virus particles suggests that 
there is little difference in size and density between the two 
particles. Early experiments by Shenk and Stollar (1973b) reported that 
DI SV could be physically separated from S virus, while later work by 
the same group (Guild and Stollar, 1975) failed to separate the two 
particles. Weiss and Schlesinger (1973) have also failed to separate DI
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SV from S virus. Bruton and Kennedy (1976) have reported that they 
could separate DI SFV from S virus by caesium chloride density gradient 
centrifugation but this destroys biological activity. Logan (1979) and 
Kaariainen et a_l. (1981) failed to separate DI SFV by sucrose gradient 
centrifugation. Centrifugation in caesium chloride indicates that DI 
particles are more dense (1.22 to 1.23 gml~^) than S virus (1.20 gml~*) 
(Shenk and Stollar, 1973a; Bruton and Kennedy, 1976) but Shenk and 
Stollar (1973b) found interfering activity across the gradient from 
densities 1.20 to 1.22 gml-*. This lack of reproducibility has made 
studies of DI particles difficult. To overcome this problem research 
into DI alphaviruses has centred on the events which occur in co­
infected cells.
ii) Alterations in the SFV replication cycle in co-infected cultures 
A number of changes have been reported in co-infected cultures. All 
workers have reported an alteration in the viral RNA species synthesised 
in co-infected cultures. A large reduction in the 42S and 26S RNA of S 
virus is observed with the concomitant appearance of sub-genomic viral 
RNA species, which are the DI RNA species (Shenk and Stollar, 1972;
Eaton and Faulkner, 1973; Levin et^  al.. 1973; Weiss and Schlesinger, 
1973; Weiss £t al., 1974; Eaton, 1975; Guild and Stollar, 1975; 
Igarashi and Stollar, 1976; Bruton £t a 1., 1976; Logan, 1979). Levin 
et al. (1973) have reported a reduction in the number of membraneous 
structures associated with the replication complexes compared with S 
virus infected cells. Weiss e£ a 1. (1974) found that DI RNA was 
polyadenylated but would not function as a mRNA iti vitro and only
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functioned poorly iji vivo and did not associate with ribosomes. Bruton 
et al. (1976) took purified DI SFV and found it was unable to carry out 
any part of the virus replication cycle other than uncoating. It was 
also unable to function as a mRNA in vivo or i_n vitro. However, Weiss 
and Schlesinger (1973) observed a new polypeptide of Mr 75,000 in cells 
co-infected with DI SV. Similarly, Guild and Stollar (1975) have 
reported a polypeptide of Mr 80,000 in DI SV co-infected cells. These 
studies would suggest that DI RNA or some DI RNAs can act as functional 
mRNAs. Fuller and Marcus (1980a, b) have suggested that early passage 
(p5) DI SV can be translated while late passage (pl5) virus cannot, 
since p5 DI SV could induce interferon production while pl5 DI SV could 
not. Although this may be true, the results of Fuller and Marcus 
(1980a, b) are open to question because it is unclear if translation was 
obtained from DI virus or contaminating S virus. However, if true these 
results may explain the difference in reported results since if the 
deletion of the DI RNA is small it is possible that the 5' initiation 
site of the 42S RNA may be retained in the DI RNA so that translation 
can occur. Conversely if the deletion is large the sequences necessary 
for initiation of translation may be deleted.
While the translational ability of DI RNA has still to be clarified 
there is agreement that alphavirus DI RNA is not transcribed or 
replicated in the absence of S virus (Shenk and Stollar, 1973a; Weiss 
et al., 1974; Bruton and Kennedy, 1976). Interference is thought to 
occur at the level of virus-specified RNA synthesis, since the synthesis 
of DI RNA takes place at the expense of S virus RNA species (see above). 
Inhibition of both S virus RNA4' and RNA~ is observed as well as the
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synthesis of double-stranded replicative intermediates (Shenk and 
Stollar, 1972; Eaton and Faulkner, 1973; Kennedy e£ al^ ., 1976; Bruton 
and Kennedy, 1976; Guild and Stollar, 1975; Guild e£ a K , 1977). 
Interference results in a reduction in the amount of total viral RNA 
synthesis (Guild and Stollar, 1975; Barrett £t^  a K , 1981) and this is 
dependent on the ratio of DI to S virus in the inoculum. This taken 
together with the results described above, is thought to explain the 
reduction in synthesis of S virus polypeptides in co-infected cells 
(Weiss and Schlesinger, 1973; Bruton e£ a K , 1976; Logan, 1979).
Bruton e£ a K  (1976) have observed that DI virus may interfere with S 
virus in co-infected cells so much that no virus polypeptides are 
synthesised and no shut off of host protein synthesis is observed.
lii) Properties and replication of alphavirus DI RNAa 
Hybridisation studies (Weiss e£ a K , 1974; Bruton et a_l., 1976; Guild 
and Stollar, 1977; Guild et a 1., 1977) and T1 oligonucleotide mapping 
(Kennedy, 1976; Kennedy et_ aj^., 1976; Stark and Kennedy, 1978) have 
led to the conclusion that all DI genomes retain some sequences from 
both the 3' and 5' ends of the S virus genome. Therefore, all deletions 
of alphavirus genomes are internal. These experiments also showed that 
DI virus RNAs are polyadenylated, positive sense (i.e. RNA*) and contain 
only virus-coded sequences. Retention of the termini are thought to be 
due to the necessity to retain the initiation sites for RNA replication 
of both RNA- and RNA*. In the S virus multiplication cycle only 42S 
RNA* is encapsidated, and not 26S RNA* or 42S RNA , thus the capsid 
binding site must be located near one of the termini to enable progeny
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DI particles to be produced. Synthesis of DI RNA has been shown not to 
involve 42S RNA- (Bruton e£ al^ ., 1976; Brzeski and Kennedy, 1978), and 
RFs and RIs equivalent in size to DI RNAs have been detected in co­
infected cells (Eaton and Faulkner, 1973; Weiss e£ a 1., 1974; Kennedy 
et al., 1976; Bruton e£ a K , 1976; Guild £t a K , 1977; Guild and 
Stollar, 1977). It is generally agreed that replication of DI RNA is 
similar to that of S virus requiring S virus RNA synthesizing enzymes, 
but is independent of any S virus RNA species except that the 42S RNA 
codes for all the viral proteins, both structural and non-structural.
iv) Interference, propagation and generation of alphavirus DI RNA 
In 1975 Johnston et^  a K  observed that SV DI RNA decreased in size during 
serial undiluted passage. Similar results were obtained by Guild e£ al.
(1977) for SV and Stark and Kennedy (1978) for SFV. Since the S virus 
termini were retained in the DI RNA a model was proposed to explain the 
sequence organisation of alphavirus DI RNAs by Kennedy (1976) and Stark 
and Kennedy (1978) for SFV (Fig. 5) and Guild and Stollar (1977) for SV. 
It was proposed that the larger DI RNAs were the progenitors of shorter 
RNAs. For example in Fig.5, serial undiluted passage would produce 
particles containing DI-A, which upon further passaging would give rise 
to particles containing DI-B with the concomitant disappearance of those 
containing DI-A. By a similar argument DI-C will replace DI-B. DI-C 
will contain all the sequences in DI-B, and all sequences in DI-B will 
be present in DI-A. Thus passaging will result in bigger internal 
deletions and smaller DI RNAs.
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Figure 5. Proposed sequence organisation of SFV PI RNAs
Solid lines represent conserved regions of the standard virus growth and 
dashed lines deleted portions. Adapted from Stark and Kennedy (1978).
5' 3' 42S RNA
5' 3’ DI-A
5’ 3' DI-B
3' DI-C
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Since Che 3' end of DI and S virus RNA is identical it was proposed that 
interference Cook place by competition between the two RNA species for 
available polymerase. Assuming that polymerase carries out synthesis of 
DI and S virus RNA* templates at an identical rate, more of the shorter 
DI RNA- will be synthesised in a given period of time. Also since the 
5' ends of DI and S virus RNA are identical, DI and S virus RNA will 
compete for available polymerase which will result in greater synthesis 
of DI RNA* by a manner analogous to that described above. By a similar 
mechanism smaller DI RNAs will out-compete larger DI RNAs.
It was further suggested that generation of DI RNA takes place by a 
recombinational event during transcription. Hsu a_l. (1974) and Frey 
et al. (1979) have shown that SV 42S RNA forms circles whose ends form a 
panhandle structure. The panhandle occurs because the 5' and 3' ends of 
the RNA are inverted complements of each other (Ou e_t a 1 ., 1983). It is 
thought that the polymerase detaches from the template and then rejoins 
it at a point nearer the S' end, thus deleting the RNA. It is proposed 
that this "jumping" takes place due to the secondary structure of Che 
RNA where the "detaching" and "rejoining" points are adjacent Co each 
other. Once generated, the DI RNA can then interfere with the S virus 
RNA species.
v ) Sequence and structure of DI RNA
Until recently, the models for interference and generation described 
above were not disputed. However, using Tj oligonucleotide mapping 
Stark and Kennedy (1978) reported one SFV DI RNA which had two
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deletions, while Dohner et_ a K  (1979) described a SV DI RNA with 
multiple deletions. The latter workers also observed that some 
oligonucleotides were present in non-equimolar amounts suggesting that 
some sequences may be present in more than one copy. Further Tj 
oligonucleotide mapping studies by Pettersson (1981) of a pli DI SFV 18S 
RNA showed that the oligonucleotides were clearly non-equimolar (in 
contradiction to all previous studies, except that of Dohner et al.,
1979).
Pettersson also found that the 5' terminal cap sequences were different 
from S virus 42S or 26S RNA and were heterogeneous:
42S RNA 7mGpppAUG
26S RNA 7mGpppAUUG
18S DI RNA 7mGpppAU(AU)nCAUG n - 4-8
Pettersson (1981) proposed that the extreme S' terminus of 42S RNA was 
not conserved in the DI RNAs and that there was heterogeneity in the 18S
p  I) •DI RNA population. These studies were continued by Kaariainen et al. 
(1981), who described the appearance of DI RNA species during serial 
undiluted passage. An 18S RNA appeared at p4 and remained the 
predominant RNA species until pi 7 when a 24S RNA species, which had been 
present in small amounts up to pl7, became predominant. A 33S RNA 
species appeared at p21. This increase in size of DI RNA during passage 
contrasted with the observations of Kennedy (1976), Stark and Kennedy
(1978) and Guild and Stollar (1977) who proposed a decrease in size of 
DI RNA during passaging. Kaariainen e£ al. (1981) showed that although
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the 18S DI RNA was replicated rapidly, it was inefficiently encapsidated 
into progeny virus particles, while the small quantities of 24S DI RNA, 
present upto pl7, were replicated poorly but encapsidated 3 to 5 times 
more efficiently than the 18S RNA. Tj oligonucleotide mapping studies 
showed that the early passage and late passage 24S DI RNAs were related, 
but not identical, while the early passage 24S DI RNA had a Tj map 
similar to 18S DI RNA. Late passage 24S DI RNA had a Tj fingerprint 
identical to 33S DI RNA. Since all the Tj maps had oligonucleotides in 
non-equimolar quantities it was proposed that the 18S DI RNA population 
was heterogeneous and contained repeat sequences which were present in 
greater numbers (5 to 10 copies) in the 24S and 33S DI RNAs.
The nucleotide sequence of DI RNAs was next determined from cloned DNA 
copies and this will now be compared to the sequences present in S virus 
RNA (see Section l.f.v). Different clones of the pli 18S DI RNA were 
found to have different sequences and each sequence contained repeat 
units (Soderlund e£ a_l., 1981; Lehtovaara e£ a K , 1981, 1982). Two 
clones, pKTH301 (Lehtovaara e_£ al^ . , 1981) and pKTH309 (Lehtovaara et 
al., 1982) were examined in detail (see Fig.6). pKTH301 was a major and 
pKTH309 a minor DI RNA species in the 18S DI RNA population. pKTH301 
contained 3 repeat units of 484 nucleotides of which the 3' terminal 
repeat has a 60 nucleotide "insert". pKTH309 consists of a duplicated 
region with flanking unique terminal sequences and 4 repeat units of 273 
nucleotides. The repeat units of the two clones were not the same. The 
3' end of the DI RNAs were all identical to that of the S virus 
(pKTH301, 302, 306 and 309 had 106, 84, 106 and 102 nucleotides 
respectively, identical to S virus). This region is very A-T rich
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Figure 6 . Diagrannnatic representation of the structure of Tw/)
Ca^ LiS) 4^0 SFV PI RNAs
Adapted from Lehtovaara et_ a 1. (1981, 1982). Sequences of DI RNAs from 
two clones, pKTH301 and pKTH309, obtained from the same DI virus 
preparation are shown. The repeat units in each clone are referred to a 
"R". DI RNA pKTH309 contains two tandemly joined repeat units, R1 and 
R2 of which each contains two smaller repeats, Ra and Rb, and Rc and Rd 
respectively. Unique refers to sequences which are present in S virus 
RNA but have been rearranged (see text).
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(75Z), as found for S virus, and is thought to be involved in polymerase 
binding. However, the 3' end of 42S RNA is identical to 26S RNA and the 
latter is not replicated, therefore additional sequences must be 
involved in replication. Although the 3' terminal sequence is conserved 
in each DI RNA, the adjoining sequences differed for each DI RNA 
studied. Thus the sequences involved in replication remain to be 
elucidated. The extreme S' terminus of S virus has also been retained 
in DI RNA but in pKTH309 this sequence has been deleted, rearranged and 
duplicated. Only 29 nucleotides are present in the 5' terminus unique 
region of pKTH301 because cloning failed to include the very 5' terminal 
sequence (approximately 200 nucleotides). The 5' terminal conserved 47 
nucleotide region in S virus is retained in DI RNA and is present in 1 
copy for pKTH309 but 3 copies for pKTH301 (1 in each repeat unit). It 
is thought this region is involved in polymerase recognition. In pKT301 
a 278 nucleotide element has been translocated from the S' terminus 
(nucleotides 39 to 317) to approximately 84 nucleotides from the 3' end 
and the sequence thought to be involved in cyclization has been removed 
(Lehtovaara e£ al_., 1981). Whether this gives DI RNA a replicative 
advantage is unknown, but no cyclization could result in less time and 
energy required for replication.
Recently sequence studies have also been carried out on SV DI RNA. The 
results obtained were similar to SFV. DI RNA was heterogeneous in size 
and contain, ed multiple deletions and sequence rearrangements (Monroe e£ 
al . .  1 9 8 2 ) .  Both DI RNAs examined retained the 3 '  end 5 0  nucleotides of 
the S  virus including the 2 0  nucleotide region regulatory element 
involved in replication. As observed for DI SFV (Pettersson, 1 9 8 1 ) ,  the
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5' terminus cap structure has a different sequence to S virus (Ou et 
al., 1983):
DI RNA 7mGpppAXAXA
42S RNA 7mGpppAUUG
but the 5* end 31 nucleotide conserved region present in S virus is 
present in SV DI RNA (Monroe e£ a 1., 1982) further suggesting that this 
sequence is involved in replication. The regulatory element in SV S 
virus RNA, which is approximately 240 nucleotides from the 3' terminus, 
is not retained in SV Dl RNA (Monroe et al^ ., 1982). Therefore it would 
appear that this sequence is not essential for replication or packaging 
of RNA genomes. Very recently, Monroe and Schlesinger (1983) have 
determined the 5' terminal sequence of 2 Dl RNAs and found that they are 
identical to cellular tRNA and thus are not of viral origin. The 
significance of this sequence is unknown at present.
From the above it is clear that some, but not all, regulatory elements 
of S virus have been retained by DI RNA. The mechanism of generation of 
DI RNA would appear to involve both a deletion mechanism and an 
amplification mechanism and cannot be simply explained by internal 
deletion as previously proposed (Kennedy, 1976; Stark and Kennedy,
1978; Guild and Stollar, 1977). How the repeat sequence units are 
formed is unknown but Ou e£ ill. (1982b) have proposed that a template 
switching mechanism may take place and the short preceeding sequence may 
aid template switching, due to the retention of the S virus polymerase 
binding site at the 3' terminus of DI RNA.
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RepeaC units in DI genomes are not unique to alphaviruses since they 
have also been found in papovaviruses, herpes viruses and phages (Fareed 
and Davoli, 1977; Ravetch et^  , 1979; Schaller, 1979). Whether this 
represents a common strategy for generation and interference by DI 
viruses remains to be seen. To date, influenza virus appears to have DI 
particles most closely related to those of alphaviruses. Studies on the 
sequences of influenza DI virus genomes have shown that some DI RNAs are 
made up of a mosaic of sequence rearrangements from segments 1 and 3 
(Fields and Winter, 1982), while Nayak e£ a 1. have shown that DI 
influenza virus contains both single and multiple internal deletions 
(Davis and Nayak, 1979; Davis ££ £l., 1980; Nayak e£ al^ , 1982; 
Sivasubramanian and Nayak, 1983).
vi .) Packaging of DI RNAs
Since it has proved difficult to separate DI particles from S virus it 
has been proposed that DI particles contain approximately the same total 
amount of RNA as the S virus genome, i.e. 4.3 x 10^ (Kennedy e£ al., 
1976; Guild e£ aK, 1977). Therefore each DI particle contains several 
molecules of DI RNA (Bruton and Kennedy, 1976; Kennedy £t al., 1976; 
Guild £t a 1., 1977). Since Bruton and Kennedy (1976) have managed to 
separate DI and S virus particles they propose that each particle 
contains more RNA per particle than S virus particles. However, this 
does not explain the single hit UV inactivation kinetics of DI virus 
(Kowal and Stollar, 1980; Barrett e£ a 1., 1981). Overall it would 
appear that there are factors (unknown at present) which control the 
packaging and production of progeny DI virus particles. This was
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confirmed by Wengler et^  ajL. (1982a) who have developed an _in vitro
nucleocapsid assembly system which has been found to have constraints on
nucleocapsid size.
\/ii) Effect of host cell upon generation and replication of PI particles 
Levin £t a_l. (1973) were the first to observe the effect of the host 
cell upon the generation and replication of alphavirus DI particles. 
Later, a detailed study by Stark and Kennedy (1978) showed that some 
cell types (e.g. mouse 3T3 and rat NRK) generated and enriched DI 
particles very rapidly, whereas others took many passages to generate DI 
particles (e.g. HeLa, 20 passages). Recently, Barrett e£ al. (1981) 
showed that DI SFV differed in its ability to interfere with S virus 
depending upon the cell type used. The reason for the difference 
between cell types is unknown but may be due to the host-coded 
components of the virus polymerase (Clewley and Kennedy, 1976) or to the 
structure of the replication complex in different cell types.
Since a(pb\i<ruse* replicate in mosquito cells, the ability of these cells 
to support the propagation of DI particles has been examined. Both SFV 
and SV DI particles have been shown to be generated and enriched .in 
mosquito cells. Early work showed that DI particles generated in 
vertebrate cells would not replicate in mosquito cells (Igarashi and 
Stollar, 1976; Eaton, 1975; King et al., 1979), however Logan (1979) 
and Tooker and Kennedy (1981) have generated DI particles in the first 
passage in cloned mosquito cells using S virus grown in vertebrate 
cells. Logan (1979) showed that DI SFV generated in mosquito cells
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interfered with the multiplication of S virus in vertebrate CEF cells. 
Tooker and Kennedy (1981) have Tj oligonucleotide mapped DI SFV 
generated in mosquito cells and found it has an essentially identical 
map to that generated in vertebrate cells, suggesting that DI RNA is 
generated in vertebrate and mosquito cells by a similar mechanism. 
However, Kowal and Stollar (1980) generated DI SV in BHK and mosquito 
cells and sized the RNA on agarose gels. The UV target size of BHK cell 
derived DI SV correlated well with the physical size of the genome, 
while the UV target size for mosquito cell derived DI SV was 25-30Z 
smaller than the physical size of the genome. This would suggest that 
the whole genome is required for interference in BHK cells but only part 
is required in mosquito cells.
Vllt) Ro88 River virus
As stated earlier, DI particles have only been reported for 3 
alphaviruses, SFV, SV and Ross River virus. In comparison to extensive 
studies of SFV and SV only one report has appeared on DI Ross River 
virus (Martin e£ a K , 1979) and this proposes that DI particles 
interfere at the level of translation. This is clearly in contrast to 
results obtained for SFV and SV where interference is thought to'take 
place at the level of RNA synthesis. If true, it would appear that DI 
Ross River virus interferes in a manner analagous to poliovirus (see 
Cole, 1975) and emphasises the point that generalizations about DI 
viruses should be made with great care.
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g) Persistent infections
Persistent infections of both tissue culture cells and the whole animal 
have been described for a number of viruses including RNA viruses (for a 
review see Holland e£ al., 1980). For a persistant infection to be 
established an individual host cell or a proportion of the population 
must survive infection, i.e. there is a balance between virus 
multiplication and death of cells. In tissue culture the cells often go 
through a period of "crisis" where most cells die, but a few survive to 
continue growing. Normally virus mutants appear which maintain the 
persistent infection and have reduced cytopathogenicity. They produce 
low levels of virus progeny and the cell population continues to grow.
A number of factors have been implicated in the establishment and 
maintenance of persistent infection including mutation of standard virus 
(particularly temperature sensitive mutants), interferon production, 
integrated DNA copies of RNA viruses, and DI particles. These have been 
extensively reviewed in Friedman and Ramseur (1979), Persistent Viruses
(1979) and Holland et al. (1980, 1982).
Huang and Baltimore (1970) were the first to propose a role for DI 
particles in the establishment and maintenance of persistent infections 
and since 1970 a number of workers have reported a role for DI particles 
in a number of virus systems for modulating persistent infections (for a 
review see Holland e£ al., 1980).
Standard alphaviruses are normally lethal for vertebrate cells and have 
yet to be shown to establish persistent infections. Meinkoth and 
Kennedy (1980), using SFV, found that persistent infections could either
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be established with an inoculum containing a high concentration of DI 
particles, or pretreatment of cells with interferon prior to inoculation 
of S virus. Similarly Weiss e£ al. (1980) established a persistent 
infection using DI SV. Once established, persistently infected cells 
released temperature sensitive virus. The DI particles used to 
establish the persistent infection failed to interfere with the 
temperature sensitive virus, but would interfere with the multiplication 
of SFV (Weiss and Schlesinger, 1981). Barrett and Atkins (1981) have 
used mutant S virus (SV) to establish a persistent infection. It would 
appear that persistent infections can involve either one or more of the 
mechanisms listed above.
In contrast to the acute virus infections in vertebrate cells, 
alphaviruses readily establish persistence in mosquito cells (for a 
review see Stollar, 1980). High levels of virus are produced with 
little or no cpe. Temperature sensitive mutants (Shenk and Stollar, 
1974) and DI particles (Igarashi e£ a K , 1977; Eaton, 1977; Tooker and 
Kennedy, 1981) have been implicated as causal agents.
h) Animal Studies
i) History
Although there is a vast literature on the biochemistry of DI particles, 
few vivo studies have been reported. Some of the earliest work on 
influenza DI particles by von Magnus described the role of "incomplete" 
virus of the A/PR8(HINI) strain in ovo and in mice (von Magnus, 1951b).
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Intranasal inoculación of dilutions of "incomplete" virus of this 
neurotropic strain resulted in mice dying from paralysis, while using 
the same route of inoculation, undiluted "incomplete" virus gave no 
paralysis and the mice survived. These experiments were probably the 
first to show an effect of DI viruses in virus infections of animals.
The possibility that DI virus may play a role in the expression of virus 
diseases was suggested by Huang and Baltimore in 1970. They proposed 
that DI particles could be important in determining the course of both 
acute and persistent virus infections in nature and speculated on their 
possible use as antiviral or prophylactic agents.
Modulation of infections of animals by DI particles has been described 
for a number of virus groups and these are described below.
ii) Rabies virus
Rabies virus, produced by undiluted passage in eggs, was found to be 
apathogenic after intracerebral inoculation in young adult mice, while 
dilutions of this virus killed mice (Koprowski, 1954). These 
experiments have been confirmed recently by studies upon similar-rabies 
virus preparations (Wiktor et a 1 ., 1977). However, since the latter 
studies did not have proper controls for the immunogenic effects of DI 
virus, it is uncertain if protection was the result of intrinsic 
interference. Other work has questioned the relationship between DI 
virus and virulence since Wunner and Clark (1980) found no correlation 
between virulence of different strains of rabies virus and their ability
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Co generate DI particles.
iii) Rift Valley Fever virus
Mims (1956), working with the bunyavirus Rift Valley Fever virus, 
observed that inoculation of "incomplete virus" lengthened the 
incubation period of the disease and reduced infectivity titres in mice. 
The "incomplete" virus was also shown to be capable of immunising mice 
since high titres of neutralising antibody were obtained after its 
administration. Mice were also protected by intracerebral inoculation 
of S virus and intravenous inoculation of "incomplete" virus.
iv) Vesicular stomatitis virus 
a) Intracerebral inoculation
Holland and co-workers have published a series of papers describing the 
modulation of disease caused by VSV in mice by DI particles. The first 
experiments, described by Doyle and Holland (1973), showed that purified 
DI VFV can protect young adult mice against the lethal encephalitis 
caused by intracerebral inoculation of S virus. However, large 
quantities (>10*®) of DI particles were required and when inoculated by 
the intracerebral route these protected against small, but nonetheless 
fatal, doses of S virus. Co-inoculation with higher doses of S virus 
only resulted in an increase in survival time before death ensued. 
Holland and Doyle (1973) also showed that DI virus reduced S virus 
multiplication in the brain but failed to directly detect DI particles 
in the brains from adult mice. These studies attributed protection to
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DI particles since protection was specific for homologous (Indiana 
serotype) virus and not heterologous (New Jersey serotype) virus, and no 
induction of interferon could be demonstrated. Further studies by 
Holland and Villarreal (1975) showed that newborn mice were also 
protected from VSV infection after intracerebral inoculation by DI VSV, 
but only low titres of DI VSV were present in protected mice. Possibly 
this is due to the low levels of virus multiplication in the brains of 
protected mice (Doyle and Holland, 1973). Generation of DI VSV could be 
demonstrated in the brains of adult mice after 2 serial undiluted 
passages in brain, however DI virus was only detected by pooling mouse 
brains and using in vitro amplification assays. From these results it 
was concluded that DI particles protected mice by their ability to 
interfere with the multiplication of S virus. No persistence of 
infectious virus was observed in protected mice, however some mice 
developed a slow progressive disease with death being greatly delayed.
Rabinowitz e_t a 1 . (1977) confirmed the studies of Holland and colleagues 
using the same strain of mouse as Holland ££ a 1. but a different isolate 
of DI virus. They observed a slow progressive disease of the central 
nervous system after intracerebral co-inoculation of DI and S VSV. 
Histopathological examination of the brains from infected mice showed 
many pathological changes not associated with S virus infection. These 
workers used 10^ DI particles to achieve modulation of the S virus 
infection (1.5 x 10'’ pfu) and this is typical of the studies with DI VSV 
where enormous numbers of DI particles are required to achieve
Oprotection. Holland e£ £l. (1978) quote a minimum number of "3 x 10 
physical particlea of active DI virus" for protection.
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In 1977, Crick and Brown repeated the experiments of Holland and 
associates and demonstrated that mice were protected by administration 
of acetyl ethyleneamine-inactivated DI VSV. Also DI VSV protected 
against heterologous strains of VSV, rabies and a neurotropic strain of 
foot-and-mouth disease virus. Crick and Brown proposed that the 
protection observed was due to activation of the host defence responses 
and not intrinsic interference by DI virus. Although both sets of 
workers used the Indiana strain of VSV, it is possible that the 
different results are due to the use of different types of DI particles 
and mice strains by the two groups. Since generation of DI RNA is a 
random process (Holland et^  al., 1976) it is conceivable that one DI RNA 
may function in the animal, while another may not. Although Holland and 
co-workers did not study host immune responses or include all the 
controls that their experiments demanded, a recent study by Jones and 
Holland (1980) has demonstrated that biologically active DI particles, 
and not UV inactivated DI or S virus, protect mice against challenge by 
VSV S virus. Hence protection would not appear to be due to a host 
immune response. Some ¿n vitro studies on DI VSV by Faulkner al. 
(1979) also support the results of Holland and co-workers. They 
reported that co-infection of cultured neurones from mice delays death 
and suppresses virus growth. These observations suggest that DI• 
particles may play a role in virus infections by interfering with the 
multiplication of S virus.
b) Intraperitoneal inoculation
In comparison to the above studies which have looked at infections of 
the central nervoua system, Fults et al. (1982a) looked at the systemic
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infection of Syrian hamsters by VSV after intraperitoneal inoculation. 
They reported that biologically active DI VSV can protect hamsters 
against the lethal S virus infection. As with previous studies with DI 
VSV, large amounts (^10^) of DI particles were required to achieve 
significant protection. Protection resulted in low levels of S virus in 
serum and tissues. Fultz et al. (1982a) suggest that protection is not 
only mediated by the intrinsic interfering capacity of DI virus. Since 
they demonstrated heterologous interference against the New Jersey 
serotype of VSV and induction of interferon by DI VSV in mice.
Protection was also observed when DI and S virus were inoculated by 
different routes. In another study, Fultz e£ al^ . (1982b) established 
persistent infections in Syrian hamsters after intraperitoneal 
inoculation of DI and S virus. Virus was detected by co-cultivation 
techniques upto 8^ months after inoculation, but preliminary studies 
indicated that the viruses isolated were temperature sensitive, small 
plaque mutants.
v) Semliki Forest virus
These are the only ûi vivo experiments with DI alphaviruses. Dimmock 
and Kennedy (1978) observed that co-inoculation of DI and S SFV by the 
intranasal route resulted in modulation of the lethal encephalitis 
caused by virulent S SFV. Mice either survived infection without 
showing any clinical signs of S virus infection ("protection") or died 
following the normal SFV pattern of disease. Simultaneous inoculation 
of the DI virus and the S virus was necessary for protection. DI SFV 
reduced multiplication of S virus in the brain by at least 10^ fold and
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DI virus was detected in the brain after amplification in tissue culture 
(which are both similar to that observed in the VSV system). In 
comparison to the VSV system where large numbers of DI particles are 
required for protection, 2 x 10  ^"pfu equivalents" of biologically 
active DI SFV particles were required to protect the majority of mice 
against 10 LD^q (6000 pfu) S virus. Dimmock and Kennedy (1978) also 
showed that protection was not due to the induction of interferon or 
stimulation of the host immune system. They concluded that protection 
of mice ws due to the interfering capacity of DI SFV. Recent studies by 
Crouch e£ a 1. ( 1982) have shown that the brains of protected mice have 
no pathological or histochemical lesions whatsoever, nor was there any 
evidence of mononuclear cell infiltration. These results would seem to 
support the view of Dimmock and Kennedy (1978) that DI SFV protects mice 
by intrinsic interference rather than by the host's immune processes. 
However, something other than intrinsic interference eventually 
eliminates S virus from the brain.
vi) Influenza virus
After the original work of von Magnus (1951b) [see section (i)], the 
next study on influenza DI virus in animals was by Holland and Doyle 
(1973). These workers showed that co-inoculation of DI and S virus of 
the A/NWS strain of influenza (H1N1) by the intranasal or intracerebral 
routes of inoculation did not prevent death but delayed the onset of 
clinical signs of infection and reduced infectivity titres in the lungs. 
Gamboa <t tl. (1976) inoculating the A/WSN strain (H1N1) by the 
intracerebral route found that mice could be protected by DI virus.
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They confirmed Che studies above and also showed Chat modulation was 
dependent upon the age of the mice. Seven week old mice were protected 
while Che virus titres were only reduced in 3 week old mice. 
Unfortunately the studies did not include controls for the immunogenic 
load of the inoculum and protection may have resulted from stimulation 
of the immune response. Frolov et al. (1978) showed that intranasal 
inoculation of mice with DI virus of the A/Hong Kong/1.68 strain (H3N2) 
reduced the acute respiratory disease caused by S virus. Similar 
results were obtained by Kantorovich-Prokudina et^  aJL. (1979) for the 
A/WSN strain of influenza virus. Rabinowitz and Huprikar (1979) showed 
that pulmonary infection of mice by the intranasal inoculation of A/PR/8  
strain of influenza virus was prevented by administration of DI virus. 
However, it was mouse strain specific and was correlated with a humoral 
immune response rather than interference with S virus replication.
vii) Arenaviruses
These studies are particularly interesting as arenaviruses naturally 
persist in their rodent hosts. Popescu and Lehmann-Grube (1977) 
observed that DI virus was present in both acute and persistent 
infections of mice with LCMV. Welsh et. ai.- (1977) have shown that 
intracerebral administration of DI LCMV prevented the central nervous 
system disease caused by S virus in 2 day old rats. The synthesis of S 
virus and LCMV antigens was reduced while no interferon or host 
immunological responses appear to have been involved in modulation. 
Aggregation of DI virus enhanced protection and no persistent virus was 
observed at 6 weeks p.i. Since the disease caused by S virus is immune
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mediated these workers propose that the modulation correlates with the 
ability of 01 LCMV to block synthesis of surface antigens in infected 
cells (Welsh and Oldstone, 1977). Coto (1980) has shown that D1 virus 
i8 generated in newborn mice infected with Junin virus and proposes that 
this is responsible for the observed delay in death and the reduced 
yield of S virus in co-infected animals.
viii) Reovirus
Spandidos and Graham (1976) demonstrated the generation, replication and 
in vivo interfering ability of DI reovirus in newborn rats after 
intracerebral and subcutaneous inoculation. They claimed that Dl virus 
was generated during the acute phase of disease and such DI virus was 
generated from the Lj segment only. Surviving rats were runted and 
chronically infected, and DI virus present in these brains contained 
virus RNA segments with multiple deletions. All but two of the 
chronically infected rats also contained virus which was identical to 
that in the inoculum. The claim that DI virus was generated de novo is 
difficult to substantiate as it cannot be proved that the inoculum ws 
free of DI virus. Thus the question of jji vivo generation of DI virus 
in this system remains unanswered.
ix) Runde virus
Traavik (1978) has reported persistent infections of mice after 
intracerebral inoculation of the Coronavirus Runde virus into suckling 
mice. He has suggestsd that this persistence is due to DI virus.
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x) Flaviviruges
Darnell and Koprowski (1974) proposed Chat DI particles may be involved 
in the genetic resistance of mice to infections by West Nile virus 
initiated by the intraperitoneal route. Cells from resistant mice 
produced interfering particles whereas cells from susceptible mice did 
not. Brinton (1983) has confirmed these studies and shown that cell 
cultures from resistant mice produce and amplify DI particles more 
efficiently than cell cultures from susceptible mice. Smith (1981) has 
implicated "interfering virus" as being involved in the genetic 
resistance of mice to infection by Banzi virus. After intraperitoneal 
inoculation, mice resistant to infection were found to have high levels 
of "interfering virus", while susceptible strains of mice had much lower 
titres. Surprisingly, "interfering virus" was detected in the spleen 
and not the brain, and cyclophosphamide enhanced the "interfering 
virus". From these results Smith has proposed that "interfering virus" 
originates in cells of the lymphoreticular system.
xi) Significance of animal studies
From the above it is clear that in many different systems DI viruses can 
alter the normal expression of disease resulting in modulation of 
infections either with complete protection of the animal or a delay in 
death. The role of DI viruses in virus infections of animals appears to 
be complex since the studies described above indicate that the age and 
strain of the animal, route of inoculation, amount of S virus and 
quantity and properties of DI virus can all affect the interaction 
between DI and S viruses ¿n vivo. Interpretation of some studies is
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difficult due to the immunogenic load of the DI virus used in the 
inoculum, but other studies have shown that this need not be a problem 
if proper controls are used. It is unfortunate that many studies have 
used intracerebral inoculation as this can infect the blood stream 
simultaneously, and has several other drawbacks (Mims, 1964).
The quantities of DI virus inoculated into animals to achieve protection 
against S virus tend to be large. For example, Jones and Holland (1980) 
quote that approximately 10 DI particles were required to protect 
against a lethal infection caused by intracerebral inoculation of 100 
pfu. This is to be expected as DI virus is not self-replicating, and is 
required to enter the same cell as S virus to exert interference. What 
is surprising is that with so many cells available for infection that 
co-infection of cells with DI and S virus should occur at all.
The DI virus-modulated infection may be more complicated than appears at 
first sight, as it seems that DI viruses are not the only variants which 
can alter the pattern of disease: in particular temperature sensitive 
mutants also have this property _in vivo (Haspel e£ a 1., 1975; Clark and 
Ohtani, 1976; Stanners and Goldberg, 1975). The possibility that DI 
viruses themselves are also temperature sensitive must also be 
considered. Serial undiluted passage which is used to propagate DI 
virus also results in the accumulation of various S virus mutants 
including temperature sensitive mutants, and Holland eit £l. (1982) have 
reported the evolution of both DI and S virus during persistent 
infections in tissue culture. These points must all be borne in mind in 
any discussion of modulation of virus infections.
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xii) PI viruses and natural infections
IC is clear that DI viruses can be generated and enriched in tissue 
culture, but to date there has been no report of the clinical isolation 
of DI virus from any natural virus infection, either of man or any other 
animal. Until such time as DI virus is clinically isolated, its role in 
the modulation of virus infections must be treated with caution. It 
should be emphasised also that, although a number of L^n vivo model 
systems have been described for the role of DI particles in virus 
infections, they all involve viruses which have either been adapted for 
growth in tissue culture or have been passaged in animals prior to use 
in experiments. Thua, the relevance of studies of these laboratory 
viruses to natural infections caused by viruses must be questioned.
This should not, however, distract from the value of model systems in 
helping to understand the potential of DI particles for modulating virus 
infections ¿n vivo.
Is there any evidence that DI viru8es may actually play a role in 
modulating a virus infection? One consideration must be the persistent 
infections caused by hepatitis B virus in which a role for DI virus has 
been suggested (but without any evidence) by Robinson (1978). More 
recently, Ruiz-Upano et al. (1982) have looked at the structure of 
hepatitis B virus DNA and suggested that supercoiled DNA is present in 
infectious virus while relaxed circular form DNA in Dane particles may 
represent DI particles. It has also been postulated that persistence of 
arenaviruses in small rodents may be caused by DI particles, but no 
evidence exists to support this theory (see review by Buchmeier et al.,
1980). From time to time, it is suggested that measles virus infection
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is modulated to subacute sclerosing panencephalitis by DI particle 
production, however there is no evidence to support this speculation 
(Hall e£ al., 1974; Cernesa and Sordi, 1960).
Finally, two isolates of human rotavirus from immunodeficient children 
have been found to have unusual genomes. Separation of the RNA segments 
by polyacrylamide gel electrophoresis has shown the presence of 3 
additional RNA species to the 11 segments observed in rotavirus virions. 
The extra segments were found not to be due to mixed rotavirus 
infections and cloned recombinant DNA rotavirus probes hybridized not 
only to the normal virion genomic RNAs but also to RNA species of both 
higher and lower molecular weights (S. Pedley, personal communication). 
Tissue culture studies with calf rotavirus have shown that serial 
undiluted passage results in the isolation of virus particles with extra 
RNA segments is additional to the normal virion RNA species. Like the 
two isolates described above, the extra RNA species had both larger and 
smaller molecular weights than the virion genomic RNA species (S.
Pedley, personal communication). Thus it is tempting to suggest that 
the two clinical isolates may be DI particles. Unfortunately, these 
clinical isolates cannot be shown to have interfering activity as they 
cannot be propagated in tissue culture. ,
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Source of Chemicals
35 . 32L-[ S]methionine (specific activity 800 Ci/mmol), [ Pjorthophosphate
(80-130 Ci/mg phosphorus), [methyl-^H] thymidine (25 Ci/mmol) and [5'-
^Hjuridine (30 Ci/mmol) were obtained from Amersham International pic,
Amersham, Bucks.
Acrylamide and N-N1-methylene bisacrylamide (specially pure grade) were 
obtained form BDH Chemicals Ltd., Poole, Dorset, U.K. N,N,N',N'- 
tetramethylenediamine (TEMED) was purchased from BioRad Laboratories, 
Richmond, California, USA. 2,5-diphenyloxasole (PPO), 2,2'-p-phenylene- 
bis]5-phenyloxasoleJ (POPOP) and toluene were supplied by BDH Chemicals 
Ltd., Poole, Dorset, U.K.
Fuji Rx X-ray film and Kodak X-Omat S were obtained from Fuji Photo Film 
Co. Ltd., Tokyo, Japan and Kodak Ltd., Liverpool, U.K. respectively.
Actinomycin D was obtained from Merck, Sharpe and Dohme, Rahway, New 
Jersey, USA. DEAE (Diethylaminoethyl)-dextran and agarose (Type II, 
high EEO) were purchased from Sigma Chemical Co., St. Louis, USA. Noble 
agar was obtained from Difco Laboratories, East Molesey, Surrey., 
Soluene-350 tissue solubiliser was obtained from Packard Instrument Co. 
Inc., Illinois, USA.
Flat-bottomed glass vials (50 x 12mm) were obtained from Regina 
Industries Ltd., Stoke-on-Trent, U.K. All media and newborn calf serum 
were purchased from Flow Laboratories. Irvine, Scotland.
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Cells
HeLa, BS-C-1, human foreskin fibroblasts (HFF) and L929 cells were 
cultured in Glasgow's modification of Eagles medium (Eagle, 1959), 
supplemented with non-essential amino acids (GMEM-NEAA) containing 10Z 
(v/v) NCS. BHK-21 cells were grown in GMEM supplemented with tryptose 
phosphate broth (GMEM-BHK) containing 10Z (v/v) NCS. Cultures of 
primary chick embryo fibroblast (CEF) cells were prepared as described 
by Morser e_t al. (1973). Cultures were maintained in medium 199 plus 5Z 
(v/v) NCS.
Cells were cultured in monolayers on either glass or tissue culture 
plastic (Nunclon (Gibco, U.K.)) flasks. All cells were grown in an 
atmosphere of 5Z CC>2/95Z air at 37°C. All media contained antibiotics 
(penicillin, 100 units/ml; streptomycin, 100 pg/ml).
Confluent monolayer cultures were prepared for subculturing by removing 
the culture medium and washing the cells with warm phosphate buffered 
saline (PBS, pH 7.4). Cells were detached from the substrate by 
incubating with 5 ml 0.05Z (w/v) Trypsin (Flow Laboratories, U.K.),
0.02Z (w/v) versene (1:5 v/v) mixture at 37°C until the cells had 
detached. Cells were gently dispersed by pipetting in 10 ml medium, 
counted in s Neubauer haemocytometer, and seeded at the required 
concentration into fresh flasks containing pre-warmed growth medium.
All media, trypsin and varsene were sterilised by membrane filtration 
through three 0.22 pa Millipore filters (Millipore UK Ltd., London).
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Storage of frozen cells
Cells were frozen in medium containing 20Z (v/v) NCS and 10Z (v/v) 
dimethyl sulphoxide. Ampoules were wrapped in cotton wool to ensure the 
temperature decreased slowly and placed at -70°C overnight and then 
placed in liquid nitrogen.
Virus
A plaque purified stock of the virulent ts + strain of SFV was originally 
obtained from Professor F. Fenner (John Curtin School of Medical 
Research, Australian National University, Canberra), and was first 
reported by Tan e£ a^. (1969). This was grown in mouse brain by 
intracerebral inoculation and plaque purified three times. A stock was 
then prepared in a subconfluent roller bottle culture of BHK-21 cells 
and virus was harvested after 48 h at 33°C. This virus stock was 
designated passage zero (pO). Unless otherwise noted, this is the 
strain of SFV uaed to derive the DI and standard virus stocks used in 
the thesis.
Virulent L10 strain (Bradish at al.. 1971) and avirulent A774 strain 
(Bradish et al., 1971) of SFV were obtained from Dr. R. Fitzgeorge and 
Dr. C. Bradish (Porton Down., Wilts.). Sindbis (originally from Dr. J.
S. Porterfield, NIMR, Mill Hill, London) and encephomyocarditia (EMC) 
(from Dr. E. Martin, NIMR, Mill Hill, London) viruses were obtained from 
laboratory stocks. EMC virus was grown in HeLa cells (moi of 0.1) for 
18 h at 37°C, and the other viruses in BHK cells (moi of 0.1) for 18 h 
at 37°C.
Standard virus stocks
pO Virus of the ts* strain of SFV was used as seed for making pi or 
standard (S) virus stocks. Roller bottle cultures of BHK-21 cells were 
inoculated with a moi of 0.1 of pO virus. After 1 h at 33°C, the 
inoculum was removed and 100 ml of maintenance medium (GMEM-BHK + 22 
(v/v) NCS) was placed in the roller bottle. Extracellular virus was 
harvested after 18 h at 33°C. Tissue culture fluids were clarified by 
centrifugation at 2000 rpm for 13 min at 4°C. Virus was then aliquoted 
and stored at -70°C.
PI virus preparations
DI virus preparations of ts + strain of SFV were all derived by serial 
undiluted passage, usually in BHK cells, with the addition of enough S 
virus to maintain constant moi of 30 pfu/cell. Cultures were incubated 
for 24 h at 37°C and extracellular virus harvested. DI virus 
preparations are all designated by the number of undiluted passages and 
a small letter to indicate sister stocks (e.g. pl3d, pl3h). Where 
appropriate the passage history of each preparation is shown by the 
number of passages in BHK (B), primary chick embryo fibroblast (C) or 
L929 (L) cells. All DI virus prparations which had in excess of. 8 
undiluted passages (DI virus p9, plO, pll, et.) were derived from DI 
virus p8 used by Dimmock and Kennedy (1978). DI virus preparations 
below p8 were generated independently from S virus as described above.
DI virus of L10 and A774 strains of SFV and SV were obtained by 
inoculating BHK cells with S virus at a moi of 30 and harvesting after
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48 h at 37°C. This preparation, pi, contained DI virus as previously 
demonstrated for the ts+ strain of SFV (Barrett e£ ml.. 1981). DI virus 
pi was propagated together with a moi of SO of S virus for 24 h at 37°C 
in BHK cells and designated p2.
Plaque assay of SFV
SFV was assayed by plaque formation on confluent monolayers of primary 
CEF cells in 5 cm plastic Petri dishes. Virus was diluted in medium 199 
plus 2Z (v/v) NCS and 200 pi samples were inoculated onto plates. After
1 h at 33°C, inocula were removed and the cells overlaid with medium 199 
containing 0.9Z (w/v) noble agar, 2Z (v/v) NCS and 0.04Z (w/v) DEAE- 
dextran. Plaques were visualised after 2 days incubation at 33°C by 
ovelaying the agar with 3 ml neutral red strain (0.01Z (w/v) in PBS) for
2 h at 33°C.
Interference assays
i) RNA synthesis inhibition assay
Mouse Lg29 cells (2 x 10^) were seeded in flat-bottomed glass tubes and 
were used after overnight incubation at 37°C. Assay dilutions were done 
in quadruplicate. DI SFV was diluted into medium containing S virus 
(moi of 50) and 2 pg/ml actinomcyin D. Control tubes were inoculated 
with S virus only or mock infected. After inoculation (250 pl/tube) for 
1 h at 37°C, medium was removed and monolayers washed once with warm 
PBS. Medium (GMEM, 250 pi) containing 2Z NCS and 2 pg/ml actinomycin D
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(maintenance medium) was placed in each tube. At 4 h p.i., the 
maintenance medium was removed, monolayers washed once with warm PBS and
into virus RNA as described by Barrett e£ a K , (1981). 
ii) Yield reduction assay is described in Figure 7.
UV irradiation
This was performed according to Dimmock and Kennedy (1978) except that 
the virus was placed 10 cm below a UV lamp (Gelman Sciences Ltd., 
Northampton, U.K.). The dosage was 14 pw/sec/cm2 except for the UV
Airradiation curve for DI virus pl3 where it was 8 pw/sec/cm . The 
dosage was checked each time using a Blak-Ray UV meter (Model J225, UV 
Product Inc., San Gabriel, California, USA).
Inteferon Assay •
Interferon was assayed by the viral RNA inhibition technique of Atkins 
et al. (1974). This method was modified by using flat-bottomed glass 
tubes. Interferon samples were diluted from 10-* to 10~^ in steps of 
10-°*5. Challenge virus was inoculated in 250 pi of maintenance medium
replaced with 250 pi maintenance medium containing
After 1 h at 37°C, the radioactive medium was removed and the tubes were 
then processed to determine incorporation of TCA insolublePlJ-uridine
and virus RNA synthesis was detected by adding
each sample. Three ml of acidified scintillant was added to each sample
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prior Co counting in a Packard liquid scintillation spectrometer. All 
assays included an internal interferon control of known titre.
To remove biologically active virus from interferon samples, samples 
were dialysed for 5 days at pH2 (152 mM HC1, 87 mM KC1) at 4°C. Samples 
were then returned to pH7 by dialysing overnight against PBS at 4°C.
Haemagglutination assay
This was performed according to Clarke and Casals (1956). A pH of 5.9 
was critical and was maintained by use of phosphate buffer. Goose cells 
were obtained from CAMR, Porton Down, Salisbury, Wilts.
Radiolabelling of intracellular virus polypeptides
Monolayers of 1*929 cells in flat bottomed tubes (prepared as for the YRA 
(Figure 7) or Petri dishes, were rinsed with PBS and incubated overnight 
at 33°C in GMEM containing 2Z NCS and 2 pCi pHj-thymidine to radiolabel 
cell DNA. Medium was then removed and the monolayers rinsed with warm 
PBS. Samples were prepared and diluted in methionine-free GMEM medium 
as necessary. Monolayers were inoculated with samples and incubated for 
1 h at 37°C. The inocula were removed and replaced with methionine-free 
GMEM medium and incubated at 37°C until 4 h p.i. Medium was Chen
removed and replaced with 50 pCi jj^sJ-methionine in 100 pi methionine- 
free GMEM medium. After 1 h at 37°C, the medium was removed and the 
cells rinsed with PBS, frosen in dry ice/methanol and thawed and 
dissolved in detergent (10Z SDS, 10 mM Tris-HCl, pH7.4). The amount of
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3 . .H-thymidrne incorporated was then determined so that the number of 
cells used for analyses of virus polypeptides could be standardised.
Analysis of virus polypeptides by polyacrylamide gel electrophoresis 
(PAGE)
Polypeptides were resolved on a 3 to 25Z gradient of polyacrylamide gel 
with a reversed linear bis-acrylamide gradient of 0.4 to 0.12Z, using 
the buffer system of Laemmli (1970). This system was used when it was 
discovered that the 10 to 30Z linear gradient gel system of Cook et^ al. 
(1979) failed to resolve all the SFV polypeptides. The gel in Figure 
13a was a 10 to 30Z linear gradient according to Cook et al_. (1979). 
Electrophoresis was at 80V for about 16 h. After washing, gels were 
dried under vacuum and exposed for autoradiography. Gel bands were cut 
out and radioactivity determined after incubating gel slices in 3 ml 
toluene scintillation cocktail (9Z NCS tissue solubiliser (Amersham- 
Searle), 0.4Z (w/v) PPO, 0.005Z (w/v) POPOP, 1Z water in toluene) at 
37°C for 48 h and then overnight at 4°C.
Measurement of virus RNA synthesis
Identical conditions to the RNA synthesis inhibition assay were used 
except that cultures were radiolabel led for 1 h periods at various times 
p.i. Incubation waa stopped by snap-freesing monolayers in a dry
ice/methanol bath
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Preparation of virus particles with radio-labelled RNA 
(^H^-uridine labelled virus RNA was prepared by propagating virus as 
described above, but with the addition of fllj-uridine and actinomycin D 
( 2 pg/ml) "to the culture medium. H  orthophosphate labelled virus was 
prepared by starving cells of phosphate in phosphate-deficient medium 
supplemented with 2Z dialysed NCS. Culture were infected and incubated 
in phosphate deficient medium containing 10 mCi orthophosphate.
Virus was grown in the presence of actinomycin D (2 ug/ml). After 
incubation the tissue culture fluid was clarified by centrifuging in a 
MSE Chilspin at 3000 g for 15 min at 4°C and then virus pelleted in a 
ultracentrifuge. RNA was extracted from the virus as described by 
Clewley et al. (1982).
Gel electrophoresis of virus RNA
RNA species were resolved by electrophoresis in 1Z (w/v) agarose gels in 
50Z (v/v) formamide by using a horizontal, submerged gel system (Clewley 
and Avery, 1982). Prior to electrophoresis the RNA sample was dissolved 
in water and an equal volume of formamide added. Samples were heated at 
65°C for 1 min immediately before loading on the gel. After 
electrophoresis for 8 h at 120V, the gel was fixed in 1 N acetio acid. 
Water was removed from the gel by three sequential 1 h washes in 
methanol. The gel was then soaked for 3 h in 3Z (w/v) PPO in methanol, 
for 1 h in water to precipitate the PPO and then dried under vacuum. 
Kodak X-Omat S film was pre-exposed for fluorography as described by 
Laskey and Mills (1975) and exposed to the gel at -70°C.
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Oligonucleotide mapping of RNA
The digestion of P^Pylabelled RNA by Tj ribonucléase and the resolution 
of oligonucleotides by 2-dimensional PAGE were carried out by the 
procedures of Clewley e£ (1977).
Mice
CFLP and Porton random bred white mice 4 to 5 weeks old, weighing about 
25 g, were obtained from Hacking and Churchill Ltd., Huntingdon, Cambs., 
and Allington Farm, Porton Down, Salisbury, Wilts, respectively and were 
used 3 to 6 days after delivery. C^H-He/Mg inbred mice came from the 
Warwick University Breeding colony and weighed about 18 g at 5 weeks of 
age. All mice used were male except where stated.
Inoculation of Mice
Intranasal (i.n.). All mice were inoculated under light ether 
anaesthesia with a 20 pi volume as described by Dimmock and Kennedy 
(1978). Treatment of mice with DI SFV comprised 2 inoculations of a DI 
SFV preparation 2 h apart. The second inoculation contained 10. LDjq S 
SFV. Control mice were inoculated in exactly the same way with non- 
infect ioua UV-irradiated S SFV replacing DI virua, in order to control 
for possible immunogenic effects and to demonstrate that the mere 
presence of SFV antigen did not prevent infection (see Results). Other 
controls received DI virus alone, UV SFV alone or diluent.
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Intraperitoneal (i.p.). Mice were inoculated intraperitoneally with a 
100 pi volume of DI virus containing 10 LDjq S virus (1.25 x 10^ 
pfu/LD^g). Control mice were inoculated with 10 LD^q but with non- 
inf ectious UV-irradiated S SFV replacing DI virus, in order to control 
for possible immunogenic effects.
Tissue sampling
When tissue samples were required mice were killed with ether. Blood 
was obtained from the heart and the serum was then removed and stored at 
-70°C. Spleen, olfactory lobes and brain (minus olfactory lobes) were 
dissected out and dispersed in medium 199 containing 2Z NCS by passing 
tissue through a 19 gauge syringe needle and the supernate was stored at 
-70°C. Olfactory lobes and brain were pooled for tissue sampling 
following i.p. inoculation.
Myocrisin treatment
Myocrisin (sodium auro-thio-malate, May and Baker, Dagenham, U.K.) was 
administered i.p. at a dose of 400 mg/Kg body weight in a volume of 200 
pi physiological saline 3 h before inoculation of virus. This dose was 
the maximum that could be administered without killing the mice.
Neutralizing antibody assay
A plaque reduction assay was used. Brain homogenate or serum was 
diluted in CMEM plus 2Z NCS containing 50 pfu of virus and incubated for
1 h at 25°C. The mixtures were then plaque assayed. The titre of 
neutralising antibody was taken as the reciprocal of Che dilution which 
gave 50Z reduction in plaques when compared Co a control containing SO 
pfu and medium only.
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Introduction
To date five types of biological assay for measuring DI virus have been 
described: a) reduction in yield of standard virus (first described for
VSV, Bellett and Cooper (1959)); b) inhibition of infectious centre 
formation (first reported by Welsh aK (1972) for lymphocytic 
choriomeningitis virus); c) a focus-forming assay which measures the 
ability of DI virus to allow individual cells to survive and proliferate 
(first described for DI lymphocytic choriomeningitis virus, Popesiu e£ 
al., 1976); d) a colorimetric assay based on neutral red dye uptake by 
DI particle protected cells described by Treuhaft (1983) for respiratory 
syncytial virus. All these assays measure the inhibition of the 
production of standard virus progeny. The fifth assay e) is based on 
the ability of DI SFV to inhibit synthesis of virus-specified RNAs 
(Barrett, 1980; Barrett ei£ a^., 1981). The latter assay, known as the 
RNA synthesis inhibition assay (RSIA), is based on the observation that 
co-infection of cells with DI and S virus results in inhibition of a 
virus RNA synthesis (Guid and Stollar, 1975; Barrett e£ a 1 . , 1981).
The RSIA differs from the other four assays described and it was decided 
to compare it with a yield reduction assay to see if the assays were 
measuring the same aspect of interference.
Results
a) Yield Reduction assay
The yield reduction assay (YRA) for DI SFV measures interference with 
the yield of infectious progeny virus and follows the design of Bellett
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and Cooper (1959) and Kowal and Stoiiar (1980). Cells were grown in 
flat-bottomed glass Cubes (50 x 12 mm, Regina Industries Ltd., Stoke on 
Trent, U.K.) for the assay which is described in detail in Figure 7.
This is the "optimized interference assay". In this assay and all other 
experiments reported below, actinomycin D was used Co prevent the 
possibility of induction of interferon.
Figure 8 shows that the decrease in progeny virus was proportional to 
the concentration of DI virus. The interference titre of DI SFV is 
defined as the reciprocal of the dilution which causes a 50Z reduction 
in the yield of infectious progeny compared with cultures infected with 
S virus alone, and is expressed in "defective interfering units" or DIU. 
Thus DI SFV titrated in Figure 8 has a titre of 10*"^ DIU/250 pi (the 
volume of the assay) or 10^’  ^DIU/ml.
Assuming that at least one DI particle (DIP) per cell is necessary to 
completely inhibit S virus synthesis by that cell, the minimum number of 
DIPs detectable by the assay can be found fromiPoiason distribution (see 
below) since infection of a cell by a DIP is a random event.
P(r) - e-” . mr 
r!
Where P(r) » the fraction of cells in the flat-bottomed tube receiving r 
DIPa where the average ratio of DIP:cell, i.e. the moi, 
i s  m.
T h e r e f o r e ,  when t h e r e  i s  50Z r e d u c t i o n  i n  S v i r u s  s y n t h e s i s  P ( r )  “  0 . 5  
a n d  P ( r )  t h a t  c e l l s  a r e  n o t  i n f e c t e d  by a  DIP i s  r  •  0 .
Figure 7. The Optimized yield reduction assay procedure
1. Tubes are soaked in distilled water overnight, dried, placed in
trays and sterilized in dry heat at 160°C for 4 h.
2. Tubes are seeded with 2 x 10^  cells per vial in 1 ml GMEM ♦ 10Z NCS
(growth medium) and incubated overnight at 37°C in an atmosphere of 
5Z CC>2 in air. This gives confluent monolayers.
3. The following day the medium is removed and the cells washed x 1 
with PBS. Tubes are then aspirated x2.
4. 10®-^ -fold dilutions of DI virus sample from 10® to 10-^ are made in
a diluent of GMEM ♦ 2Z NCS + 2 pg/ml actinomycin D (maintenance 
medium) containing S virus at a moi of 3. Virus controls are 
maintenance medium containing S virus at a moi of 5.
3. 230 pi aliquots of each dilution and control are placed in vials in
quadruplicate.
6. After 1 h at 37°C the inoculum is removed and replaced with 1 ml 
maintenance medium.
7. At 16 h p.i. the culture fluids are harvested and infectivity 
measured by plaque assay.
i'«
L O G 1 0  D I L U T I O N  O F  Dl  V I R U S
1
3
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Figure 8. A yield reduction assay (YRA) measuring the decrease
in yield of infectious progeny brought about by PI SFV
This assay is described in Figure 7. Virus controls represent cultures 
infected with S virus only. Error bars show 1 standard error of mean.
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Therefore, Pr - 0.5 » e m . m°
o !
m - 0. 7
Therefore on average 702 of the cells must be infected by one DIP. The 
minimum number of DIPs detectable is 702 of the number of cells in a 
flat-bottomed tube • 0.7 x 2 x 10^. Therefore the assay will detect a 
minimum of 1.4 x 10^ DIPs. Hence the interference titre calculated from 
Figure 8 is 10^'^ DIO/ml and this represents a minimum of 10^"^ DlP/tnl.
b) Optimisation of the YRA
i) Cell Type
It is known that interference by DI viruses is expressed to different 
extents in different cell types (Stark and Kennedy, 1978; Barrett et 
al., 1981). Hence this was investigated in order to obtain the most 
sensitive cell system for the YRA (Table 3). Cell types could be 
ordered to display a gradient of interference by the DI virus with Lg29 
giving the highest interference titre and no detectable interference in 
chick embryo fibroblasts. A similar spectrum was obtained with.the RSIA 
(Barrett e£ a_l., 1981). It is interesting that DI SFV can be propagated 
in CEF cells even though it exerts no interference in these cells as 
measured by either assay.
ii) Temperature, incubation time and m.o.i.
Maximum interference titres were attained by using a moi of S virus of 5
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Table 3 Interference titres of DI SFV pll by the YRA in different
_ _ * cell types
Cell Type Origin Interference Titre (DIU/tnl)
l929 mouse 140
BHK hamster 63
BS-C-1 monkey 20
HFF human 20
CEF chicken <4
Assays were carried out as described in Methods except that different 
cell types were used. All vials contained 2 x 10^ cells except for CEF
cells where 6 x 10^ cells were used
11
Table 4 Optimisation of the YRA
Temperature 
of incubation
Time of 
harvest 
(h pi)
moi of S virus Interference titre 
(DIU/ml)
33 8 5 398
16 200
50 141
160 45
37 8 5 224
16 200
50 50
160 32
33 16 5 447
16 178
50 126
160 N.D.
37 16 5 1122
16 250
50 63
160 50
33 24 5 251
16 251
50 126
160 63
37 24 5 1122
16 500
50 398
160 16
N. D not done
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pfu/cell and harvesting at 16 h p.i. (Table 4). Titres tended to 
decrease with increasing moi of S virus such that a moi of 160 reduced 
interference by 20 to 70-fold. The fact that DI virus titres vary with 
the moi of S virus may indicate that one DIP per cell is not sufficient 
to inhibit S virus synthesis by that cell, contrary to the suggestion by 
Sekellick and Marcus (180). There was little difference in titres 
obtained after 16 and 24 h incubation and results obtained at 33°C and 
37°C.
c) Comparison of interference titres by YRA and RSIA
Interference by a number of DI SFV preparations was assayed by both the 
YRA and RSIA (Barrett £t^  al., 1981). Both assays use -^^ 29 cells, the 
same number of cells, inoculum volume and temperature of incubation so 
allowing interfering properties to be directly compared.
Reproducibility of the assays for interference by one DI SFV preparation 
(p5) is shown in Table 5. The mean and standard deviation (for 
explanation see Appendix) are shown for a number of measurements of the 
interference titre of DI SFV pS by each assay. In statistical analysis 
it is usual to look at the standard error (see Appendix). Thus the 
reliability of a sample mean in indicating the true mean of the.whole 
population can be described. It is also useful to attach confidence 
limits at a certain level of probability (usually 95%, see Appendix).
Therefore, in Table 5 the mean YRA interference titre lies between 38.9 
and S3.8 DIU/ml, the mean RSIA interference titre lies between 28.5 and
38.3 DIU/ml and the ratio of the YRA to RSIA lies between 1.29 and 1.49
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These results were extended by comparing the interference titres by the 
2 assays for 11 DI SFV preparations which had been passaged between 5 
and 19 times at high multiplicity (Table 6). Two conclusions emerged, 
firstly, that the amount of interference measured by both assays varied 
between preparations and was not related to passage level. Secondly, 
there was no consistency in the ratio of the titre obtained by the YRA 
and the RSIA between preparations. When 95Z confidence limits were 
applied to the interference titres in Table 6 the YRA:RSIA ratios of DI 
viruses p5, p6, pll, pl3h, pl7a, pl7c and pl8 were significantly 
different.
If the two assays measured the same interference property, the ratio of 
the titres (YRA:RSIA) should be constant from preparation to 
preparation. Instead the ratio varied up to 46-fold (pl7a is 0.16 and 
pll is 7.29) indicating that there are at least two types of 
interference mediated by DI SFV preparations. Therefore, it is 
concluded that DI SFV preparations are biologically heterogeneous and 
that their properties vary from passage to passage. However, sister 
preparations at passage 13 and passage 17 were relatively constant in 
interference titre and the ratio of YRA titre to RSIA titre varied by 
only 3-fold, indicating that variation was not random.
Clearly the two assays do not give the same interference titre for the
DI SFV preparation.
Table 6 Comparison of assays for measuring interference by PI SFV
DI SFV Interference Titre (DIU/ml) YRArRSIA titre
Preparation YRA RSIA
p5 (B5) 46 + 3.8 33 + 2.6 1.40 + 0.05
p6 (B6) 502 + 19.8 343 ± 27.4 1.47 ± 0.04
P9 (B9) 22 + 3.5 31 ♦ 6.0 0.69 0.14
pll (BID 170 + 20.6 23 ♦ 3.4 7.29 0.70
pi 3d (B13) 103 14.7 83 6.1 1.24 0.07
pl3h (B13) 200 ± 0.0 66 + 3.2 3.02 ± 0.09
pi 7a (B16 Cl) 39 6.5 235 ± 16.0 0.16 ♦ 0.02
pi 7b (B16 Cl) 71 ♦ 8.0 143 + 43.1 0.50 + 0.10
pi 7c (B16 Cl) 39 + 6.5 187 1 13.0 0.16 0.02
pl8 (B17 Cl) 59 + 4.3 36 4.0 1.63 ♦ 0.11
p!9 (B17 C2) 946 ♦ 54.7 1012 1 219.6 0.93 0.13
All estimates of errors correspond to 1 standard error of the mean
(sse Table 5)
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d) Sensitivity of the RSIA and YRA interference assays to 
UV irradiation
The evidence presented above suggests that the RSIA and YRA interference 
assays measure different parameters of interference. To explore this 
possibility further, the kinetics of UV inactivation of interference by 
DI viruses pl3d and p20c were investigated (Figures 9a and 9b). The 
inactivation curves for both DI viruses show that interference is more 
resistant than infectivity to UV irradiation as has been described for a 
number of systems (VSV: Huang a K  , 1966; Winship and Thacore, 1979; 
Bay and Reichmann, 1979; lymphocytic choriomeningitis virus: Welsh ££ 
al., 1972; Popescu et_ a K , 1976; influenza virus: Nayak e£ a K  , 1978; 
SV: Kowal and Stollar, 1980; and SFV: Dimmock and Kennedy, 1978; 
Barrett ^t , 1981). Both DI viruses were inactivated by single hit 
kinetics and for both pl3d and p20c interference measured by RSIA was 
more resistant to inactivation.
From this data the following conclusions can be made:
i) It appears that a nucleic acid, and not a protein was the radiation 
sensitive target since interference was inactivated at 256 nm, and the 
amount of this emission would not affect protein. Therefore a • 
functional RNA is required for interference in both assays. This also 
suggests that interference takes place intracellularly and not at the 
level of attachment.
ii) The inactivation curves for both S and DI virus are exponential,
i.e. single hit kinetics. This indicates that there is one functional
/
Time of irradiation ( s )
Figure 9a. UV inactivation curve of interference by DI SFV 
preparation p!3d 1
1 ml aliquots were irradiated as described in Methods and titrated for 
infectivity (•) and interference by RS1A (o) and YRA (A).
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Figure 9b. UV inactivation curve of DI SFV preparation p20c
1 ml aliquots were irradiated as described in Methods and titrated for 
infectivity (#) and interference by RSIA (o) and YRA (A).
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nucleic acid per virus particle for S virus and DI virus as measured by 
both assays.
As mentioned above, interference measured by the RSIA was more resistant 
than that by the YRA implying that the size of the RNA required for RSIA 
is smaller.
The measurement of target sizes from UV inactivation data is based upon 
the failure of nucleic acid transcription to extend beyond the site of a 
UV lesion (Michalke and Bremer, 1969; Abraham and Banerjee, 1976; Ball 
and White, 1976). UV irradiation causes lesions on a RNA molecule by 
generating pyrimidine dimers at sites where these nucleotide residues 
are adjacent (Miller and Plagemann, 1974) and this results in premature 
termination of transcription (Hackett and Sauebier, 1975). The target 
size for interference by the RSIA and YRA can be determined from 
statistical analysis of the UV inactivation curve for interference and 
infectivity shown in Figures 9a and 9b (see Appendix). Therefore, for
DI SFV pl3d in Figure 9a the t ^ or inactivity is 9 sec; while for
r
interference measured by the RSIA it is 54 sec and by the YRA 32 sec. 
Thus interference by RSIA requires the activity of 9/54 “ 16.71 as much 
virus RNA as does plaque formation. Hence the relative sensitivity of 
interference by the RSIA is about 16.7Z of infectivity. If it is 
assumed that the complete S  virus genome is required for infectivity 
and the Mr of S virus RNA is 4.3 x 10^ (Kaariainen and Soderlund, 1978), 
the target size of the DI SFV pl3d which causes interference by the RSIA 
is 16.7% of 4.3 x 106 “ 7.2 x 10^. By similar calculations the other UV 
target sizes of interference for the two DI virus preparations can be
Table 7
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UV target sizes of interference by RSIA and YRA for PI 
viruses pi 3 and p20
DI virus UV target size of interference*
RSIA YRA
Pl3 7.2
p20 2.7
x 105 1.2 x 106
x 105 5.4 x 105
t UV target size relative to S virus genome (4.3 x 10^)
determined (Table 7). The UV target size of interference by the YRA is
twice that of the RSIA for both DI viruses examined.
e) Estimate of M, of DI SFV RNAs by gel electrophoresis 
To physically size DI SFV RNA species/ ^ Hf-uridine labelled RNA from
purified DI virus preparations, pl3 and p20, was extracted and sized on 
a formamide-agarose gel (Figure 10). The physical size of DI RNAs 
relative to chicken ribosomal RNA markers shows that both DI viruses 
have genomes closely similar in size.
f) Differential effects of DI virus on cellular and viral *1
polypeptide synthesis in co-infected cells 
The experiments described above have shown that DI virus preparations 
differ in their ability to interfere as measured by reduction in total 
virus RNA synthesis, yield of S virus. In this section the latter was 
studied in more detail by looking at the effect of DI virus on 
polypeptide synthesis in co-infected cells.
1) Virus RNA synthesis in cells co-infected with DI and S virus 
These experiments were undertaken before investigating polypeptide 
synthesis to determine the extent to which DI virus inhibits and/or 
delays virus RNA synthesis and the time at which maximum interference is
rate of total virus RNA synthesis. Actinomycin D was present throughout
exerted. Cultures were
CELL P 13 P20
28S  _____
RN A
«
Figure 10. Agarose gel electrophoresis of virus RNA
RNA was extracted from extracellular virus and sized on an agarose gel. 
DI SFV preparation (pl3), DI virus preparation (p20), 
ribosomal RNA ( c E L l) .
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RNA and to exclude possible effects of interferon. In the absence of 
added DI virus, RNA synthesis in infected Lg29 cells peaked at 5 h p.i. 
and decreased thereafter (Figure 11). On addition of DI virus at the 
time of infection, the resulting virus RNA synthesis was reduced but 
peaked at the same time as S virus infected cultures. Inhibition of 
virus RNA synthesis was proportional to the concentration of DI virus 
inoculated, cultures co-infected with the most concentrated DI virus had 
7.2Z of f3H}uridine incorporation by S virus alone. Contrary to 
expectation DI virus did not delay virus RNA synthesis. DI virus 
interfered with RNA synthesis at all times during infection and the 
maximum effects were observed between 4 and 5 h p.i. (Figure 12).
2) Inhibition of cellular and SFV-specified polypeptide synthesis 
In the following studies mouse Lg29 cells were used. This system 
differs from hamster (BHK) and chick (embryo fibroblast) cells in that 
the synthesis of non-structural polypeptides is not detected until 2 to 
3 h p.i. Virus structural polypeptide synthesis and shut off of host 
protein synthesis are not detected until 3 to 4 h p.i. Virus RNA 
synthesis peaks at 4 to 5 h p.i. (Figure 11), so it appears that SFV 
replication takes place more slowly in Lg29 Chan BHK cells (Bruton and 
Kennedy, 1975; Clegg e£ al., 1976).
The affects of three DI SFV preparations, p6, pl2e and p20a, on 
polypeptide synthesis in co-infected cells were compared. Cultures 
infected with DI virus alone had a pattern of polypeptide synthesis 
indistinguishable from those in uninfected cultures and no DI virus- 
specified polypeptides were observed.
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Figure 11. Virus RNA synthesis in Lqqq cells at different times
after infection with S virus (moi of 50) ♦ PI virus p!3f 
or S virus only
Mock-infected cellsA; S virus (moi of 50) infected cells 0; S virus 
(moi of 50) infected cells co-inoculated with 1/1 DI SFV o; with 1/10 
DI SFV Q; with 1/100 DI SFV^ . Cells were pulsed for 1 h with£JH]- 
uridine and harvested at the times indicated. Actinomycin D (2 pg/ml) 
was present throughout infection to inhibit cellular RNA synthesis.
Time (hrs)
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Figure 12. Determination of the time of maximum interference by 
PI SFV p!3f
Interference was measured according to Barrett ^t a_l. (1981) by pulsing 
cells for 1 h periods with j^ llj-uridine throughout infection.
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i) Inhibition of cellular and viral polypeptide synthesis by 
DI SFV p6 and p!2e
In the first experiments cultures were co-infected with a constant 
multiplicity of S virus of SO together with various concentrations of PI
by PAGE showed that in cultures infected with the highest concentrations 
of PI virus pl2e, the pattern of polypeptide synthesis was identical to 
that in mock-infected cultures (Figure 13a). Thus PI SFV pl2e not only 
inhibits virus polypeptide synthesis but also the virus-induced
again resulted in no detectable virus-specified polypeptides, but host
synthesis of virus structural polypeptides resumed and this increased 
inversely with the concentration of PI virus. Another PI virus, p6,
virus structural polypeptides, and the non-structural polypeptides nsp63 
and nsp90 (Clegg ££ £ K , 1976; Clewley and Kennedy, 1976; Logan, 1979) 
were inhibited (Figure 13b).
ii) Inhibition of cellular and viral polypeptide synthesis by 
PI SFV p20a
Figure 14 shows that PI SFV p20a, like p6 and pl2e, inhibited the shut 
off of host protein synthesis, but PI virus p20a differed in that it 
failed to completely inhibit virus structural polypeptide synthesis. 
Although polypeptides El and E2 were undetectable at high concentrations 
of PI virus, there were significant amounts of the structural precursor
virus pl2e and pulsed with P ’d  methionine from 4 to 5 h p.i. Analysis
inhibition of host protein synthesis. Pilution of PI virus (10-®*^)
protein synthesis was shut off. As PI virus was further diluted (^10-*)
shut off host protein synthesis and the synthesis of both
A
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i) Inhibition of cellular and viral polypeptide synthesis by 
D1 SFV p6 and p!2e
In the first experiments cultures were co-infected with a constant 
multiplicity of S virus of SO together with various concentrations of DI 
virus pl2e and pulsed with P 5*] methionine from 4 to 5 h p.i. Analysis 
by PAGE showed that in cultures infected with the highest concentrations 
of DI virus pl2e, the pattern of polypeptide synthesis was identical to 
that in mock-infected cultures (Figure 13a). Thus DI SFV pl2e not only 
inhibits virus polypeptide synthesis but also the virus-induced 
inhibition of host protein synthesis. Dilution of DI virus (10-®"^) 
again resulted in no detectable virus-specified polypeptides, but host 
protein synthesis was shut off. As DI virus was further diluted (^10~^) 
synthesis of virus structural polypeptides resumed and this increased 
inversely with the concentration of DI virus. Another DI virus, p6,
shut off host protein synthesis and the synthesis of both 
virus structural polypeptides, and the non-structural polypeptides nsp63 
and nsp90 (Clegg ££ , 1976; Clewley and Kennedy, 1976; Logan, 1979)
were inhibited (Figure 13b).
ii) Inhibition of cellular and viral polypeptide synthesis by 
DI SFV p20a
Figure 14 shows that DI SFV p20a, like p6 and pl2e, inhibited the shut 
off of host protein synthesis, but DI virus p20a differed in that it 
failed to completely inhibit virus structural polypeptide synthesis. 
Although polypeptides El and E2 were undetectable at high concentrations 
of DI virus, there were significant amounts of the structural precursor
s U DI
|__S_+_Logj2_d¿li£ ion JD ¡_v¿rus_^___^_^^__t
0  0 5  1-0 1-5 2 0  2-5 3-0 40
p62—
s U DI
S + Log,0 dilution DI virus
0  0 5  1-0 1-5 2 0  2-5 3 0  40
C -
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Figure 13a. SFV polypeptides synthesised in cultures co-infected
with S virus and various concentrations of PI SFV p!2c. S
S virus (moi of 50) (S); uninfected cells (U); 
S virus (moi of 50) plus various concentrations 
Cultures were pulsed with P*d methionine from 4
DI SFV pl2c only (DI); 
of DI SFV pi2c (S ♦ DI). 
to 5 h p. i.
s
S  DI S
—  nsp90 
— p62— nsp63
— E2 
— El
—  C
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Figure 13b.
Uninfected 
50) pi us DI 
from 4 to 5
Inhibition of non-structural polypeptide synthesis in 
cultures co-infected with S virus and DI SFV p6
I; standard virus (moi of 50) (S); standard virus (moi of 
SFV p6, (S ♦ DI). Cultures were pulsed with methionine
h p. i.
nsp90 —
p62 —
nsp63'/—  
E2 —  
E1/
C —
I
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Figure 14. Polypeptides synthesised in cultures co-infected with 
S virus and different concentrations of DI SFV p20a
Standard virus (moi of 50) (S); 
(DI); Standard virus (moi of 50) 
p20a (S + DI). Cultures were pul
uninfected cells (U); DI SFV p20a only 
plus various concentrations of DI SFV 
sed with r«si methionine from 4 to 5 h
p. i •
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p62 and core polypeptides present throughout. This contrasts with the 
data in Figures 13a,b where virus polypeptide synthesis is seen only 
after host protein synthesis has been inhibited.
Inspection of Figure 14 showed that there was significant synthesis of 
the non-structural polypeptides in the presence of DI virus p20a, a 
marked difference to the effects of Dl virus p6 (Figure 13b). However, 
quantitation of radioactivity (Figure IS) showed that their synthesis 
had been affected unequally. In particular, synthesis of nsp90 was 
barely affected and there was synthesis of significant amounts of nsp63 
even in the presence of the most concentrated (10 to 10 samples of 
DI virus. Compared with S virus there was considerable variation in the
relative amounts of virus polypeptides synthesised in cultures co-
0 —2infected with high concentrations of DI virus (10 to 10 ). On further 
dilution of DI virus the ratio of virus polypeptides returned to that 
seen in cultures infected with S virus alone.
Apart from nsp90, inhibition of virus polypeptide synthesis showed a 
linear response over a 1000-fold range of DI virus dilution. The 50Z
inhibition point was very reproducible occurring between 10~^'^ and 10~
(Figure 13). Under identical conditions (Barrett e£ £l., 1981) the 
30Z inhibition of virus RNA synthesis (RSIA) occurred at 10-^‘®, the 
difference presumably reflecting an amplification resulting from 
repeated translation of mRNAa.
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Figure 15. Radioactivity incorporated into virus polypeptides
synthesised in cultures co-infected with S virus and 
different concentrations of DI SFV p20a
Polypeptides in Figure 14 were excised from the gel and the 
radioactivity determined as described in Methods. Core o; El •; 
p62A; nsp90D; nsp63
E2 A;
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g) Propagation of PI virus at constant multiplicity 
Interference by 8 DI SFV preparations was further investigated by 
measuring three parameters of interference (inhibition of virus 
polypeptide synthesis, inhibition of infectious virus production and 
synthesis of DI virus) in parallel. Each DI virus preparation was 
inoculated onto L929 cells at a constant interference titre (4 DIP/cell) 
based on the value obtained by the YRA or the value obtained by the 
RSIA. Conditions were the same as those of the YRA and RSIA except that 
a moi of 50 pfu/cell was used to obtain sufficient virus polypeptide 
synthesis.
1) Virus polypeptide synthesis
Polypeptide synthesis in cells inoculated with DI SFV standardised by 
the YRA is shown in Figure 16A. The major virus-induced polypeptides 
(p62, El, E2, C) were excised and radioactivity in each was determined. 
The synthesis of all polypeptides was equally depressed and the 
synthesis of individual polypeptides was expressed as a percentage of 
that synthesised by cells inoculated with standard virus alone. These 
values were summed and the means presented in Table 8. Most DI virus 
preparations reduced standard virus polypeptide synthesis to 10-15Z of 
the normal value, but DI viruses pl9 and pl3d allowed only 3 and 4Z 
synthesis respectively. DI virus p5 inhibited less efficiently (30Z 
synthesis). DI virus inocula standardised by the RSIA showed greater 
variation in polypeptide synthesis (Figure 16B), while most (5/8) 
inhibited virus polypeptide expression to below 4Z, the others (3/8) 
allowed 27 to 35Z synthesis (Tsble 8). Clearly there was no correlstion 
between interference titre of the inoculum DI virus and its sbility to
11
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Figure 16. Polyacrylamide gel electrophoresis of virus polypeptides
Panel A: cultures inoculated with 4 DIP/cell as determined by the YRA. 
Panel B: cultures infected with 4 DIP/cell as determined by the RSIA. 
In addition all virus infected cultures received S virus (moi of 50).
VC = cultures infected with S virus (moi of 50) only; U, uninfected 
cultures. Tracks were loaded with equal numbers of cells as determined
synthesised in Lqqq cells inoculated with a constant 
multiplicity of PI virus and S virus.
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affect the synthesis of virus polypeptides. None of the DI viruses 
specified the synthesis of any novel protein.
All DI virus preparations shut off host cell protein synthesis except 
pl7a (Figure 16B) even though it was less efficient than the others at 
inhibiting virus polypeptide synthesis. It seems, therefore, that the 
expression of virus polypeptides does not necessarily cause the 
inhibition of host cell protein synthesis, and this is at odds with 
current theories (Wengler, 1980). Another DI SFV preparation, p20a, 
also failed to shut off host protein synthesis (see Figure 14).
2 )  Y i e l d  o f  i n f e c t i o u s  v i r u s
Most (6/8) DI virus preparations standardised by the YRA and half
of those standardised by RSLA reduced production of infectious virus to 
7Z or less (Table 8). The notable exception was DI virus pl8 which gave 
titres of infectious progeny of 74Z or more relative to standard virus, 
although polypeptide synthesis was greatly decreased (to about 10Z) and 
considerable amounts of DI virus were synthesised. Other DI virus 
preparations gave intermediate levels of interference. The apparent 
inability of DI virus pl8 to interfere with virus production, when it 
clearly did so in the YRA assay shown in Table 6, may have been 'the 
result of using a moi of SO pfu/cell rather than S pfu/cell in the YRA 
assay. Table 9 confirms this suggestion and demonstrates that another 
DI virus (pl3d) interfered equally wall at a high or low moi.
3) Yield of DI virus
Yields of DI virus varied upto 100-fold when measured by the YRA and
Table 9 Interference titres by the YRA in Lqqq cells infected
with standard virus at different multiplicities of 
infection
DI virus DIU/ml
m . o . i .  «  5 m . o . i  = 50
p l 3 d 80 126
p l 8 64 « 4
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upto 10-fold by Che RSIA (Table 8). Cells inoculated with DI virus 
preparation which had a high YRA titre relative to the RSIA titre, gave 
either progeny with a similar ratio of interference titres or with the 
ratio reversed. For example, DI virus pl7b yielded progeny DI virus 
which gave interference which registered predominantly by the YRA 
whereas pll, inoculated at the same YRA titre, gave interference 
detectable only by the RSIA.
In summary, cells inoculated with a standardised interfering dose of DI 
SFV of different passage history showed different parameters of 
interference. These varied without respect to the interfering titre of 
the inoculum: thus cells inoculated by DI virus standardised by the 
YRA:DI virus pl9 caused the greatest inhibition of infectious progeny 
(99Z), a low yield of DI virus by the YRA and a high yield by the RSIA; 
DI virus pl8 gave a similarly high yield of DI virus by Che RSIA, 
reduced polypeptide synthesis by 89Z and hardly affected the production 
of infectious progeny; lastly DI virus pl3d inhibited virus polypeptide 
synthesis the most efficiently, reduced infectious progeny by 97Z but 
gave a small yield of DI virus by either assay. The exception Co this 
extreme variation were the sister stocks of pl7 which behaved similarly, 
although host protein synthesis was less inhibited in the presence of 
pl7a. Thus it seems that extensive differences appear on passage, but 
in the short term, the inoculum determines the biological properties of 
the progeny DI virus. Possible explanstions will be discussed lster.
1 04
h) Variation in homotypic and heterotypic interference
DI viruses were generated for one avirulent (A774) and two virulent (L10 
and ts + ) strains of SFV (see Methods) and assayed for interfering 
activity by RSIA using S virus from each of the three SFV strains. The 
results (Table 10) show that avirulent (AV) DI virus pi interfered with 
the replication of AV S virus and gave no detectable interference with 
either of the virulent strains. L10 DI virus pi interfered with all 
three S viruses equally and ts* DI virus pl9 interfered strongly with 
L10 and ts + S viruses but weakly with AV S virus. These results show 
thst DI viruses derived from different strains of SFV have the ability 
to differentially interfere with the various S viruses, thus some 
mechanism must operate which allows discrimination in the interference 
event.
These observations were extended by investigating the stability of the 
observed spectrum of interference activity after one further passage, 
and by comparing interference with SV, another alphavirua which is 
serologically distinct but has a similar molecular biology (Table 11). 
Interference by ts* DI virus was unchanged upon passage and the DI virus 
demonstrated strong heterotypic interference with SV. After the 
additional passage L10 DI virus no longer interfered equally wifh the 
other SFV straina, showing reduced interference against AV S virus and 
none with ts* S virus. L10 DI virus p2 also interfered with Sindbia S 
virus. The second passage of AV DI virus interfered with all four S 
viruses equally in contrast to the previous passage which only 
interfered in the homologous reaction. Sindbis DI virus p2 gave strong 
homologous interference, reduced interference with L10 and ta* and none
t AV is avirulent strain A774 
L10 is virulent strain L10 
ts+ is virulent strain ts+
( t
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Table 11 Interference measured by RSIA of different strains of
SFV DI virus after one further passage and interference
by Sindbis DI virus
DI virus
AV
Standard virus
L10 ts+ Sindbis
/■p2 AVT 16 16 14 20
p2 L10 6 14 <4 8
P20 ts+ 63 501 501 562
p2 Sindbis <4 18 10 100
* Interference titre (DIU/ml)
t AV is avirulent strain A774 
L10 is virulent strain L10 
ts+ is virulent strain ts +
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with AV S virus. There was no detectable interference between the 
various combinations of different S viruses indicating that the results 
obtained above were due to DI virus-mediated interference. Interferon 
was not involved in the interference phenomena since actinomycin D was 
present throughout the RSIA. Thus, the specificity of interference 
between DI viruses of different strains of SFV can vary on passage.
This confirms the results of experiments described above showing that 
the interference properties of DI SFV vary upon passage.
Discussion
Evidence has been presented that DI SFV preparations are biologically 
heterogeneous and that each parameter of interference varies on passage. 
Further, it is suggested thst the putative different interfering 
elements within a DI virus population interfere at more than one step in 
the SFV replication cycle. Interference titres obtained by the YRA and 
RSIA show that some prepsrations have a higher titre by one assay than 
another and in others the ratio is reversed. It sppesrs that the two 
assays measure independently varying parameters of interference .acting 
at the level of virus RNA synthesis (RSIA) snd st an unknown level 
(YRA). UV inactivation kinetics confirmed this theory and showed that 
the two parameters of interference had different sensitivities to UV 
irradiation. Another assay could be devised based on the inhibition of 
virus protein synthesis (Figures IS snd 16) and this again would 
represent an independent variable. The practical implication of these
1 08
findings is Chat it is impossible Co passage DI SFV and Co reCain Che 
properCies of Che parenC (Table 8). Thus one is limiced Co working wich 
apparently unrelaCed baCches of 01 virus. ForCunaCely Chough, siscer 
scocks appear Co be very similar.
The YRA and RSLA indicaCe ChaC Che exCenC of inCerference by a 
parCicular DI virus preparaCion depends on Che racio of DI SFV:S SFV per 
cell since Che exCenC of inCerference decreases as infecCiviCy is 
increased (Table 4), buC Chere are excepCions Co Chis generalisacion 
(Table 9). This conCrasCs wich Sekellick and Marcus (1980) who 
concluded ChaC Che presence of one DI parcicle/cell abrogaCed Che 
producCion of S virus. A second poinC made in Table 8 is ChaC 
inCerference (measured by several parameCers) by differenC preparaCions 
of DI virus in cells inoculaCed wich apparencly Che same amounC of DI 
virus is variable.
ExaminaCion of Che UV inacCivaCion kineCics of inCerference showed ChaC 
inCerference as measured by RSIA was more resiscanc Chan YRA Co UV 
irradiacion for boch DI viruses examined (Figure 9). This would supporc 
Che proposal ChaC Che Cwo assays are measuring differenC paramecers of 
inCerference. Since UV inacCivaCion of inCerference Cook place .wich 
single hie kineCics ic would appear ChaC Chere ia only one funcCional DI 
RNA genome per virus parcicle.
The UV CargeC sice for inCerference by Cwo DI viruses was larger by YRA 
Chan for RSIA. This suggeaCs ChaC only pare of Che DI virus genome is 
required for inCerference eC Che level of RNA synchesis, while all Che
10'
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genome is required for interference with the production of S virus 
progeny. This may indicate that DI RNA competes with S virus RNA at the 
level of virus assembly and this possibility will be considered later. 
Similar results have been reported by Kowal and Stollar (1980), which 
have shown for SV that the UV target size of interference (measured by 
YRA) was similar to the physical size of the 01 virus genome for virus 
grown in BHK cells, but smaller than that of DI SV derived from mosquito 
cells. Also, Bay and Reichmann (1979), working with VSV, have obtained 
a DI virus with a UV target size smaller than the physical size of the 
genome. Sequence studies on SFV DI RNA by Lehtovaara ejc a 1. (1981,
1982) have shown that DI RNA consists of repeat units and it may be that 
the UV target size of interference by the RSIA corresponds to repeat 
unit(s) of the DI RNA for DI virus p20c. This possibility is supported 
by a repeat unit of 484 nucleotides (1.6 x 10^) for DI SFV clone pKTH301 
(Lehtovaara e£ tl., 1981) a figure similar to the UV target size of 
interference by the RSIA for DI virus p20c.
The results of interference between different strains of SFV showed that 
DI SFV is capable of homotypic and heterotypic interference as measured 
by RSIA which varied upon passage (Tables 10 and 11). These findings 
are contrary to the general opinion that interference by DI virus is 
specific to the homologous S virus although DI particles of the Indiana 
serotype (HR DI 0.46) of VSV can interfere with S virus of the New 
Jersey serotype (Prevec and Kang, 1970; Schnitzlein and Reichmann, 
1976). These observations give further support to the view that 
interference by DI SFV preparations varies on passage (Table 8) and also 
the specificity of interference varies on passage, be it at the level of
11
ratio of YRA: RSIA or homotypic interference.
Examination of the effects of DI virus on virus-polypeptide synthesis in 
co-infected cells also showed that different DI virus preparations 
behaved differently. Co-infection with the highest concentrations of DI 
virus preparations p6 and pl2e abrogated the shut off of host protein 
synthesis and no virus protein synthesis was detectable. Progressive 
dilution of DI virus led successively to shut off of host cell protein 
synthesis, without virus protein synthesis, and then the appearance of 
virus structural polypeptides. This suggests that virus RNAs and not 
proteins are responsible for inhibition of host protein synthesis in 
infected cells, and this has also been suggested by Wengler (1980). 
However, co-infection of cultures with high concentrations of DI SFV 
p20a resulted in the limited synthesis of certain virus-specified 
polypeptides without shut off of host protein synthesis. A similar 
phenomenon was observed with DI SFV pl7a (Figure 16B). This situation 
differs from infection of cells with S virus where shut off of host 
protein synthesis preceeds synthesis of virus structural proteins. The 
differential inhibition of nsp90 and nsp63 is difficult to interpret 
since little is known of their synthesis and their relationship to the 
non-structural polypeptides reported by other groups is uncertain. The 
reason for the difference in interference at the level of polypeptide 
synthesis between DI virus preparations p6/pl2e and p20a is unknown.
Inhibition of virus polypeptide synthesis was 20-fold greater than virus 
RNA synthesis as would be expected from the ampi ificstion which occurs 
on translation of tha mRNA. This extensive inhibition of virus-
111
specified polypeptides could be used as a sensitive assay for DI virus- 
mediated interference but the time needed to perform the assay makes it 
of little use in routine work. However, this indicates that the DI 
virus preparation used contains 20-fold more biologically active 
interfering particles than had been previously calculated by the RSIA 
(Barrett ££ a_K, 1981).
The reduced synthesis of both virion RNA and S virus polypeptides by co- 
infection with DI virus probably both contribute to the reduction in 
numbers of progeny virus particles. Presumably DI and S virus RNA will 
compete for a limited amount of structural proteins available for 
assembly of progeny virus particles. Therefore it can be envisaged that 
interference by DI SFV takes place not only during RNA synthesis, but 
also during assembly of virus particles. These two processes could be 
involved in the reduction in progeny S virus measured in the YRA since 
it is conceivable some DI RNAa interfere efficiently or poorly with 
virus RNA synthesis (RSIA), and then the DI RNAs may also be 
encapsidated efficiently or poorly (YRA?). The results of Kaàriâinen et 
al. (1981) may support this theory (see below).
Synthesis of non-structural polypeptides was inhibited by co-infection 
with DI virus p6. Since these form part of the virus polymerase 
(Clewley and Kennedy, 1976) it would appear that virus polymerase 
activity is reduced in co-infected cultures. Less polymerase would 
result in a reduction in the total amount of virus RNA synthesised as 
observed (Cuild and Stollar, 1975; Barrett e£ *JL., 1981; and Figure 
11). Reduction in synthesis of non-structural polypeptides, may result
1 1 2
from inhibición of translación from Che 42S genomic RNA of Che infecCing 
virus or, more likely, from competición between 01 RNA and Che inpuC S 
virus RNA for newly synthesised polymerase. In contrasc, there was 
little inhibition of synthesis of non-structural polypeptides after co- 
infection with DI virus p20a, suggesting that polymerase activity is not 
inhibited by all DI SFV preparations. Thus, DI virus mediated 
interference of S virus replication should not be thought of as 
"interference at the level of RNA synthesis", but rather interference at 
the level of polymerase synthesis, RNA synthesis and virus assembly.
The results described above suggest that the extent of interference at 
each step will depend on the DI SFV preparation. This theory is
«I Osupported by Kaariainen et a 1. (1981) who have observed that some DI RNA 
species are replicated efficiently, whereas others are not; Chen some 
DI RNA species are encapsidated efficiently, and again others are not.
It is clear from the studies described above that DI SFV preparations 
are heterogeneous in their ability to interfere and vary with each 
parameter examined.
1 1 3
Chapter 2
Protection of Mice by DI SFV
11
Introducción
In mice, virulent strains of SFV cause a lethal encephalitis after i.n. 
inoculation and in 1978 Dimmock and Kennedy reported that administration 
of DI SFV p8 prevented disease and death. Co-inoculation of DI SFV p8 
plus 10 LDjq S SFV was necessary for maximum protection; inoculation of 
DI virus before or after infection resulted in a reduction in the 
protection. Optimally DI virus was given as two inoculations, 2 hours 
apart, with the second containing 10 LD^q S SFV. In this way the 
majority (50-90Z) of DI SFV p8 treated mice were protected. It is 
interesting that protection was achieved with non-purified tissue 
culture fluid containing only 2 x 10^ "pfu equivalents" of biologically 
active DI SFV particles whereas most other systems (see General 
Introduction) have involved high concentrations of purified DI virus. 
Controls showed that protection was not due to the immunogenic load of 
virus inoculated into the mice. Dimmock and Kennedy (1978) also 
presented evidence that DI virus was able to interfere with S virus in 
vivo and reduce multiplication of S virus in the brain by at least 10^ 
fold. Cell culture amplification assays also showed the presence of DI 
virus in the brains of protected mice. A recent study by Crouch et l/ 
(1982) supported the results of Dimmock and Kennedy (1978) and showed 
that the brains of mice protected by DI SFV p8 had no histological or 
histocheaical pathology whatsoever.
In the previous chapter, DI SFV preparations were shown to be 
biologically hatarogeneoua in their ability to interfere mi vitro. To 
date all the in vivo studies with DI SFV have involved DI SFV p8,
therefore the ability of a number of different DI SFV preparations to 
protect mice against 10 LDjg S SFV was examined.
Results
a) Determination of a sub-immunogenic dose of SFV antigen 
In order to analyse the modulation of SFV infection in mice by DI SFV it 
was necessary to distinguish between the intrinsic interfering 
properties of the DI virus and its effects as an immunogen.
Consequently, preliminary experiments were carried out to determine the 
threshold of iomunisation for SFV antigen inoculated by the i.n. route. 
The amount of antigen was measured by haemagglutination (Clarke and 
Casals, 1958) and all DI SFV preparations tested were found to contain 
<4 HAU/ml (Table 13). Using a non-infectious non-interfering antigen, 
prepared by UV-irradiating S SFV, it was found that mice given two 
inoculations of 20 pi of a preparation containing 4HAU/ml 2 h apart, did 
not resist challenge by 100 LD^g S SFV administered i.n. 21 days later 
(Table 17). Consequently this amount of virus antigen could be used in 
the inoculum without the complication of immunogenic effects.
b) Protocol for protection experiments
Aa an  i n t e r n a l  c o n t r o l  f o r  i m mu no g en ic  e f f e c t a  o f  DI v i r u a ,  c o n t r o l  m i c e  
w e r e  i n o c u l a t e d  w i t h  UV i n a c t i v a t e d  S v i r u s  (UV S F V)  d i l u t e d  t o  4 
HAU/ml.  I n o c u l a t i o n  o f  UV SFV t o g e t h e r  w i t h  10 L D j g  S v i r u a  a e r v e d  a l a o  
t o  c o n t r o l  t h e  p o a a i b i l i t y  t h a t  DI v i r u a  was  p r e v e n t i n g  a c c e s s  t o  c e l l
1 16
receptor sites. Table 12 shows this did not occur as the same number of 
mice died after inoculation with 10 LD^g only or 10 LD^g + UV SFV. In 
the experiment shown in Table 12, 10Z (1/10) of mice survived infection 
with 10 LDjg + UV SFV while 70Z (7/10) of mice treated with DI SFV ♦ 10 
LD^g survived. To calculate the extent of protection, the percentage of 
mice surviving 10 LDjg ♦ UV SFV is substracted from the percentage 
surviving after treatment with 10 LDjg ♦ DI SFV. Thus in Table 12, the 
DI SFV protected 60Z of mice. All future experiments will quote the 
protection rather than the actual number of survivors. With 10 LD^g +
UV SFV there were either no survivors or 10Z survivors. Non-inoculated 
control mice or control mice inoculated with UV SFV only or DI SFV only, 
survived infection. In all experiments control mice survived infection 
and will not be discussed further.
c) DI SFV preparations
Details of the passage history, haemagglutination assay, infectivity and 
interference titre (by both RSIA and YRA) of the DI SFV preparations 
used in protection experiments are shown in Table 13. As can be seen,
e oin addition to DI virus DI SFV preparations contain between 10J and 10 
pfu/ml S virus. Since in CFLP mice there are about 600 pfu/LD^g (in 
20|il inoculated by the i.n. route) it was necessary to remove the excess 
infectivity present in DI virus preparations. Although it would be best 
to physically separate S and DI virus, this is not possible for 
alphaviruses (see General Introduction). An effective alternative 
procedure is to inactivate the larger S virus genome (4.3 x 106) by UV 
irradiation which will result in comparatively little inactivation of
117
Table 12 Protection of mice by i.n. inoculation of 10 LDgn and 
PI virus p!3a
Inoculum Survivorst Protection*
No.surviving X
No.inoculated *I
0mQO 1 / 1 0 10
10 LD50 ♦ UV SFV* 1 / 1 0 10
10 LD50 + DI SFV$ 7/10 70
UV SFV only A/A 100
DI SFV only A/A 100
Uninfected* A/A 100
t Survivors at day 9 p.i.
♦ Protection is given by the proportion of mice protected from 10 LDjq 
by inoculation of DI SFV (70Z here) minus the survivors of inoculation 
of 10 LD50 ♦ UV SFV (10Z here).
I UV SFV is UV irradiated non-infectious S virus diluted to a 
concentration of A HAU/ml.
$ DI SFV was UV irradiated to remove infectious virus so that no 
infectivity is detectable by plaque assay afterUV irradiation.
* Control mice were mock-infected with diluent.
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Che smaller DI virus genome (-^ 1 x 10^). The length of exposure was 
chosen Co ensure Chat irradiaCed DI virus preparations contained no 
infectivity detectable by plaque assay. The time of UV irradiation used 
for each reference to DI virus preparation is shown in Table 13.
All reference Co DI virus in this section is to UV-irradiated 
preparations. The effect of irradiation on interfering activity in 
vitro was assayed by the RSIA and YRA. Table 13 shows that there was 
significant inactivation of the interfering activity, but later results 
(see below) indicated that interference measured ^n vitro was of little 
relevance to the ¿n vivo situation. Table 13 also shows that 
interference measured by RSIA was more resistant to UV inactivation than 
that recorded by YRA. The same was observed in the previous chapter 
(Figure 9). There was some variation in the rate of inactivation of 
interference measured by RSIA (for example, DI virus p6 was several 
times more sensitive than other DI virus preparations) which would imply 
that there are variations in the size of Che DI virus genome(s).
d) Prevention of death in SFV-infected mice by DI SFV 
The disease induced in adult CFLP mice inoculated i.n. with 10 LD^q S 
SFV follows a reproducible pattern (Table 14). Mice remain apparently 
healthy until 3 to 4 days p.i. when they show signs of malaise indicated 
by ruffled fur and inactivity. The first signs of central nervous 
system involvement are behavioural changes. These include "vertical 
walking" against Che side of their cage and "continuous aimless walking" 
when they will walk over, rather than around, litter mates. Such
the smaller DI virus genome (<£1 x 10^). The length of exposure was 
chosen to ensure that irradiated DI virus preparations contained no 
infectivity detectable by plaque assay. The time of UV irradiation used 
for each reference to DI virus preparation is shown in Table 13.
All reference to DI virus in this section is to UV-irradiated 
preparations. The effect of irradiation on interfering activity in 
vitro was assayed by the RSIA and YRA. Table 13 shows that there was 
significant inactivation of the interfering activity, but later results 
(see below) indicated that interference measured ^n vitro was of little 
relevance to the in vivo situation. Table 13 also shows that 
interference measured by RSIA was more resistant to UV inactivation than 
that recorded by YRA. The same was observed in the previous chapter 
(Figure 9). There was some variation in the rate of inactivation of 
interference measured by RSIA (for example, DI virus p6 was several 
times more sensitive than other DI virus preparations) which would imply 
that there are variations in the size of the DI virus genome(s).
d) Prevention of death in SFV-infected mice by DI SFV 
The disease induced in adult CFLP mice inoculated i.n. with 10 LDjq S 
SFV follows a reproducible pattern (Table 14). Mice remain apparently 
healthy until 3 to 4 days p.i. when they show signs of malaise indicated 
by ruffled fur and inactivity. The first signs of central nervous 
system involvement are behavioural changes. These include "vertical 
walking" against the side of their cage and "continuous aimless walking" 
when they will walk ovar, rather than around, litter mates. Such
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alternations in the pattern of normal behaviour vary between individual 
mice. Malaise is succeeded by partial paralysis, usually of the hind 
limbs and this is followed by complete paralysis and death by day 5 or 
6. Any survivors on day 7 survive the infection. The virology confirms 
that the brain is the target organ (see Figure 17), and that infectivity
q  i nreaches titre of 10* to 10 pfu/g tissue. Crouch e£ al^ . (1982) showed 
that there was a characteristic though not extensive histopathology, 
involving selective destruction of hippocampal pyramidal cells and 
perivascular cellular infiltration.
Table 14 shows the course of disease in DI virus-treated mice which 
either follow the disease pattern of mice treated with 10 LD^q + UV SFV 
or remain healthy throughout the whole experiment. Similarly there is 
no significant delay in death of DI virus-treated mice.
The reproducibility of the protection experiments is shown in Table IS. 
The mean percentage protection by DI SFV pl3a is 58.6Z. As can be seen 
the results are reproducible and, calculation of the 95Z confidence 
limits (see Appendix) shows that there is little variation in the 
results (50.6Z to 66.4Z). Another DI virus, p4, which has also been 
used in many experiments (Table IS) gave a similar percentage (63.6Z) 
protection and shows the reproducibility of protection between DI virus 
preparat ions.
Table 16 summarises the effects of different DI SFV preparations on the 
outcome of the lethal SFV encephalitis described above. All CFLP mice 
inoculated with S SFV together with all DI SFV preparationa used in this
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Table 16 Protection of mice against a lethal SFV encephalitis
b7 administration of various preparations of DI SFV
DI SFV Survivors+ Mean (.x S.E.M. ) Interference
titre
Preparat ion Z Z RS LA YRA
p4 ★ 63.6 ± 4.4 8 44
P5 0, 10 5.0 14 <4
p6 0. 0, 0 0.0 ± 0.0 44
p8 60, 70 65.0 100 N.D.
p9b 60, 67 63.5 8 44
P91 30 - 1 1 44
pll 30, 30 30.0 <4 44
pl2g 0, 0, 10 3.3 t 3.3 n<4 44
pi 3a * 58.6 i 4.0 6 8
pl3d 44, 50, 50, 70 53.5 i 5.7 16 8
pl3h 30, 50, 50, 60, 70 52.0 t 6.6 28 12
P23 0, 0 0.0 «4 44
t From Table 13; after UV-irradiation.
♦ At 9 days after p.i.; each figure represents a separate experiment in 
which 9 or more mice were inoculated with 10 LDjq ♦ DI SFV.
* See Table 15
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study either follow the normal course of infection or show no sign of 
infection whatsoever. There are three categories of DI virus: 1. those 
which protect over 50Z of infected mice given 10 LDjg (DI virus 
preparations p4, p8, p9b, pl3a, pl3d, pl3h); 2. those which protect a 
minority of mice (p91, pll, pl2g), and 3. those which do not protect 
(pS, p6, p23). This variation was specific for individual DI virus 
preparations and the extent to which an infection was modulated was 
reproducible. DI virus p8 was the same preparation used by Dimmock and 
Kennedy (1978) and gave the same level of protection as described by 
these workers.
e) Correlation between protection by DI SFV and its passage history 
No correlation was seen between the ability of DI viruses to protect 
mice and their passage history. For example, DI virus p4 gave 
protection but lost this property when passaged to produce DI virus p5 
or p6. On the other hand, mouse protection can be gained on passage as 
DI virus pl2, which protected poorly, gave rise to DI viruses of pl3 
which all gave good protection. However, the properties of DI virus 
preparations did not arise at random but were determined by the parental 
inoculum aince the aiater atocks pl3a, pl3d and pl3h all had a aiailar 
ability to protect. Similar characteriatics on passage were also seen 
with interfering properties _in vitro (see Table 6).
1 25
f) Comparison between protection in vivo and interference 
titre-in vitro by PI SFV preparations 
There was no correlation between ability of DI virus to protect mice and 
their interference titres in cell culture measured by the RSIA and YRA 
(Table 16). Although DI virus p8 had a high titre by RSIA it protected 
mice only as well as DI viruses pl3a, pl3d or pl3h which had a 4-fold or 
more lower titre. DI viruses p5, pl3a, pl3d and pl3h had similar 
interference titres by RSIA but only DI virus of the passage pl3 level 
protected mice. Interference measured by the YRA was no better guide to 
the ability to protect mice since DI virus p4 and p9b, which had no 
detectable YRA titre, protected as well as DI viruses pl3a, pl3d and 
pl3h which registered a positive value. It is concluded that DI virus 
which protects mice is qualitatively different from the DI virus which 
interferes in the ¿n vitro assays.
g) Challenge of DI SFV-protected mice by S SFV at 21 days 
after the initial infection
Mice which had been protected by DI virus from a lethal SFV infection 
were challenged at 21 days p.i. with 100 LDjq i.n. to determine if they 
had developed a protective immune response (Table 17). All mice 
inoculated with UV SFV, the immunogen control which contained 4 HAU/ml,. 
succumbed to the challenge as did mice inoculated with the DI virus 
preparations alone. Thus the non-infectious virus preparations are not 
immunogenic.
When mice which had survived inoculation with 10 LDjq through
126
Table 17
io ld50
Ability of mice which had been protected from SFV
administration ÎT DI virus to survive a second
z
inoculation of
First inoculum 
DI
virus
SFVt
UV SFV 
ant igen
Survivors 
No. Surviving 
No. Inoculated
0/19 0
- - ■4 0/17 0
- p4 - 0 /1 2 0
♦ p4 - 1 / 2 1 5
- p8 - 0/8 0
4- P8 - 1/18 6
- p9b - 0/6 0
4» p9b - 6 /1 2 50
- Pll - 0/8 0
4» Pll - 1 /8 13
- pl3a - 2 / 1 1 18
♦ pl3a - 17/21 81
- pl3h - 0/8 0
4 pl3h - 11/13 85
t Mice were given 100 LDjq i.n. 21-24 days after the first inoculum. 
Results shown are with mice taken from the type of experiment described
in Table 16
Table 18 Ability of mice which had survived administration of
10 LDçn +• UV PI virus, or PI virus only to survive
a second inoculation of 10 LD jq S SFV
First inoculum Challenge survivors*
No. surviving Z
No. inoculated
Uninfectedt 0/9 0 
UV DX virus p4 0/4 0 
10 LDjq+UV DI virus p4 14/15 93 
UV DI virus pl3a 0/4 0 
10 LDjq ♦ UV DI virus pl3a 3/4 75
* Mice were given 10 LD^q i.n. 21-24 days after the first set of 
inoculations.
t Mice were inoculated with diluent only
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administration of DI viruses p6, p9b, pl3a or pl3h were challenged 21 
days later with 100 LD^g SFV, the majority (>50Z) were completely 
resistant and showed no signs of infection. However, those mice which 
had received 10 LD^g plus DI viruses p4, p8 or pll were susceptible to 
the challenge and died after infection had followed its normal course.
Thus although DI viruses p4 and pl3a modulated the primary SFV infection 
to the same extent (64 and 59Z survivors respectively, Table 15) they 
differed entirely in their ability to establish an adaptive immunity 
against the challenge by 100 LD^g S virus. To determine whether 
adaptive immunity was all-or-nothing mice protected by DI viruses p4 and 
pl3a were challenged with 10 LD^g S virus at 21 days p.i. (Table 18).
The results show that DI virus p4 treated mice are resistant to 
challenge by 10 LDjg S virus while control mice succumbed. Thus the 
extent of adaptive immunity of mice infected with different DI virus 
preparations varies rather than being all-or-nothing. This may explain 
the result of mice treated with 10 LDjg ♦ DI SFV p9b where 50Z survive 
challenge with 100 LDjg (Table 17).
h) DI virus preparations standardised for haemagglutination and 
interference titre
For clarity, the different types of modulatory effects of DI SFV 
preparations described above are illustrated by reference to 3 DI virus 
preparations, p4, p5 and pl3a (Table 19). These 3 DI viruses contain 
the same amount of SFV antigen by haemagglutination (4 HAU/ml) and 
similar interference titres by RSIA. DI viruses p4 and p5 had no
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detectable interference titre by YRA, while DI virus pl3a had a low 
titre (8 DlU/ml). DI viruses p4 and pl3a protected similar numbers of 
mice (64 and 59Z respectively) while DI virus p5 protected only 5Z 
(Table 16). Although DI viruses p4 and pl3a protected similar numbers, 
DI virus p4-treated mice were susceptible to challenge by 100 LD^q S 
SFV, while pl3a-treated mice were resistant. Thus, although all 3 DI 
virus preparations contained the same amount of SFV antigen and similar 
interference titres as measured by RSLA there were clearly two 
categories of DI virus, those which protected mice (p4 and pl3a) and 
those which did not (p5). Similarly although different DI virus 
preparations may protect similar numbers of mice, the mice may have weak 
or strong adaptive immune responses. It is concluded that there are at 
least 3 qualitatively different categories of DI virus preparations with 
respect to their ability to protect mice against a lethal SFV 
encephalitis.
i) Neutralizing antibody induced during SFV infections of mice 
The inability of some DI SFV preparations to protect against re­
infection by 100 LDjq SFV was further investigated by measuring serum 
and brain neutralizing antibody (Table 20). As a control, mice.were 
inoculated i.n. with avirulent SFV and these mice all responded with a 
mean serum titre of 1683 (Table 20). In contrast, both groups of mice 
protected by DI virus responded poorly and few p4 (3/11) and pl3a (3/12) 
treated mice had titres exceeding 10Z of the avirulent value. These 
results indicate that the ability of DI SFV pl3a to initiate a strong 
immune response ie not reflected by the serum neutralizing antibody
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or undetectable: avirulent SFV-infected mice had low titres (average ” 
61), while of mice inoculated with 10 LDjq virulent SFV only 2/11 
treated with DI virus pl3a had detectable antibody (titre ” 14).
For DI virus-treated mice there was little correlation between the titre 
of neutralizing antibody in the serum and that in brain. IgM antibody 
levels were not determined.
titres. comparison, all brain neutralising antibody titres were low
j) Effect of DI SFV upon a heterologous virus infection 
Since DI viruses p4 and pl3a protect similar numbers of mice against 10 
LD^q yet differ in their post-infection immune status, it is possible 
that DI SFV p4 protected mice by stimulation of a non-adaptive immune 
response such as interferons, natural killer cells or macrophages. This 
was examined by co-inoculating mice with a heterologous neurotropic 
picornavirus, encephalomyocarditis (EMC) virus. EMC virus causes a 
flacid paralysis readily distinguishable from SFV and death ensues at 4 
days p.i. Mice inoculated with DI SFV p4 or pl3a + 10 LD^q SFV * 10 
LD50 EMC all died although in parallel groups the DI viruses protected 
against SFV alone as expected (Table 21). Calculation of the mean day 
of death showed that DI SFV did not delay death in mice inoculated with 
EMC. These findings suggest that there is no overwhelming non-adaptive 
immune response involved in the protection of mice against 10 LOjq SFV 
by either DI SFV p4 or pl3a.
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Table 21 Effect of DI SFV on a heterologous virus infection in mice*
Inoculum* Survivors* z Mean day of death*
EMC 0 /10 0 4.1
EMC + UV SFV 0/8 0 4.1
SFV + UV SFV 0 /10 0 4.9
SFV ♦ EMC ♦ UV SFV 0 /10 0 4.9
DI virus pl3a + SFV 7/10 70 5.4
DI virus pl3a + EMC 1 / 1 0 10 3.7
DI virus pl3a ♦ EMC ♦ SFV 0/11 0 4.6
DI virus p4 ♦ SFV 5/10 50 5.2
DI virus pl3a ♦ EMC 0 /10 0 4.6
DI virus pl3a ♦ EMC + SFV 0/11 0 5.1
* Mice were inoculated according to Methods. For EMC in CFL.P mice there
are 100 pfu/LD^Q (in 20 pi inoculated by the i.n. route).
* 10 LD50 EMC; 10 LD50 SFV.
t number of mice surviving/ number of mice inoculated.
t Mean day of death is the sum of the day on which each mouse died 
divided by the number of dead mice.
k) Do interferons affect protection of mice by DX SFV?
The results described above with EMC virus suggest that non-adaptive 
immune responses such as interferon are not involved in protection. To 
examine this possibility further, the DI virus preparations used in 
protection experiments were assayed for the presence of interferon.
Since DI SFV preparations are propagated in BHK cells and used in mice 
they were tested for the presence of hamster or mouse tA. and 
interferons. Table 22 shows that no interferons were detected in any of 
the DI SFV preparations assayed (p4, pl2g, pl3a) and that hamster 
interferon was inactive on mouse cells and vice versa.
A different way to test for the possible role of interferon was to 
actually add the substance to DI virus prior to co-inoculation of mice. 
Table 23 shows that 1000 units intereron (in a 20 pi volume) did
not prevent the disease caused by 10 LD^q S SFV. Also this dose of 
interferon did not enhance protection by DI viruses p4 and pl3a, and the 
non-protecting DI SFV pl2g did not protect when interferon was added to 
the inoculum. Therefore there is no evidence to suggest that interferon 
plays any role in the protection of mice by DI SFV preparations. 1
1) Effect of mouse-strain upon the extent of protection by DI SFV 
Different mouse strains were compared to see if the genetic background 
of the host influenced their capacity to be protected by DI virus 
against the lethal encephalitis caused by i.n. inoculation of 10 LDjq S 
virus (Table 24). Both CFP and Porton random bred strains of mice had a 
similar pfu:LDjg ratio (6 x 10^ pfu) while that of an inbred strain,
1 35
Table 22 Presence of Interferon in DI SFV preparations
Sampiet Interferon Titret (logjQ units/ml)
Mouse Cells Hamster Cells
DI SFV p4 {0.6 { 0.6
DI SFV pl2g {0.6 {0.6
DI SFV pi 3a { 0.6 { 0.6
Mouse interferon 3.2 { 1 .6
Hamster interferon { 1 .6 3.0
t DI virus preparations were treated as described in Methods 
to remove biologically active virus.
t Samples were titrated on 1,929 cells to measure mouse interferon 
and Chinese hamster ovary cells to measure hamster interferon, 
interferon standards were prepared by induction of the two cell types 
above with Newcastle disease virus. Therefore these standards consist 
of a mixture of cr and S interferon species. Interferon titres are
expressed in arbitary units
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Table 23 Protection of mice by 10 LD g^ DI SFV with the addition 
of interferon to the inoculum
Inoculumt Protection (Z)
10 LD50 + UV SFV 0
" ♦ UV SFV ♦ IFN* 10
" ♦ DI SFV p4 73
'• ♦ DI SFV p4 -t- IFN 60
" ♦ DI SFV pl2g 0
" ♦ DI SFV pl2g ♦ IFN 0
" > DI SFV pi 3a 55
" ♦ DI SFV pi 3a ♦ IFN 50
t Mice were inoculated with the protocol described in the Methods.
Where indicated 10 units of IFN was present in each inoculum.
* IFN • interferon.
Table 24 Variation in the ability of different strains of mice 
to be protected from SFV-mediated lethal encephalitis 
by administration of D1 SFV
Protection* (Z)
Mouse strain PFU/LD^q
10LD50 DI virus p8 IOLD^q DI virus pi 3a
Porton 6 x 102 12.5 N.D.
CFLP 6 x 102 70 70
CjH-He/Mg 1.5 x 104 N.D. 0
t Protection is number surviving/number inoculated
N.D. - not done
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C3H-He/Mg was 1.5 x 10^ pfu. Inoculation of DI SFV p8 plus 10 LD^g into 
CFLP mice results in 70Z of mice surviving the lethal encephalitis, 
while inoculation of the same virus combination into Porton mice gave 
only 12.5Z survivors. Since the LDjq of S virus is the same in both 
strains of mice, it is concluded that host factors are influencing the 
extent of DI virus-mediated protection. Inoculation of DI SFV pl3a plus 
10 LD50 into CFLP and C3H-He/Mg mice protected 70Z of CFLP mice but none 
of the C3H-He/Mg treated mice. As with experiments with CFLP mice, 
Porton and C3H-He/Mg mice inoculated with DI SFV plus 10 LD^q either 
remained completely healthy throughout the experiment or died of 
apparently the same disease contracted by mice inoculated with S SFV 
alone. Death was not delayed nor were there any aberrant signs of 
disease in DI SFV-treated mice. The lack of protection in C3H-He/Mg 
mice probably results from the 25-fold greater amount of S SFV required 
for a lethal dose.
Although these results indicate that host factors are involved in the 
protection phenomenon, Table 25 shows that protection of CFLP mice was 
not affected by the sex of mice inoculated. DI viruses pA and pl3a 
protected both sexes equally.
a) Effect of concentration of DI and S virus upon protection by DI SFV 
The aaount of DI virus required for protection was determined by 
inoculating mice with serial dilutions of DI SFV together with 10 LDjg S 
SFV (Table 26). The results show that with both DI viruses exaained (p4 
and pl3a) the concentration of DI virus inoculated was critical for
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Table 25 Protection of male and female CFLP mice from SFV-mediated 
encephalitis by the administration of D1 virus
Inoculum
Protection* (%)
Male mice Female mice
10 LD^q ♦ DI virus p4 77 64
10 LD^q ♦ DI virus pl3a 45 41
t Protection is number surviving/number inoculated 
At least 14 mice were inoculated in each group.
Table 26 Protection of CFLP mice against 10 LDc;» S SFV using
dilutions of DI SFV
Dilution of DI virus
Protection* (Z)
10 LD50 DI virus p4 10 LDjq DI virus pl3a
1 / 1 73 60
1 / 2 9 20
1/5 10 10
1 / 1 0 0 0
tProtection is number surviving/number inoculated
M l
protection of mice, since a 2-fold dilution of DI virus was sufficient 
to reduce protection. This result may explain why some DX SFV 
preparations appear unable to protect mice although there was still 
slight protection with a 5-fold dilution of DI virus.
To follow this up it was determined if protection depended upon the 
absolute amount of DI virus inoculated per mouse or the ratio of DI 
virus: S virus. Table 27 shows that increasing the quantity of S virus 
inoculated reduced protection by both DI virus p8 and pl3a, suggesting 
that the ratio of DI virus to infectivity is a critical factor in 
protection.
n) Infectivity content of DI SFV preparations
As described above (section c) DI SFV preparations were UV irradiated 
until they contained no infectious virus detectable by plaque assay 
(^2.5 pfu/ml) before administration into mice. On a few occasions some 
mice inoculated with such apparently non-infectious preparation died 
with a typical SFV disease. To understand why these mice were dying two 
sets of experiments were performed. Firstly, three DI virus 
preparations were each UV irradiated for 50 sec to reduce the amount of 
infectivity present (Table 28). The plaque assays showed a lack of 
proportionality in the dose-response relationship since more plaques 
were obtained at 1 / 1 0  dilution than at undiluted.
Secondly, it was determined whether or not the DI virus present in a DI 
virus preparation could inhibit the formation of plaques by adding a
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Table 27 Protection of mice by PI virus against inoculation of various 
amounts of S SFV
No. LD^q inoculated
Protection (Z)
DI SFV p8t DI SFV pl3a*
3 25 N.D.
10 12.5 60
20 N.D. 30
30 0 13
t DI SFV p8 was inoculated into Porton mice and DI SFV pl3a into 
CFLP mice.
N.D Not done
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Table 27 Protection of mice by PI virus against inoculation of various 
amounts of S SFV
Protection (%)
No. LD^q inoculated
DI SFV p8t DI SFV pl3af
3 25 N.D.
10 12.5 60
20 N.D. 30
30 0 13
t DI SFV p8 was inoculated into Porton mice and DI SFV pl3a into 
CFLP mice.
N.D. ■ Not done
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Table 28 Infectivity titration of UV irradiated PI SFV preparations
DI SFV 
preparation
dilution of plaque assay of UV irradiated DI SFVt
1/1 1/10 1/100
P5 0 0
pi 3d 3 9 1
pl3h 0 4 0
t 1 ml samples of each DI virus preparation were taken and UV irradiated 
for 30 sec. according to the procedure described in Methods. Residual 
infectivity was titrated by plaque assay.
known number of pfu to UV-irradiated DI virus (Table 29). DI SFV 
preparation pl3d which had been irradiated for 50 sec was used as a 
diluent for a preparation of S virus which itself contained no 
detectable DI virus by either RSLA or YRA.
The infectivity titration using a PBS diluent produces a normal plaque 
assay titration and DI virus alone gave a small number of plaques. 
However, with undiluted UV DI SFV as diluent, plaque formation was 
greatly inhibited. This inhibition diluted out at 1/10 and 1/100.
Thus the plaque assay is not a reliable guide to residual infectivity 
present in DI virus preparations and the presence of a considerable 
amount of infectious virus could be concealed. To overcome this problem 
all UV DI SFV preparations were tested in mice prior to use in 
protection experiments. The above findings may explain the different 
results obtained for the ratio of biologically active DI virus to 
particle quoted in the literature (Schlesinger at al.. 1972; Logan, 
1979; Kowal and Stollar, 1980).
Discussion
Evidence has been presented that DI SFV preparations are heterogeneous 
in their ability to protect mice. Some protect and others do not; of 
those which protect some (e.g. DI SFV pl3a) confer strong immunity to a 
subsequent lethal challenge, whilst others (e.g. DI SFV p4) leave the 
mice with weak immunity. It would appear that the extent of immunity to
Table 29 Infectivity titration of a S virus preparation using a
DI SFV preparation as diluent
LogjQ dilution of Log^g dilution of S virus in DI SFV "diluent"t
DI SFV used as
diluent 5 6 7 8 9  None
0 30 15 10 5 0 3
1 CONt CON 53 22 11 9
2 CON CON 35 A 5 1
3 CON CON 28 2 0 N.D.A
PBS* CON CON 37 3 0
t DI SFV preparation pl3d was UV irradiated for 50 sec and then used as 
diluent for an infectivity titration of a S virus preparation.
+ PBS was used as diluent in place of UV DI SFV.
* CON: confluent plaques; N.D. : not done
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Table 29 Infectivity titration of a S virus preparation using a 
PI SFV preparation as diluent
Log|Q dilution of Logjg dilution of S virus in DI SFV "diluent”t
DI SFV used as
diluent 5 6 7 8 9 None
0 30 15 10 5 0 3
1 CONt CON 53 22 11 9
2 CON CON 35 4 5 1
3 CON CON 28 2 0 N.D.*
PBS* CON CON 37 3 0
t PI SFV preparation pl3d was UV irradiated for 50 sec and then used as 
diluent for an infectivity titration of a S virus preparation.
♦ PBS was used as diluent in place of UV PI SFV.
é CON: confluent plaques; N.P.: not done.
challenge varies with Che DI virus used Co proCecC mice. ProCecCion 
varied independently of passage history buC sisCer sCocks proCecCed mice 
Co similar exCenCs. This variabiliCy of DI SFV j_n vivo is consisCenC 
with che findings ChaC inCerfering propercies of DI SFV ^n vicro are 
heCerogeneous (see ResulCs, ChapCer 1). None of Che 3 aspecCs of 
inCerference sCudied in vitro (RSIA, YRA and virus proCein synchesis) 
appear Co correlaCe wich inCerference in Che infecCed mouse. Thus Che 
RSIA and YRA cannoC be used Co predicC which DI virus preparacions 
modulaCe SFV infecCions ^n vivo and consequenCly may be of no use in 
measuring DI virus in Che mouse (see ResulCs, ChapCer 3).
ProCecCion was shown Co resulc in mice being eicher suscepCible or 
resisCanC Co re-challenge wich 100 LD^q depending upon Che DI SFV 
preparaCion used. Alchough mice CreaCed wich 10 LD^q + DI virus p4 were 
suscepCible Co challenge wich 100 LD^q , Chey resisCed challenge wich 10 
LD^q . Clearly immuniCy Co challenge is noC a 11-or-noChing buC raCher 
sCrong or weak depending on Che DI virus preparaCion used Co proCecC 
mice. If DI viruses such as p4 only sCimulaCe weak adapCive immune 
rsponses, ic is difficulc Co envisage Chese processes conCribuCing 
(ready Co recovery from Che SFV infecCion. Wich such SFV DI virus 
preparacions ocher facCora muse be involved in proCecCion since BI SFV 
preparaCiona p4 (weak adapCive immune response) and pl3a (ecrong 
adapCive immune response) proCecCed similar numbere of mice (64 and 59X 
res pecCively). Possibly, proCecCion ia mediaCed entirely through DI 
virus-mediated inCerference as wich DI lymphocytic choriomeningicia 
virus (Welsh £t a_l., 1977), or DI virus stimulates non-adapeive immune 
responses (such as interferons, macrophages, natural killer cells) as
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suggested for DI VSV in hamsters (Fultz al., 1982a). The fact that 
the SFV disease is so rapid also suggests that adaptive responses will 
not play a role in recovery. Stimulation of non-adaptive responses was 
investigated by co-inoculation with EMC virus, which is sensitive to the 
effects of interferon (Gresser e_c a 1., 1976). No modulation of the EMC 
virus infection was observed by administration of DI SFV suggesting that 
non-adaptive immune responses are not involved in protection. However, 
it should be remembered that the above experiment cannot exclude a 
localized non-specific response to infection which would affect SFV but 
not EMC virus. The possibility that protection was mediated through 
interferon present in the inoculum was discounted (Table 22), and 
similarly it was shown that administration of interferon in the inoculum 
did not enhance protection. Although interferon has not been assayed in 
the DI virus-treated mice, the results above suggest that interferon 
does not play a role in the protection of mice by DI virus. The current 
situation argues that protection of mice by some DI virus preparations 
may be mediated through DI virus-mediated interference and/or non­
specific immune responses yet to be identified.
Chapter 3
inInhibition of SFV multiplication tissues of DI virus-treated mice
Introduction
The studies in the previous chapter have shown that DI SFV preparations 
can protect mice against 10 LD^q S SFV. Therefore, it was decided to 
investigate interference in virus multiplication in the mouse. DI virus 
p4 and pl3a protected similar numbers of mice, but those protected by DI 
virus p4 had a weak adaptive immune response while those protected by DI 
virus pl3a had a strong adaptive immune response. This suggests 
differences in the way in which these 2 DI viruses protect mice and 
therefore both viruses were further investigated. Mice were inoculated 
as before with 10 LDjq together with DI SFV p4 or pl3a, and at intervals 
after infection, tissues were examined for infectivity and the presence 
of DI virus.
Results
a) Growth curve of infectivity in mice after i.n. inoculation 
Figure 17 shows the growth curve of 10 LDjq (600 pfu/LD^Q> S SFV in CFLP 
mice after i.n. inoculation. The serum, spleen, brain (minus olfactory 
lobes) and olfactory lobes were assayed for infectivity. Virus Was 
first detected in the olfactory lobes at 12 h and this increased up to 3 
days p.i. Virus appeared to spread posteriorly and appeared in the 
rest of the brain at 1 day p.i. Infectivity increased until 4 days 
p.i. when peak titres (up to 10^ pfu/brain) ware, detected. Virus was 
only detected in spleen and serum from day 2 p.i. where virus titres 
reached 106 pfu/mouse. Mice showed clinical signs of disease on day 3
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Figure 17. Growth curve of S SFV in CFLP mice after i.n. 
inoculation of 10 LD^n ♦ UV SFV
Groups of 8 mice were killed at various times p.i. and 
for infectivity. Error bars are * 1 S.E.M. On day 5 
mouse was alive for sampling. brain (minus olfactory 
olfactory lobes A; spleen#; serum i.
tissues assayed
p.i. only one 
lobes) o;
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and died either on day A or day 5 p.i. It is rare for an animal to 
survive until day 6.
b) Multiplication of virus in mice co-infected with PI and S SFV 
Groups of 8 mice were inoculated with DI SFV plus 10 LDjg S virus or 10 
LD50 S virus plus UV SFV according to the protocol described previously 
(Dimmock and Kennedy, 1978). Mice were killed at intervals after 
inoculation and the infectivity present in serum, spleen, brain (less 
olfactory lobes) and olfactory lobes determined. The results obtained 
for DI SFV preparations pA and pl3a are shown in Figures 18 and 19 
respectively. Death of mice after day A p.i. reduced numbers of mice 
available for sampling.
c) Mice treated with DI SFV pA
Comparison of the infectivity titres in mice treated with 10 LD^q + DI 
SFV pA with those found in mice inoculated with 10 LD^q ♦ UV SFV (Figure 
18) shows that the DI virus-treated mice can be divided into two 
classes: 1 ) those which have virus titres reduced by £99Z and, 2 ) those
which have titres which were not significantly different. The 
distribution of the two classes of virus titres in the four tissues 
examined is shown in Table 30. Overall 58Z of the DI virus treated mice 
infectivity titres from the four tissues examined were in the reduced 
infectivity group. This figure compares favourably with lethality 
studies where 6AZ survived (Table IS). Thus the first group can be 
equated with mice which would have been protected from death by DI virus
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Figure 18a Multiplication of SFV in mice inoculated with 
10 LD.;n and treated with PI SFV p4 - brain, 
and olfactory lobes
Mice were inoculated with 10 LDjg ♦ UV SFV or 10 LDjq ♦ DI SFV p4 and 
sacrificed at various times after infection. Curves represent mean 
infectivity titres of detectable virus for sample 10 LD^q ♦ UV SFV. 
Arrows with adjacent number refers to the number of mice with 
undetectable infectivity. 10 LDjq + UV SFV #; 10 LD^q ♦ UV DI SFV p4
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Figure 18b Multiplication of SFV in mice inoculated with 
10 LDun and treated with PI SFV p4 - serum, 
and spleen
Mice were inoculated with 10 LDjq ♦ UV SFV or 10 LD^g ♦ DI SFV pA and 
sacrificed at various times after infection. Curves represent mean 
infectivity titres of detectable virus for sample 10 LDjq ♦ UV SFV. 
Arrows with adjacent number refers to the number of mice with 
undetectable infectivity. 10 LDjq ♦ UV SFV #; 10 LDjq ♦ UV DI SFV p4
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Table 30 Proportion of infectivity in tissues from mice treated with 
1_0_LD50 ♦ PI SFV p4
Time p.i. Proportion of infectivity titres reduced in tissue samplet
(days) olfactory lobes brain spleen serum
0.5 0 /8 0/8 0/8 0/8
1 8/8 0/8 0/8 0/8
2 3/8(-2)* 2/8 2/8C-1 ) 5/8(—3)
3 6/8 7/8 8/8C-1 ) 8/8
4 4/8 5/8 5/8 7/7C-1)
5 4/4 4/4 4/4C-2) 4/4C-2)
t No. mice with reduced infectivity/No. mice sampled.
Reduced infectivity is defined arbitrarily as >99Z reduction in 
infectivity compared to mean infectivity of mice treated with 10 LDjq 
♦ UV SFV. All samples after day 5 p.i. had reduced infectivities.
* number in bracket refers to number of mice from group infected with 
10 LD50 ♦ UV SFV which have "reduced" or no detectable infectivity.
Data from Fig. 18.
and the second group with mice which would have died with the disease 
following its normal course. Of course, interpretation would be easier 
had 01 virus been 100Z protective. Examination of Figure 18 shows that 
up to day 2 p.i. infectivity titres in the brain, olfactory lobes and 
spleen in DI virus-treated and non-treated mice were virtually 
identical, whereas infectivity titres in the serum were lower in DI 
virus-treated mice than non-treated mice. However, the majority of 
samples from DI virus-treated mice taken from day 3 onwards have lower 
infectivity titres than those of untreated mice. Many of these samples, 
and all taken from day 7 p.i. onwards, had undetectable levels of 
infectivity (brain 83Z, olfactory lobes 96Z, spleen 100Z, serum 90Z of 
mice sampled contained ^ 400 pfu/tissue).
d) Mice treated with DI SFV pi 3a
Infectivity titres obtained from mice infected with 10 LDjq plus DI SFV 
pl3a can again be divided into two classes (Figure 19). the 
distribution of the two classes of infectivity titres in the four 
tissues examined is shown in Table 31. Sixty-eight percent of all the 
infectivity titres from the four tissues examined were in the group 
defined as having titres reduced by ^99Z compared with mice not treated 
with DI virua. This figure is close to the 59Z survival achieved by 
treatment with DI SFV pl3a in lethality experiments (Table 13). The 
pattern of infectivity titrea in DI SFV pl3a-treated mice was different 
from that found in DI SFV p4-treated mice. Whereas the latter group had 
infectivity titres identical to non-treated mice up to day 2 p.i., mice 
which had been inoculated with 10 LDjq plus DI SFV pi3a had reduced
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Figure 19a Multiplication of SFV in mice inoculated with
10 LD5Q and treated with UV PI SFV p!3a - brain, 
and olfactory lobes
Mice were inoculated with 10 LD^q + UV SFV or 10 LD^q ♦ UV DI SFV pl3a 
and sacrificed at various times after infection. Curves represent mean 
infectivity titres of detectable virus for sample 10 LDjq ♦ UV SFV. 
Arrows with adjacent number refers to the number of mice with 
undetectable infectivity. 10 LDjq ♦ UV SFV •; 10 LD^q ♦ UV DI SFV pl3a
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Figure 19b. Multiplication of SFV in mice inoculated with
10 LDgi] and treated with UV PI SFV p!3a - serum, 
and spleen
Mice were inoculated with 10 LD^q ♦ UV SFV or 10 LD^q ♦ UV DI SFV pl3a 
and sacrificed at various times after infection. Curves represent mean 
infectivity titres of detectable virus for sample 10 LDjq + UV SFV. 
Arrows with adjacent number refers to the number of mice with 
undetectable infectivity. 10 LD^q + UV SFV 10 LD^q ♦ UV DI SFV pl3a
A ..
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Table 31 Proportion of infectivity in tissues from mice treated with 
10 LD;o ♦ PI SFV p!3a
Time p.i. Proportion of infectivity titres reduced in tissue samplet
(days) olfactory lobes brain spleen serum
0.5 0/8 0/8 0/8 0/8
1 5/8(-2 )* 0/8 0/8 0/8
2 4/8 6/8 4/8C-1) 8/8C- 1  )
3 5/8 5/8 4/8C-1) 7/8(-l )
4 7/8 7/8C-2) 8/8 8/8
5 3/5 4/5 4/5(—1 ) 5/5<-l)
t No. mice with reduced infectivity/No. mice sampled.
Reduced infectivity is defined arbitrarily as ^99Z reduction in 
infectivity compared to mean infectivity of mice treated with 10 LDjg 
♦ LTV SFV. All samples after day 5 p.i. had reduced inf ec t ivit ies.
* number in bracket refers to number of mice from group infected with 
10 LDjq ♦ UV SFV which have "reduced"or no detectable infectivity.
Data from Fig. 19.
infectivity titres at all time points examined. There was little virus 
in serum (compared with other tissues) of DI virus-treated mice, but 
infectivity titres in the spleen on days 2 and 3 p.i. showed little 
reduction compared to mice which did not receive DI virus. These 
results demonstrate that DI virus not only prevents the encephalitis but 
also prevents spread of virus into other tissues. Inspection of 
infectivity titres of mice which comprise the group of individuals in 
which titres were reduced ^99Z showed that majority contained no 
detectable virus (brain 81Z, olfactory lobes 92Z, spleen 92Z, serum 92Z 
of mice sampled contained <400 pfu/tissue). At days 7, 11 and 14 p.i. 
no mouse had virus detectable «400 pfu/mouse) in any of the tissues 
investigated. An exception was a single mouse which at day 14 had a
A Qbrain infectivity titre of 10 pfui but none in the other three 
tissues examined.
e) Disproportionate reduction in infectivity titres in some tissues 
of some mice in which infections were modulated by DI SFV p!3a 
As discussed above, mice inoculated with DI SFV pl3a fell into two 
classes (a) those with infectivity titres reduced by ^99Z compared with 
mice infected with 10 LDjq ♦ UV SFV and (b) those with titres unaffected 
by inoculation of DI virus. In the majority of mice, the levels of 
infectivity in each of the four tissues investigated were either 
consistently low or consistently high, and the latter were 
indistinguishable from mice inoculated with 10 LDjq * UV SFV (Figure 
17). However, 9 mice treated with DI virus pl3a had infectivity titres 
which did not fit with either pattern. These had high titres in one or
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more tissues and low titres in the others (Table 32). For example, 
mouse 6 on day 2 had no detectable virus in brain and serum, and yet 
there were high titres in the olfactory lobes and spleen, whereas no DI 
virus-treated mice (mouse 1 on day 2 ) had similar titres in the 
olfactory lobes and spleen, but MO^-fold more virus in the brain and 
•^10 • -fold more virus in the serum. It must be emphasised that only 
9/62 (14.52) had this unusual pattern of virus infection. This effect 
was only seen with DI virus pl3a and none of the mice treated with DI 
virus p4 showed an unusual pattern of virus infectivity. Particularly 
noteworthy is the presence of virus in brain at 14 days after infection 
when one would have expected immune processes to have cleared virus 
completely.
f) Failure to detect DI virus in DI virus-treated mice
It was of obvious interest to follow the levels of DI virus in the above 
experiments. In an attempt to do so the YRA and RSIA were used as these 
appear to measure different parameters of interference. Both assays 
failed to detect DI virus in either brains or olfactory lobes of DI 
virus p4 or pl3a treated mice. This result was unexpected since it has 
been demonstrated that inoculation of DI virus prevents death and 
inhibits virus multiplication. Possible explanations are that the 
assays may not be sufficiently sensitive (both the YRA and RSIA detect a 
minimum of 10^*^ DI particles/250 pi), that DI virus which interferes 
in mice does not register by these assays, or that DI virus is not 
propagated in the mouse. The latter suggestion would conflict with the 
results of Dimmock and Kennedy (1978) who detected DI virus in mouse
Table 32 Infectivity titres in tissues of individual mice
inoculated 'with 10LDcn ♦ UV DI SFV pi 3a*
Day p.i. Mouse No. Infectivity (logjg pfu/tissue)
brain olfactory lobes spleen serum
2 1 7.3 6.9 3.2 4.4
2 < 2.0 <1.7 2.6 < 2.6
3 <1.7 5.7 3.0 < 2.6
3 1 8.8 6.5 4.0 5.2
2 <1.3 < 2.0 3.6 4.3
4 <1.3 5.2 3.0 < 2.0
6 4.0 4.2 3.3 3.1
8 5.2 <1.7 <1.4 < 2.6
5 1 7.5 5.7 2.8 4.6
2 3.4 5.1 < 2.0 4.1
3 < 1 .6 <1.7 2.7 3.3
14 4 4.9 <1.7 < 2.0 < 2.0
* Data from Fig. 19.
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brain after an amplification step. It would appear more likely that the 
apparent absence of DI virus is due to the insensitivity of the assays 
used.
To test these possibilities mice were co-inoculated with DI virus p8 
plus 7 x 10^ LD^q . Although DI virus p8 would not protect mice against 
this high dose of S virus the chance of co-infection, and therefore 
enrichment of DI virus, would be high and Figure 20 shows that DI virus 
p8 did not inhibit the multiplication of S virus. More importantly the 
interference assays (RSIA and YRA) failed to detect the presence of DI 
virus in any of the brain samples. No amplication assays were 
attempted. Thus the problem has not been resolved.
g) Protection of mice by mouse brain homogenate
To test the possibility that the DI virus propagated in brain does not 
register by in vitro assays, brain homogenates were used as a source of 
DI virus in mouse protection experiments. Preliminary experiments 
(Table 33) showed that co-inoculation of brain homogenate from 
uninfected mice, protected mice against 10 LDjq but not 100 LDjq S 
virus. Identical results were obtained by using 2 inoculations of brain 
homogenate 2 h apart. This non-specific effect was lost when brain was 
diluted 10“ 1 or more. Uninfected mouse brain homogenate protected cells 
against SFV challenge in iji vitro interferon assays (see Methods) and 
protection was specific for mouse cells since hamster (BHK) cells were 
not protected (Table 34). This result was supported by the failure of 
uninfected mouse brain homogenate to inhibit SFV plaque formation in CEF
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Figure 20. Growth curve of S SFV and S SFV plus pfl PI SFV in 
the brains of mice
Mice were inoculated by the i.n. route according to Methods. S virus 
was 7 x 10^ * LD^q . S virus ♦ DI virus p8; ^  S virus only.
Table 33 Protection of mice against SFV lethal encephalitis by
administration of brain homogenate from uninfected mice
Inoculumt
Survivors X
10 ld50 1/10* 10
10 ld50 ♦ 1/1 MB 8/10 80
10 LD50 ♦ 1/10 MB 1 / 1 0 10
10 LD50 + 1/100 MB 2 /10 20
io ld50 0 /10 0
10 LD50 + 1/1 MB 6/9 67
100 LD^q 0/10 0
100 LD50 ♦ 1/1 MB 1/9 11
t Mice were inoculated by the i.n. route in a 20 ul volume.
MB “ uninfected mouse brain homogenate. Control mice inoculated 
with MB only survived without disease.
♦ No. surviving/no. inoculated.
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Table 34 Assay for 'interferon' in uninfected mouse brain homogenate
Sample Interferon titref (Log^g units/ml) 
Lg29 cells ^929 ce^ s BHK cells
(- AMD) (♦ AMD) (- AMD)
Uninfected mouse 2.7 3.2 -41.0
brain homogenate
mouse interferon )t 3.1 <1.0 <1.0
t Interferon assay was performed either on mouse L929 or hamster BHK 
cells. Samples were inoculated either with or without 2 pg/rnl 
actinomycin D (AMD). Interferon titres are expressed in arbitrary 
units. *
* Mouse interferon was a standard prepared by induction of L929 cells 
with Newcastle Disease virus, and as such consists of a mixture of or 
and S interferon species.
£ 1
i
l
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cells. Thus Che brain Cissue debris was not directly "neutralising" 
infectivity. However, the protection factor was not interferon since 
actinomycin D did not inhibit protection. (Actiomycin D prevents 
depression of host cell genome by interferon by inhibiting host cell RNA 
synthesis). The nature of this protection factor is unknown but would 
appear to be similar to that reported by Woodward and Smith (1975) and 
Woodward e£ al^ . (1978).
As this non-specific protection diluted out at 1/10 dilution, the 
protecting abilities of brain homogenate from mice co-inoculated with 10 
LD^q + DI SFV could nonetheless be tested. Infectious virus was removed 
from mouse brain by UV irradiation of 1/10 dilution of brain homogenate 
for 30 sec so that all infectivity was removed (UV inactivation kinetics 
of infectious virus in 1 / 1 0  dilution of brain homogenate were identical 
to that in tissue culture fluid: data not shown). Although uninfected 
mouse brain did not protect mice, small numbers (<30Z) of mice were 
found to be protected against 10 LDjq by brain homogenate from mice 
originally treated with DI virus pA or pl3a (Table 35). This could 
therefore represent DI virus which did not register by ^n vitro assays 
as postulated above. However, brain homogenates from 10 LDjq + UV SFV 
infected mice also protected mice to the same extent. Mouse brains 
collected at 21 days p.i. from mice inoculated with 10 LDjq ♦ DI SFV 
also protected mice as did brain homogenate from mice inoculated with DI 
SFV pl3a only. On the other hand, brain homogenates from mice 
inoculated with avirulent SFV did not protect mice. This would 
indicate that brain homogenates will only protect against the homologous 
strain of SFV. Thus it is possible that the protection phenomenon is
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due to DI virus but Che presence of protection in brains from mice 
treated with 10 LD^g + LTV SFV or DI virus only, and in brains collected 
at 21 days p.i. suggests that DI virus is stable in brain cells or some 
other, unknown, phenomenon is responsible for protection (which is not 
interferon or neutralising antibody).
Discussion
The above studies have shown that the DI SFV preparations, p4 and pl3a, 
differ in the ways in which they inhibit the multiplication of S virus 
in the mouse. Control mice inoculated with 10 LD^g + UV SFV showed that 
infection was not modulated by the immunogenicity of the added non- 
infectious virus. Mice treated with DI SFV pl3a had low infectivity 
levels throughout infection (except for spleen at 2 days p.i.), while DI 
SFV p4 treated mice have infectivity titres identical to non-treated 
mice for Che first 2 days of infection. From day 3 post-infection only 
low infectivity levels were obtained. These results are a paradox since 
in the previous results section reported that mice treated with DI SFV 
pl3a had strong immunity to challenge, while those treated with DI SFV 
p4 had weak immunity. Since mice treated with DI SFV p4 had the same 
distribution and amount of infectivity at day 2 p.i. as non-treated mice 
one would have expected there to have been sufficient immunogenic 
stimulus to mount a strong immune response to infection. Conversely, DI 
virus pl3a-treated mice had reduced levels of infectivity throughout 
infection (apart from spleen) one might have expected immunity to be
169
impaired. Neither prediction was upheld by experimental observation.
Two possible explanations are that DI SFV pl3a treated mice synthesize 
sufficient non-infectious SFV antigen to be immunizing or that DI SFV p4 
is immunosuppressive.
In an attempt to resolve the problem outlined above, mice were infected 
i.n. with different quantities of virulent or avirulent SFV to determine 
if it is possible to get undetectable levels of SFV in a mouse and yet 
to develop immunity to challenge. The results obtained are shown in 
Table 36. Inoculation of virulent SFV indicates that the LD^g is also 
the infectious dose^g (iD^g) and that mice inoculated with less than 1 
LD^g had no detectable virus in brain at day 4 p.i. and were susceptible 
to subsequent challenge with 100 LD^g at 21 days p.i. Inoculation of 
avirulent SFV resulted in similar virus titres in brain on day 4 p.i. 
(the peak day of infectivity) and all but one survived challenge with 
100 LD^g. It is concluded that in a SFV infection where DI virus has 
not been inoculated, mice which have no detectable virus in brain 
develop no protective immunity and will succumb to challenge. 
Nonetheless, mice treated with 10 LD^g* DI virus pl3a must express 
sufficient SFV antigen to stimulate protective immunity but the nature 
and distribution of this SFV antigen is unknown at present.
Although both interference assays failed to detect DI virus in the 
brains of DI virus-trested mice, low levels of DI virus (^10^*^ DI 
particles) may be present in the mouse. Alternatively, the DI virus 
which interferes ijj vivo may not register in the in vitro assays.
Indeed such interfering activity was induced in mouse brain after
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infection. Further support for this category of DI virus arises from 
the data in Table 16 which shows that in vivo protection does not 
correlate with interference titres measured vitro. These ideas would 
require there to be several different DI SFV genomes and indeed
I  | l ,  H  ,Kaariainen e£ al. (1981) have shown DI SFV RNA to be heterogeneous.
Analysis of the infectivity titres in mice treated with DI SFV pl3a 
revealed an anomolous distribution of infectivity in 9 individuals. 
Sampling means that we cannot know if these mice would have survived, 
possibly carrying a persistent infection which may have produced disease 
in later life (see next section). However, these results do indicate 
that besides resulting in the rapid clearance of virus from infected 
tissues, DI SFV can cause a more subtle modulation of infection.
1Persistence of Vi
Chapter 4
rus in Mice Protected by DI virus
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Introduction
To date much has been reported of DI viruses being involved in the 
establishment and maintenance of persistent infections in tissue culture 
(for a review see Holland et^  al.. , 1980). Only a few studies, with 
arenaviruses and VSV, have been performed ^n vivo. In nature, 
arenaviruses cause persistent infections and it has been suggested that 
either these infections are autoregulatory, such that multiplication 
takes place without destroying infected cells, or that DI particles 
regulate infection (for reviews see Buchmeier £t al_. , 1980 and Rawls et 
al., 1981). Fultz ££ aK (1982b) have shorn that VSV persists in the 
LSH strain of hamster following co-inoculation of DI and S virus. 
Infectivity was detected up to 8 months after infection but only after 
co-cultivating for 1 to 4 passages.
In the previous chapter, infectious virus was found in the brain of one 
mouse at 14 days p.i. which had been protected by co-inoculation of DI 
virus pl3a. As this appeared to be a persistent infection it was of 
interest to see if this result was representative of a general 
phenomenon. Thus a number of protected mice were examined for the 
presence of infectious virus at 12-21 days p.i. These times were chosen 
as mice not treated with DI viruses became ill on day 3 and died on day
5.
1Results
a) Presence of infectious virus in the brains of protected mice 
A total of 70 mice which had been protected by administration of DI 
virus pA or pl3a were sacrificed between days 12 and 21 p.i. Brains 
were removed and plaque assayed directly for infectivity (Table 37). 
Although all the mice were clinically healthy, 3 mice (16.1Z) treated 
with 10 LD^q ♦ DI virus pA, and 2 mice (3.1Z) treated with 10 LDjq ♦ DI 
virus pl3a had infectious virus detectable in their brains.
It is difficult to find suitable controls for the above experiment since 
mice inoculated with 10 LDjq ♦ LTV SFV all die at day 3. However, mice 
were inoculated with an avirulent strain of SFV (A77A) which at the dose 
used causes transient clinical signs of malaise. Mice recovered 
completely by day 10 p.i. (unpublished observations). Infectivity 
peaked in brain at day A to 6 p.i. and no mice sampled between 12 and 21 
days p.i. had detectable infectious virus (0/32 or ^3Z). The latest 
positive isolation of virus in brain (or elsewhere) was at 10 days p.i. 
This suggests that the isolation of infectivity from DI virus-treated 
mice, as shorn in Table 37 is indicative of a persistent infection.
Brains containing detectable virus had infectivity titres which varied 
from totals of A x 10^  to A x 10"* pfu. No DI virus was detected in 
these mouse brains by either the RSIA or YRA in vitro interference 
assays. Since the 2 assays detect >105 ' 7 DIU/brain it ia possible that 
low levels of DI virus are present. With low levels of infectivity in 
brain low levels of DI virus would be expected.
1b) Properties of one isolate of infectious virus from the brain of 
a PI virus protected mouse
Virus isolated on day 14 from a mouse infected with 10 LD5Q + DI virus 
4 9pl3a (10 ‘ pfu/brain; see Table 37) was examined in detail. This 
virus is coded I13a/14. Virus was passaged in BHK cells at a moi of 
0.05. After incubating for 18 h at 37°C an infectivity titre of 1 x 10^ 
pfu/ml was obtained. A repeat passage with 40 h incubation gave a titre 
of 2 x 10^ pfu/ml. Since a number of workers have shown that infectious 
virus isolated from persistant infections has altered properties, such 
as tempeature senstivity and virulence (see review by Holland £t^  al., 
1980), I13a/14 was examined for any changes from the properties of the 
parental ts + S virus used in the inoculum.
Plaque formation by I13a/14 was neutralised by rabbit antisera against 
SFV showing that the virus was indeed SFV. The virulence of 113a/14 was 
compared to the original S virus inoculum (Table 38). Intranasal 
inoculation of 10 LD^q pfu-equivalents (6 x 10^ pfu) of the I13a/14 
isolate killed all the mice tested as did inoculation of 10 LD^q S SFV. 
All mice inoculated with 10 LD^q pfu-equivalents of avirulent SFV 
survived infection. Thus the isolate is at least as virulent as the 
parental virus.
Temperature sensitivity of plaque formation by I13a/14 was examined next 
to see if the virus had changed by multiplication in mice (Table 39). 
I13a/14 virus had the same plaque efficiency (39°C:33°C) as S virus. (S 
virus was known to be temperature sensitive [Barrett, 1980]). Plaque 
size and morphology were the same for both viruses. Thus, it would
Table 37 Presence of infectious virus in braina of mice protected
by DI SFV or mice inoculated with avirulent SFV
Inoculi! Infectivity titret Virus isolation^*
(log10 pfu/brain)
day 1 2) 5.6, 2.5, 1.85, 1.6 4/12)
day 13) 10 LD^g + 0/6) 5/31
day 14) DI virus p4 0/5) ( 16.1Z)
day 2 1) 4.75 1/8)
day 1 2 ) 
day 13) 
day 14) 
day 2 1)
10 LDjg ♦
DI virus pl3a
1 .6
4.9
1/14)
0/6)
1 /6)
0/13)
2/39 
(5.IX)
day 1 2) 0/6)
day 14) 0/6)
day 15) avirulent SFV 0/5) 0/32
day 16) 0/6) (<3.3%)
day 2 1) 0/9)
t all infectivities were undetectable (¿1 /6 pfu/brain) uniess stated.
•f no. mice with detectable virus/no. mice sampled.
mice were inoculated by 
in Methods or avirulent
the i.n. route with DI virus 
SFV (8 x 104 pfu).
as described
Table 38 Lethality of virus isolated at 14 days p.i. (I 13a/14)
Inoculumt Survivors^
S virus 0/10
I 13a/14 0/10
avirulent SFV 10 /10
3T mice were inoculated i.n. with 6 x 10 pfu (« 10 LDjg 
S virus) in 20 ill. S virus is standard virus of the ts + 
strain of SFV.
no. of mice surviving/no. of mice inoculated at 9 days p.i.
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Table 39 Infectivity titrations of I 13a/14 virus and standard SFV 
at different températures
Temperature Titre (pfu/ml)
(° C )
Efficiency of 
plaquing*
Z
Standard SFV 33 1 . 2 x 109 100
39 2.0 x 1 0 7 1.7
I 13a/14 virus 33 1.5 x 106 100
39 2.5 x 104 1.7
* titre 39°/titre 33°.
1appear that the virus isolated from the brain is similar, if not 
identical to that used to inoculate the mice initially.
c) Neutralising antibody levels in protected mice
Brain infectivities and neutralising antibody titres present in the 
brain and sera of mice were taken on days 13 to 14 p.i. and were 
compared (Table 40). Although few (4/23) protected mice have high 
levels of neutralising antibody in the serum (^1000) the mouse with 
infectivity in the brain was one of them. It had no detectable antibody 
in brain. Therefore serum neutralising antibody titres did not 
correlate with the presence or absence of infectivity in the brain.
Mice infected with avirulent SFV had high serum neutralising antibody 
titres but no detectable infectivity in the brains. Few protected mice 
had neutralising antibody titres in brain and these did not correlate 
with high serum neutralising antibody titres. Generally, avirulent SFV 
infected mice had significant neutralising antibody in brain.
Discussion
Infectious virus was isolated from the brains of a minority (10Z) of DI 
SFV-protected mice examined between 12 and 21 days p.i. Infectivity was 
isolated from more mice treated with DI virus p4 (16Z) than those 
treated with DI virus pl3a (5X). The greater number of isolations from 
DI virus p4 treated mice may correlate with their weak adaptive immune
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Table 40 Brain infectivities and neutralizing antibody titres in
mice at 13-14 days p.i.
Inoculum^ Brain infectivity*. Neutralizing antibody titret
(pfu/mouse) brain serum
Avirulent i all <1 1 .6 x<9 3162
2 16 1778
3 35 891
4 89 1584
5 158 1000
10 LDS0 1 all ¿ 1 . 6 all ¿9 CM
♦ DI 2 s<5
virus 3 <9
p4 4 N<9
5 ¿ 2 0
6 « 2
7 9
8 32
9 2000
10 2 0 0 0
11 N. D. 3162
Table 40 (continued)
Inoculum^ Brain infectivity+
(pfu/mouse)
Neutralizing antibody titret 
brain serum
10 LDS0 i all < 1 .6 «9 x<9
+ DI 2 n<9
v iru9 3 <9 >59
pl3a 4 <9 9
5 V<9 10
6 <9 18
7 s<9 22
8 <9 398
9 4.9 1000
10 < 1 .6 14 141
11 < 1 .6 14 501
12 < 1 .6 N.D. 22
t Results taken from Table 20.
4 Results taken from Table 37.
^ Mice were inoculated with avirulent SFV (8 x 10* 4 pfu) or 
10 LDjq ♦ DI virus as described in Methods.
N.O. » not done.
t
1response. Although isolations were made at a comparatively short time 
(1 2 - 2 1 days) after infection there is no doubt that the virus is 
persisting relative to non-treated mice which die on day 5 or avirulent 
SFV-infected mice which do not yield infectious virus after day 10. 
Whether or not this is a "persistent infection" depends on how this is 
defined. Protected mice were clinically healthy throughout all 
experiments and a group of 12 mice protected by DI SFV pl3d have been 
observed up to 85 days p.i. and have remained healthy throughout this 
period. Thus there is no evidence of a persistent infection leading to 
disease. However, if only 10Z mice are persistently infected such a 
small group of mice would not be expected to show clinical signs of 
disease.
Since infectious virus could be directly isolated from protected mice, 
co-cultivation techniques such as required by Fultz et al. (1982b) to 
detect VSV under similar experimental conditions were not used, so it is 
possible that infectious virus may be present in a higher proportion of 
protected mice. Only one isolate was compared with the inoculum virus 
and did not differ in temperature sensitivity characteristics and 
lethality. This contrasts with the rsults of Fultz et^  al. (1982b) who 
found that the viruses isolated from hamsters were temperature 
sensitive, small plaque mutants. It is intriguing that a mouse can 
remain clinically healthy with a high level of virulent virus in its 
brain. Perhaps the infectious virus is localised to a specific area, 
possibly in equilibrium with an undetectable amount of DI virus. This 
mouse had a high level of serum neutralising antibody, but no detectable 
neutralixing antibody in the brain. Clearly serum neutralixing antibody 
is ineffective at clearing infectivity.
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Chapter 5
Modulation of SFV infection by DI SFV after intraperitoneal inoculation
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Introduction
In the General Introduction it was shown that the majority of studies of 
DI viruses in animals have involved infections of the central nervous 
system after either i.c. or i.n. inoculation. There have been only 
three reports on the prophylactic effects of DI particles inoculated by 
other routes. Early studies by Mims (1956) on Rift Valley fever virus 
in mice showed that intravenous inoculation of "incomplete" virus 
protected mice against i.c. inoculation of S virus. Recently, Fultz et^ 
al. (1982a) reported that hamsters could be protected against a lethal 
VSV infection, initiated by i.p. inoculation, by biologically active DI 
particles, also inoculated by the i.p. route. However, there was also 
heterologous interference by DI particles of the New Jersey serotype of 
VSV and induction of interferon by DI VSV in mice, suggesting that 
protection was not due to the intrinsic interfering ability of DI virus. 
Smith (1981) has proposed that "interfering virus" is involved in the 
genetic resistance of mice to the flavivirus, Banzi, since after i.p. 
inoculation, mice which were resistant to infectioflhad high levels of 
"intefering virus", while susceptible strains of mice had much lower 
titres.
This section reports on the ability of DI SFV to prevent the lethal 
encephalitis in mice initiated by SFV inoculated by the i.p. route. DI 
SFV was also inoculated i.p.
Results
Defective interfering Semliki Forest virus preparations 
Details of the passage histories, haemagglutination and interference 
assay titres of the DI SFV preparations used in the experiments are 
shown in Table 41. In addition to DI virus these preparations also 
contained between 10 and 10 pfu/ml infectious virus. S virus was 
inctcbvotai by UV irradiation as before, and the length of exposure was 
chosen to ensure that the irradiated DI virus preparations contained no 
infectivity detectable by plaque assay (Table 41). Thus DI virus 
preparations used in this section of the work were exactly the same as 
those in the experiments using the i.n. route of inoculation.
Determination of a sub-immunogenic dose of SFV antigen
In order to analyse the modulation of SFV infection in mice by DI SFV it 
was necessary to distinguish between the intrinsic interfering 
properties of the DI virus and its effect as an immunogen. The total 
amount of SFV antigen in DI virus preparations was determined by 
haemagglutination and the DI SFV preparations used contained a maximum 
antigenic mass of 4 HAU/ml. Non-infectious SFV antigen, prepared as 
previously, by UV irradiating S SFV, was diluted to a concentration of 4 
HAU/ml, and used as a control for the immunogenic effects of DI virus. 
Such UV SFV antigen did not alter the course of disease caused by 10 
LDjq S virus and did not reduce its lethality (Table 42). This control 
also excluded the possibility that the DI virus was preventing infection 
by blocking attachment to cellular receptor sites.
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Table 42 Effect of SFV antigen on lethality in mice of 10 LDgq 
S virus after i.p. inoculation
Inoculumt Surv ivors t Mean day of death^
10 ld50 1 / 1 0 6.61
10 LD50 ♦ UV SFV 1/10 6.85
t Mice were inoculated with 10 LD^q diluted in medium or 10 LD^q diluted 
in UV SFV. UV SFV is non-infectious UV irradiated S virus at a 
concentration of 4 HAU/ml.
•f Number of surviving mice/number of mice inoculated on day 14 p.i.
^ Mean day of death is the sum of the day on which each mouse died 
divided by the number of mice.
i 6 6
c) Modulation of SFV-induced disease by administration of DI SFV
The encephalitis in mice after i.p. inoculation and the disease induced 
in adult CFLP mice inoculated with 10 LD^g followed a reproducible 
pattern. Mice remained apparently healthy until 5 days p.i. and then 
showed signs of malaise (ruffled fur and inactivity), which was followed 
within 24 h by paralysis of the hind limbs. This progressed to complete 
paralysis and by day 8 p.i. most mice were dead. Usually with 10 LD^g, 
90Z of mice die and the remainder appear to have a silent infection 
which is nevertheless immunizing (see Table 47).
Mice were inoculated with a mixture of 10 LD^g S virus together with DI 
virus pl3a; controls received 10 LD^g plus non-infectious UV irradiated 
S virus (UV SFV; 4 HAU/ml) as described above. Table 43 shows that DI 
SFV pl3a modulated the course of the disease by retarding the onset of 
clinical signs, and the progression through paralysis to death. For 
example, at 6.75 days p.i. 67Z mice infected with 10 LD^g ♦ UV SFV were 
dead compared with 11Z of those inoculated with 10 LDjg + DI SFV pl3a. 
The mean time of death for 10 LD^g ♦ UV SFV ws 6.6 days and this was 
extended to 9.2 days for 10 LD^g + DI SFV pl3a. Overall inoculation of 
mice with 10 LD^g + DI SFV pl3a resulted in more than double the number 
surviving inoculation with 10 LD^g + UV SFV. Control mice inoculated 
with only UV SFV or only DI SFV pl3a remained healthy.
d) Comparison of the ability of different DI SFV preparations to modulate 
SFV-induced disease
It is not possible to purify DI SFV from S SFV, therefore quantitative
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comparisons between DI SFV preparations are difficult. Since DI SFV 
preparations contain different quantities of antigen, infectivity and 
interference titres by ^n vitro assay (see Table 41), only qualitative 
comparisons between DI SFV preparations can be described.
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The ability of DI SFV preparations to protect mice after i.p. 
inoculation is shown in Table 44. All 4 DI SFV preparations tested 
modulated the disease to some extent but this appeared to have two 
manifestations: mice survived the infection and showed no signs of
disease, and up to 51.5Z were protected in this way (DI SFV p6). 
Secondly, death was delayed over the mean day of death for 10 LD^q + UV 
SFV of 6.7 days. All DI SFV preparations (except p4 ) delayed death 
significantly. There appears to be no correlation between the extent of 
delay in death and number of survivors for DI SFV-treated mice. For 
instance, both DI SFV preparations p4 and pl3a modulated the disease to 
some extent and similar numbers of mice survived (27 and 22Z 
respectively) without signs of disease. However, these two DI viruses 
differed in their ability to modulate infection by delaying death. DI 
SFV pl3a delayed death by 1.5 days, while mice treated with DI SFV p4 
died at the same time as controls inoculated with 10 LDjq ♦ UV SFV. 
Similarly, although DI virus p6 protected 51.5Z it only delayed-death in 
the others by 1.7 days, a figure close to that seen with DI virus pl3a 
(1.5 days) which protected much less efficiently (22Z). Thus, (a) 
survival from infection without showing signs of disease and (b) delay 
in death may reflect different mechanisms of interference. There was no 
correlation between either _in vitro interference aseay (RSIA or YRA) and 
either of the above effects of DI virus inoculated i.p.
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Effect of inoculation of DI virus prior to and after infection 
vith S SFV
DI SFV was administered to mice i.p. at different times relative to i.p. 
inoculation of 10 LDj q , to determine if this affected modulation of the 
lethal encephalitis. Post-inoculation did not protect, while pre- 
inoculation protected no better than co-inoculation with DI virus when 
compared to control mice inoculated with UV SFV.
f) Effect of Myocrisin on the ability of DI SFV to modulate S SFV infection 
Macrophages are thought to play an important role in host immune 
mechanisms, particularly in the peritoneal cavity (Mogensen, 1979) and 
this role has also been demonstrated for SFV infections after i.p. 
inoculation (Allner al_., 1974; Bradish ££ , 1975; Oaten £t al. ,
1980; Mehta and Webb, 1982; Pathak and Webb, 1983). Macrophage 
activity can be diminished by treatment with colloidal gold salts such 
as Myocrisin (sodium auro-thio-malate) and this procedure has been used 
to determine if macrophages were contributing to the DI SFV-mediated 
modulation of SFV encephalitis. Table 45 confirms previous studies 
(Allner e£ al., 1974; Oaten e£ £l., 1980) that Myocrisin enhances the 
lethality of the 10 LDjq dose by reducing the mean day of death. Death 
of mice treated with DI SFV in the presence of Myocrisin was delayed by 
1.5 days, from 5.4 to 6.9 days p.i. However, there were no survivors, 
suggesting that under these conditions macrophages are required for 
survival.
The LDjq of SFV in mice treated with Myocrisin was 3 x 102 pfu compared
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with 1.25 x 10^ pfu in control mice. Using 10 (Myocrisin) LDjg SFV 
there was the same proportion of survivors as in non-Myocrisin treated 
mice, but no difference in the mean day of death (Table 46). This 
experiment suggests that modulation of infection by DI virus is mediated 
partly through DI virus itself and partly via macrophages.
q^Effect of administering DI virus and S SFV by different routes 
Since the encephalitis caused by i.n. inoculation of SFV can be
prevented by i.n. inoculation of DI SFV it was of interest to see if
i.n. administration of DI virus would protect mice against the 
encephalitis resulting from i.p. inoculation of S virus. DI SFV pl3a
was administered intranasally in two inoculations each of 20 pi, one two
hours before and the other at the same time as the 10 LDjq were 
inoculated into the peritoneal cavity. DI virus inoculated by the i.n. 
route failed to modulate the disease caused by S virus after i.p. 
inoculation and no delay in death was observed. It should be remembered 
that only 40 pi DI virus wss administered by the i.n. route, while 100 
pi was inoculated i.p., so that direct comparisons between the two 
routes cannot be made. Administration of DI virus by the i.n. route at 
later times relative to i.p. inoculstion of S virus were not examined.
C h a l l e n g e  o f  DI S K V - p r o t e c t e d  m i c e  by S v i r u s  a t  21 d a y s  a f t e r  
t h e  i n i t i a l  i n f e c t i o n
M ic e  w h ic h  h ad  s u r v i v e d  t h e  i n i t i a l  i n f e c t i o n  w e r e  c h a l l e n g e d  w i t h  100  
LD^q S v i r u s  a t  21 d a y s  p . i .  t o  d e t e r m i n e  i f  t h e  m ic e  h ad  d e v e l o p e d
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solid protective immunity in response to the initial infection. All 
other survivors were also challenged. Table 47 shows that all DI virus 
protected mice were resistant to challenge. However, the majority of 
mice inoculated with DI virus alone or non-infectious UV SFV alone 
generated a protective immune response (although of course this was 
insufficient to prevent the initial infection). DI SFV p23 only 
protected 44Z mice challenged. In comparison, the majority of mice 
inoculated with DI virus or UV SFV only by the i.n. route were 
susceptible to challenge (Table 17). However, it should be remembered, 
a smaller amount of virus is inoculated by the i.n. route. The result 
for DI virus p4 + 10 LD^g is in contrast to that obtained after i.n. 
inoculation where mice are protected in the absence of an adaptive 
immune response (see Table 17). Presumably the difference may reside in 
the efficiency of DI virus p4 as an immunogen by the i.p. route.
jProduction of infectious virus in DI SFV-treated mice 
Since DI virus can delay the mean day of death or prevent disease and 
death in a proportion of animals, it was of interest to see how levels 
of infectivity were affected. SFV is neurotropic and causes an 
encephalitia after i.p. inoculation and in CFLP mice SFV reaches peak 
infectivity titres in the brain at day 5 p.i. (unpublished 
observations). Mice were infected with 10 LDjq ♦ UV SFV or 10 LDjq ♦ DI 
SFV pl3at killed at day 3 p.i. and infectivity titres in the brain, 
spleen and serum determined. Table 48 shows that there was low or no 
detectable levels of infectivity in the sera and spleens in mice of both 
groups. Comparison of infectivity titres in brain showed that there was
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Table 47 Ability of mice which had survived the infection with 
10_LD50 SFV by treatment with DI SFV preparations to 
survive a second i.p. inoculation of 100 LDçr» SFVI
First inoculum Survivors
No. survivors X
No. inoculated
10 LD50 + UV SFV
Uninfected
UV SFV
DI virus p4
10 LDjg ♦ DI virus p4
DI virus p6
10 LD^q + DI virus p6
DI virus pl3a
10 LD^q + DI virus pl3a
DI virus p23
10 LDS0 ♦ DI virus p23
15/15 100
0/16 0
12/14 86
6/6 100
14/14 100
5/5 100
6/6 100
8/10 80
1 2 / 1 2 100
4/9 44
6/6 100
t at 21 days p.i
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Table 47 Ability of mice which had survived the infection with 
10 LDçn SFV by treatment with DI SFV preparations to 
survive a second i.p. inoculation of 100 LD n^ SFVt
First inoculum Survivors
No. survivors X
No. inoculated
10 ld50 + UV SFV 15/15 100
Uninfected 0/16 0
UV SFV 12/14 86
DI virus p4 6/6 100
10 LDjp ♦ DI virus p4 14/14 100
DI virus p6 5/5 100
10 LD^g * DI virus p6 6/6 100
DI virus pl3a 8/10 80
10 LD^g ♦ DI virus pl3a 1 2 / 1 2 100
DI virus p23 4/9 44
10 LDjg DI virus p23 6/6 100
t at 21 days p.i
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no significant difference between the two groups. In 27Z (3/11) of the 
DI SFV treated group and 22Z (2/9) of the 10 LDjq ♦ UV SFV group no 
virus was detected. Brain infectivity titres were the same with means 
of 106 - 01 + 101 - 57 (1 s.e.m.) pfu/mouse in DI SFV-treated mice and 
1q5 . 5 7  ^  j q 1 . 5 9  pfu/mou8e ¿n non-treated mice. In the control 
experiment, 36Z (4/11) of DI SFV treated mice survived compared to 16Z 
(2/1 2 ) of non-treated mice, and there was a delay in death of l.S days. 
This presents a paradox since infectivity titres are similar, but there 
was both significant delay in death and double the number of survivors 
in DI SFV treated mice.
Production of DI virus in mice inoculated with DI SFV and S virus 
Assays for DI SFV by the RSIA and YRA were performed on the mice 
described above. Using the RSIA, DI virus was present in 4/11 sera of 
DI SFV-treated mice, whereas all the sera of mice inoculated with 10 
LD^g ♦ UV SFV were negative (Table 48). Insufficient sera remained for 
YRAs. No DI virus was detected in brain or spleen samples from either 
group of mice. Why DI virus was detected in serum where there was 
little infectious virus (Table 48) and not in the brain is unknown.
D i s c u s s i o n
E v i d e n c e  h a s  b e e n  p r e s e n t e d  t h a t  DI SFV p r e p a r a t i o n s  i n o c u l a t e d  i . p .  a r e  
a b l e  t o  m o d u l a t e  t h e  c o u r s e  o f  i n f e c t i o n  i n i t i a t e d  by i . p .  i n o c u l a t i o n  
o f  S v i r u s .  A n t i g e n  c o n t r o l s  sh ow ed t h a t  p r o t e c t i o n  w a s  n o t  du e  t o  th e
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Table 48 Virus titres in mouse tissues at day 5 p.i . after i
administration of 10 LD ♦ DI SFV pl3a50
Inoculumt Infectivity Interference ti
(mouse (log
10
pfu/mouse4) (1°8io DIU/mousinumber)
Brain Spleen Serum Serum
10 LD 1 50+
oo'•4' ¿1.81 ¿1.60 ¿ 1 .2
2 5.90 ¿0.70 ¿2.60 ¿ 1 .2
UV SFV 3 4.45 1.18 ¿1.60 ¿ 1 . 2
4 6.87 ¿0.70 ¿1.60 ¿ 1 . 2
5 5.90 1.30 2.08 ¿ 1 . 2
6 ¿ 1.00 ¿0.70 1.90 ¿ 1 . 2
7 1.95 2.20 2.78 ¿ 1 . 2
8 7.60 ¿0.70 ¿1.60 ¿ 1 . 2
9 6.34 1.70 2.60 ¿ 1 . 2
10 LD 1 50 7.60 ''a o o ¿2.60 ¿ 1 . 2♦ 2 7.95 1.30 ¿2.60 2.6
DI 3 7.90 1.30 ¿2.60 ¿ 1 . 2
virus 4 6.54 ¿0.70 2.64 ¿ 1 . 2
pi 3a 5 oovs 1.74 ¿1.60 ¿ 1 . 2
6 6.08 ¿0.70 ¿1.60 3.1
7 4.41 ¿0.70 2.08 2.8
8 ¿ 1.00 0.70 ¿1.60 ¿ 1 . 2
9 ¿ 1.00 ¿0.70 ¿1.60 ¿ 1 . 2
10 5.00 ¿0.70 1.60 ¿ 1 . 2
11 2.60 ¿0.70 ¿1.60 3.4
I LTV SFV is non-infectious UV irradiated S virus at a concentration of 4 
HAU/ral. DI SFV pl3a was UV irradiated for 60 sec before use.
•4 For calculations of virus titre/mouse the volume of the brain is 
assumed to be 0.3ml, spleen 0.2ml, and serum 4 ml (Kaliss and 
Pressman, 1930).
^ Obtained by the RSIA. DI virus was only detected in sera.
In these experiments up to 51.SZ of mice survived a lethal infection 
through administration of DI SFV. The data presented shows that DI SFV 
is also capable of delaying both the onset of disease and the mean day 
of death of mice inoculated with 10 LD^q SFV. The extent to which DI 
SFV modulates infection as judged by both mean day of death and 
proportion of survivors varied between different DI SFV preparations.
For example, similar numbers of mice could be protected with either no 
delay in death (e.g. DI virus p4) or delay in death (e.g. DI virus 
pl3a). As with the i.n. results, no correlation between ^n vitro 
interference titre and protection of mice was observed.
The data do not explain how DI virus modulates the lethal encephalitis 
since infectivity titres in the brains of mice inoculated with 10 LDjq ♦ 
DI SFV are as high as in control mice infected without DI virus.
However, DI virus was detectable in the serum of DI virus-treated mice. 
It is possible that brains contain low quantities of DI virus which are 
undetectable by ^n vitro assay and if so, these may act by stimulating 
local host immune responses. The detection of DI virus in the sera 
recalls the findings of Smith (1981) who reported that "interfering" 
virus originates in cells of the lymphoreticular system. The results 
also indicate that host imnune responses are involved in DI SFV-induced 
modulation of infection since macrophages are required for maximum 
protection (Table 45).
immunogenicity of the DI SFV or its ability to block the attachment of
infectious virus to cell surface receptors.
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Comparison of DI virus modulation of SFV infection initiated by the i.p. 
route and the i.n. route reveals a number of differences. Firstly, 
administration of DI virus by the i.n. route did not alter the time of 
death and secondly, some DI virus preparations which modulated infection 
when inoculated by the i.p. route were inactive by the i.n. route (Table 
49). For example, DI SFV p6 protected 51.5Ï mice inoculated 
intraperitoneally but none by the i.n. route. Also, DI virus p6 
protected more mice than DI viruses p4 and pl3a by the i.p. route, while 
the reverse applies by the i.n. route. This may indicate that, 
protection of mice by DI SFV inoculated by the i.p. route occurs by a 
mechanism different from that operating after i.n. inoculation. This 
idea is supported by the observations that i.n. inoculation of DI virus 
inhibits multiplication in brain (Figs. 18 and 19), whereas i.p. 
administration had no affect on brain infectivity (Table 48). This may 
mean that DI SFV preparations stimulate different host functions 
depending on the route of inoculation. However, it should be remembered 
that different quantities of DI virus have been inoculated by the 2 
routes and this may be partly responsible for the results obtained.
Table 49 Summary of the protection of mice against a lethal
encephalitis by administration of various DI SFV
preparations
DI SFV 
préparât
¿•P.
ion Survivors
(Z)
inoculât iont
Delay in death 
(days)*
i.n. inoculât ion4- 
Survivors
(Z)
I* 27 ♦ 0.1 64
p6 51.5 + 1.7 0
pi 3a 22 + 1.5 59
P23 20 ♦ 1.3 0
t Details of experiments are taken from Table 44.
■4 Results are taken from Table 16.
* There was no delay in death with i.n. inoculation.
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The majority of work on DI particles has involved tissue culture 
studies. These have led to the suggestion that DI viruses have a role 
in modulating both acute and persistent virus infections in nature (for 
a review see Holland et^  a K , 1980). Unfortunately, few animal studies 
have been carried out to investigate these ideas.
In this thesis it has been shown that DI SFV preparations can prevent 
the lethal encephalitis in mice which follows i.n. inoculation of S SFV. 
Not only was death prevented, but mice remained clinically healthy (i.e. 
they were "protected" from disease). These experiments were carefully 
controlled and it was shown that the immunogenic load of virus was not 
the cause of protection. The above results confirmed those obtained by 
Dimmock and Kennedy (1978). Few studies on other viruses have shown the 
same extent of protection as we have obtained with the SFV system, the 
exceptions being Welsh et_ al. (1977) and Jones and Holland (1980) using 
lymphocytic choriomeningitis virus and VSV and their DI viruses 
respectively. The results from experiments with DI SFV have been 
obtained using DI viruses from unconcentrated tissue culture fluids and 
this contrasts with the studies using VSV and lymphocytic 
choriomeningitis virus, where large numbers of DI particles were 
required for protection.
The multiplication of SFV in mice treated intranasally with DI virus 
showed that, in general, infectivity was greatly reduced io most tissues 
throughout infection (see below for exceptions). Thus DI virus limits 
the spread of virus throughout the animal and infectious virus is 
rapidly eliminated. In a few mice an altered pattern of infectivity was 
seen in which infectivity titres were reduced in some, but not all of
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Che tissues examined. It would appear thaC DI virus can cause subtle 
tissue specific affects in a minority of DI virus-treated mice. The 
detection of infectious virus in the brains of a few protected mice 
between 12 and 21 days p.i. suggests that DI virus is modulating the 
acute infection and causing it to become persistent. Before these 
experiments SFV was considered only to cause acute virus infections in 
vertebrates and it had not been reported to cause persistent infections. 
Fultz ££ al^ . (1982b) have produced the only other study reporting a 
persistent infection in animals initiated by DI virus, using VSV in 
hamsters. However, VSV was recovered only after co-cultivation of 
brain, while SFV differs as virus can be directly isolated from brain. 
The low level (10%) of "persistence" makes experimental observations 
difficult and clearly more mice need to be sampled and later time points 
after infection examined. Co-cultivation of brains with no detectable 
infectivity is required before the results can be fully evaluated. 
Nonetheless, the SFV system may provide an excellent model for studying 
the role of DI viruses in persistent virus infections.
The prevention of acute SFV infections in mice by DI virus supports the 
suggestion that DI viruses play a role in modulating virus infections in 
nature. Possibly DI viruses are involved in recovery from virus 
infections since they would cause a reduction in levels of S virus in 
the infected hosts. Alternatively, the presence of DI virus may cause a 
virus infection to be sub-clinical rather than manifesting signs of 
disease. The data obtained sheds no light on the role of DI virus in 
maintaining persistent virus infections. Future studies are required in 
this direction. In view of the results obtained with DI SFV in mice, a 
role for DI viruses, may be speculated for persistent virus infections
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in nature. For example, virus antigens or particles can be detected in 
the neurological diseases subacute sclerosing panencephalitis and 
multifocal leukoencephalopathy in man and visna in sheep, while other 
persistent infections cause minimal damage to the host (e.g. 
cytomegalovirus, polyoma-like (JC and BK) and papilloma viruses in man, 
and lactic dehydrogenase virus and lymphocytic choriomeningitis virus in 
mice). At the moment all this is speculation and will only be 
understood with further studies.
Evidence has also been presented that DI SFV preparations are 
biologically heterogeneous and the various parameters of heterogeneity 
are described in Table 50. The ratio of interference titres by two in 
vitro interference assays (RSIA and YRA) differed between preparations, 
as did inhibition of polypeptide synthesis, and homotypic and 
heterotypic interference in cell culture. In mice, different 01 virus 
preparations gave a similar level of protection but differed in their 
post-infection immune status, suggesting that protection of mice takes 
place by more than one mechanism. This suggestion was supported by 
examination of infectivity levels in mice following i.n. inoculation of 
DI virus. Mice treated with DI virus p4 had infectivity levels 
identical to non-treated mice upto day 2 p.i. but declined thereafter.
In comparison, infectivities in DI virus pl3a-treated mice were reduced 
throughout infection. The lack of neutralising antibody in most 
protected mice suggests that humoral immune responses play at best a 
minor role in protection. However, short lived IgM levels have not been 
measured in protected mice so humoral immune responses cannot be 
completely excluded. As there is no IgM memory this could account for 
the failure to detect an adaptive immune response in mice protected by
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Table 50 Evidence of biological heterogeneity of DI SFV preparations
1. The raCio of interference titres measured by RSIA:YRA varies from 
preparation to preparation.
2. Inhibition of polypeptide synthesis in co-infected cells may affect:
a) virus structural polypeptides and/or
b) virus non-structural polypeptides and/or
c) host polypeptides.
3. Homotypic and heterotypic interference vary between preparations.
4. Protection of mice from 10 LD^g after i.n. inoculation with 
different DI virus preparations gives:
a) protection with strong adaptive immune response or
b) protection with weak adaptive immune response or
c ) no protection.
5. Protection of mice from 10 LD^g after i.p. inoculation with 
different DI virus preparations gives variable
a) protection,
b) delay in death.
6. No correlation between protection by DI virus preparations obtained 
by the i.n. route and that obtained by i.p. inoculation.
7. No correlation between ¿n vitro interference properties and 
protection of mice by i.n. or i.p. routes.
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DI virus p4.
DI virus was also found Co modulate Che lechal encephalitis after co­
inoculation of DI and S virus by the i.p. route. Again, modulation took 
place by two mechanisms which were exemplified by DI viruses p4 and
pl3a.
It is concluded from this evidence that DI SFV preparations are 
biologically heterogeneous and have different interfering properties but 
the origin of these variations have not yet been fully explored.
Sequence analyses by others have shown that SFV DI particle RNA is 
physically heterogeneous. A pll DI SFV preparation contained more than 
one DI RNA species, and these RNAs differed in the extent of virus 
genome sequences deleted, sequence rearrangements and repetitions of an 
approximately 300 to 500 nucleotide sequence (Pettersson, 1981; 
Kaariainen e£ a_l. , 1981; Soderlund e£ aj^ ., 1981; Lehtovaara et^ al. , 
1981, 1982). Kaariainen e£ al^ . (1981) also observed that the population 
of DI RNAs varied on passage and this may explain the biological 
heterogeneity of DI viruses described in this thesis. It is possible 
that a preparation of DI SFV consists of a population of particles of 
defined but differing RNA sequences which vary in proportion during 
passage and this would result in the variation in interfering properties 
described in this thesis. A further source of variation may well arise 
from changes in the sequence of individual DI RNAs during replication. 
Additional opportunity for variation would occur if there was 
interference between DI viruses in a population as described with DI VSV 
(Rao and Huang, 1982). The lack of correlation between hi vitro and hi 
vivo interference may be explained by only a minority of DI RNA species
2U6
in Che population being able Co interfere in vivo. This suggestion is 
supported by a preliminary Tj oligonucleotide mapping study. DI SFV 
preparation pS was taken and digested with Tj ribonuclease and the 
oligonucleotides separated by PAGE (Figure 21a). The "fingerprint" of 
DI virus p5 differs little from that of DI virus p8 described by Kennedy 
(1976) (Figure 21b). Although Tj mapping only represents 10Z of the 
virus genome it would appear, at a gross level, that the 2 DI viruses 
are similar. However, DI virus p8 protects mice after i.n. inoculation, 
while DI virus p5 does not. Thus the above suggests that only some (a 
minority?) of Che DI RNA species in the population will interfere in 
vivo. Thus it can be envisaged that only DI SFV preparations which 
contain certain DI RNA species in the population will be able to 
interfere in vivo. To analyse biological heterogeneity further it will 
be necessary to examine structure-function relationships between 
different DI SFV preparations and the population of DI RNA species 
within the preparations. This will require Tj oligonucleotide mapping 
of DI SFV preparations and quantitation of the molar ratios of 
oligonucleotides to determine if a preponderance of certain 
oligonucleotides correlates with particular biological properties.
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Figure 21a oligonucleotide map of DI SFV p5
The lower cross is the bromophenol blue dye marker and the upper cross 
is the xylene cyanol dye marker.
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Statistical formulae
i) Standard error of the mean and confidence limits
The mean, x, is the point about which Che distribution is symmetrical 
and is described by:
Where S - standard error, 0"» standard deviation and n * number of 
measurements.
Therefore the reliability of a sample mean in indicating the true mean 
of Che whole population can be described. It is useful to attach
confidence limits at a certain level of probability. Thus, for any 
normal distribution 95% of measurements will be 1.96 standard deviations 
either side of the mean (i.e. the mean has a probability of 95% of being
n
where x are the values obtained on n number of measurements.
The standard deviation, er; is a measure of the variability of the
measurements about this mean and is described by:
The "standard error" (i.e. the standard deviation of the mean) is
described by:
S - <r
! É
2 2 b
between these limits) or: 
x + 1.96 s
â
ii) Statistical analysis of UV inactivation kinetics
Since the process of inactivation is random, it follows the Poissonian 
distribution. Therefore, the possibility of any single template 
remaining functional (i.e. unhit) is given by:
Where Pr * probability of the template having received r hits, where the 
average is x hits per template.
If the average * 1 hit per template 
x - 1
Therefore, Pr that any single template remains active (i.e. unhit) is r 
“ o.
Therefore Pr - e"1 - 1 - 0.3679
e
Thus at the time at which there is an average of 1 hit per template
36.8% of the templates are still unhit and involved in SNA synthesis.
37%This time is known as t (Ball, 1977).
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